0001493152-23-016758.txt : 20230512 0001493152-23-016758.hdr.sgml : 20230512 20230512173035 ACCESSION NUMBER: 0001493152-23-016758 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230512 DATE AS OF CHANGE: 20230512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Greater Cannabis Company, Inc. CENTRAL INDEX KEY: 0001695473 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 300842570 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-56027 FILM NUMBER: 23917227 BUSINESS ADDRESS: STREET 1: 15 WALKER AVE, STREET 2: SUITE 101 CITY: BALTIMORE STATE: MD ZIP: 21208 BUSINESS PHONE: (443) 738-4051 MAIL ADDRESS: STREET 1: 15 WALKER AVE, STREET 2: SUITE 101 CITY: BALTIMORE STATE: MD ZIP: 21208 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ Quarterly Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act Of 1934

For the quarterly period ended March 31, 2023

☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act Of 1934

For the transition period from ______________ to ______________

Commission File Number: 000-56027

THE GREATER CANNABIS COMPANY, INC.

(Exact name of registrant as specified in its charter)

Florida

30-0842570

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

15 Walker Avenue Suite 101

Baltimore, MD 21208

(Address of principal executive offices, including Zip Code)

(443)-738-4051

(Issuer’s telephone number, including area code)

Not applicable

(Former name or former address if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: 732,638,436 shares of common stock as of May 15, 2023.

TABLE OF CONTENTS

		Page
PART I	FINANCIAL INFORMATION
Item 1	Financial Statements	F-2
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operation	4
Item 3	Quantitative and Qualitative Disclosures About Market Risk	6
Item 4	Controls and Procedures	6

PART II	OTHER INFORMATION
Item 1	Legal Proceedings	7
Item 1A	Risk Factors	7
Item 2	Unregistered Sales of equity Securities and Use of Proceeds	7
Item 3	Defaults Upon Senior Securities	7
Item 4	Mine Safety Disclosures	7
Item 5	Other Information	7
Item 6	Exhibits	8
Item 7	Signatures	9

Cautionary Note Regarding Forward Looking Statements

This quarterly report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “may,” “should,” “could,” “will,” “plan,” “future,” “continue, “and other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters identify forward-looking statements. These forward-looking statements are based largely on our expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond our control. Therefore, actual results could differ materially from the forward-looking statements contained in this document, and readers are cautioned not to place undue reliance on such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this document will, in fact, transpire or prove to be accurate. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks in the section entitled “Risk Factors” that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by any forward-looking statements.

Important factors that may cause the actual results to differ from the forward-looking statements, projections or other expectations include, but are not limited to, the following:

	●	risk that we will not be able to remediate identified material weaknesses in our internal control over financial reporting and disclosure controls and procedures;

	●	risk that we fail to meet the requirements of the agreements under which we acquired our business interests, including any cash payments to the business operations, which could result in the loss of our right to continue to operate or develop the specific businesses described in the agreements;

	●	risk that we will be unable to secure additional financing in the near future in order to commence and sustain our planned development and growth plans;

	●	risk that we cannot attract, retain and motivate qualified personnel, particularly employees, consultants and contractors for our operations;

	●	risks and uncertainties relating to the various industries and operations we are currently engaged in;

	●	results of initial feasibility, pre-feasibility and feasibility studies, and the possibility that future growth, development or expansion will not be consistent with our expectations;

	●	risks related to the inherent uncertainty of business operations including profit, cost of goods, production costs and cost estimates and the potential for unexpected costs and expenses;

	●	risks related to commodity price fluctuations;

	●	the uncertainty of profitability based upon our history of losses;

	●	risks related to failure to obtain adequate financing on a timely basis and on acceptable terms for our planned development projects;

	●	risks related to environmental regulation and liability;

	●	risks related to tax assessments;

	●	other risks and uncertainties related to our prospects, properties and business strategy.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this report. Except as required by law, we do not undertake to update or revise any of the forward-looking statements to conform these statements to actual results, whether as a result of new information, future events or otherwise.

As used in this quarterly report, “Greater Cannabis,” the “Company,” “we,” “us,” or “our” refer to The Greater Cannabis Company, Inc., unless otherwise indicated.

THE GREATER CANNABIS COMPANY, INC.

MARCH 31, 2023

FORM 10-Q

INDEX

	Page
PART I- FINANCIAL INFORMATION	F-2
ITEM 1. Financial Statements	F-2
Consolidated Balance Sheets as of March 31, 2023 (Unaudited) and December 31, 2022	F-2
Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022 (Unaudited)	F-3
Consolidated Statements of Stockholders’ Deficiency for the three months ended March 31, 2023 and 2022 (Unaudited)	F-4
Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022 (Unaudited)	F-5
Notes to Consolidated Financial Statements (Unaudited)	F-6

F-1

PART I- FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

THE GREATER CANNABIS COMPANY, INC.

CONSOLIDATED BALANCE SHEETS

March 31, 2023 (unaudited) and December 31, 2022

	March 31, 2023			December 31, 2022
	(Unaudited)

ASSETS
CURRENT ASSETS
Cash	$	251,553		$	270,030
Total current assets		251,553			270,030

OTHER ASSETS
Right of first refusal agreement cost (less accumulated amortization of $15,833 and $14,583)		9,167			10,417

Total assets	$	260,720		$	280,447

LIABILITIES AND STOCKHOLDERS’ DEFICIENCY

CURRENT LIABILITIES
Accounts payable	$	5,993		$	16,251
Accrued interest		46,189			42,589
Accrued officers’ compensation		293,000			263,000
Loans payable to related parties		260,000			260,000
Notes payable to third parties		243,437			243,437
Total current liabilities and total liabilities		848,618			825,277

STOCKHOLDERS’ (DEFICIENCY)
Preferred stock; 19,000,000 shares authorized, $.001 par value: Series A Convertible Preferred-issued and outstanding 9,111,998 and 9,111,998 shares, respectively		9,112			9,112
Common stock; 2,000,000,000 shares authorized, $.001 par value, as of March 31, 2023 and December 31, 2022, there are 732,638,436 shares outstanding, respectively		732,639			732,639
Additional paid-in capital		3,006,321			3,006,321
Accumulated deficit		(4,335,970	)		(4,292,902	)

Total stockholders’ (deficiency)		(587,898	)		(544,830	)
Total liabilities and stockholders’ (deficiency)	$	260,720		$	280,447

The accompanying notes are an integral part of these consolidated financial statements.

F-2

THE GREATER CANNABIS COMPANY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

Three Months Ended March 31, 2023 and 2022 (Unaudited)

	March 31, 2023			March 31, 2022
	(Unaudited)			(Unaudited)
Revenue:
Product sales	$	-		$	-
Consulting fees		-			-
Total revenue		-			-

Cost of product sales		-			-
Gross profit (loss)		-			-

Operating Expenses:
Officers compensation		30,000			30,000
Amortization of Right of First Refusal Agreement cost		1,250			1,250
Other operating expenses		8,218			11,180
Total operating expenses		39,468			42,430

Income (loss) from operations		(39,468	)		(42,430	)

Other income (expenses):
Interest expense		(3,600	)		(6,914	)
Amortization of debt discounts		-			(98,342	)
Total other income (expenses)		(3,600	)		(105,256	)

Income (loss) before provision for income taxes		(43,068	)		(147,686	)
Provision for income taxes		-			-

Net loss	$	(43,068	)	$	(147,686	)

Basic and diluted income (loss) per common share	$	(.00	)	$	(.00	)
Weighted average common shares outstanding-basic and diluted		732,638,436			508,638,436

The accompanying notes are an integral part of these consolidated financial statements.

F-3

THE GREATER CANNABIS COMPANY, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIENCY

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

For the three months ended	Shares		Amount		Shares		Amount		Capital		Deficit			Total
	Series A Preferred								Additional
	stock				Common Stock				Paid in		Accumulated
For the three months ended	Shares		Amount		Shares		Amount		Capital		Deficit			Total
March 31, 2022:
Balances at December 31, 2021		9,111,998	$	9,112		508,638,436	$	508,639	$	2,945,821	$	(3,932,634	)	$	(469,062	)

Net loss for the three months ended March 31, 2022				-				-		-		(147,686	)		(147,686	)
Balances at March 31, 2022		9,111,998	$	9,112		508,638,436	$	508,639	$	2,945,821	$	(4,080,320	)	$	(616,748	)

For the three months ended March 31, 2023:

Balances at December 31, 2022		9,111,998	$	9,112		732,638,436	$	732,639	$	3,006,321	$	(4,292,902	)	$	(544,830	)
Beginning balances, value		9,111,998	$	9,112		732,638,436	$	732,639	$	3,006,321	$	(4,292,902	)	$	(544,830	)

Net loss for the three months ended March 31, 2023				-				-		-		(43,068	)		(43,068	)
Net loss				-				-		-		(43,068	)		(43,068	)

Balances at March 31, 2023		9,111,998	$	9,112		732,638,436	$	732,639	$	3,006,321	$	(4,335,970	)	$	(587,898	)
Ending balances, value		9,111,998	$	9,112		732,638,436	$	732,639	$	3,006,321	$	(4,335,970	)	$	(587,898	)

The accompanying notes are an integral part of these financial statements.

F-4

THE GREATER CANNABIS COMPANY, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

Three Months Ended March 31, 2023 and 2022 (Unaudited)

	March 31, 2023			March 31, 2022
	(Unaudited)			(Unaudited)
OPERATING ACTIVITIES
Net income (loss)	$	(43,068	)	$	(147,686	)
Adjustments to reconcile net income (loss) to net cash provided (used) in operating activities:
Amortization of Right of First Refusal Agreement cost		1,250			1,250
Amortization of debt discounts		-			98,342
Changes in operating assets and liabilities:
Accounts payable		(10,259	)		1,250
Accrued interest		3,600			6,913
Accrued officers’ compensation		30,000			30,000
Net cash used in operating activities		(18,477	)		(9,931	)

INVESTING ACTIVITIES
Purchase of Right of First Refusal Agreement		-			-
Net cash used in investing activities		-			-

FINANCING ACTIVITIES
Proceeds from notes payable to third parties		-			-
Net cash provided by financing activities		-			-

NET INCREASE (DECREASE) IN CASH		(18,477	)		(9,931	)

CASH BALANCE, BEGINNING OF PERIOD		270,030			377,520

CASH BALANCE, END OF PERIOD	$	251,553		$	367,589

Supplemental Disclosures of Cash Flow Information:
Interest paid	$	-		$	-
Income tax paid	$	-		$	-

The accompanying notes are an integral part of these consolidated financial statements

F-5

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations

The Greater Cannabis Company, Inc. (the “Company”) was formed in March 2014 as a limited liability company under the name, The Greater Cannabis Company, LLC. The Company was a wholly owned subsidiary of Sylios Corp (“Sylios”) until March 10, 2017.

On July 31, 2018, the Company acquired 100% of the issued and outstanding shares of Class A common stock of Green C Corporation (“Green C”) in exchange for 9,411,998 newly issued shares of the Company’s Series A Convertible Preferred Stock (the “Exchange”). Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock. Since after the Exchange was consummated, the former shareholders of Green C and their designees owned approximately 94% of the issued and outstanding voting shares of the Company, Green C is the acquirer for accounting purposes. Prior to the Exchange, the Company had no assets and nominal business operations. Accordingly, the Exchange has been treated for accounting purposes as a recapitalization by the accounting acquirer, Green C, and the accompanying consolidated financial statements of the Company reflect the assets, liabilities and operations of Green C from its inception on December 21, 2017 to July 31, 2018 and combined with the Company thereafter.

Green C was incorporated on December 21, 2017 under the laws of the Province of Ontario Canada with its principal place of business in North York, Ontario.

Green C was the owner of an exclusive, worldwide license for an eluting transmucosal patch platform (“ETP”) for non-invasive drug delivery in the cannabis field as further described in the exclusive license agreement dated June 21, 2018 with Pharmedica Ltd. (see Note J).

After the consummation of the above-described transactions, the Company switched its business model in fiscal 2018 and no longer intended to pursue E-commerce, advertising, licensing (except as specified below) or direct investment operations. Instead, the Company is now engaged in the development and commercialization of innovative cannabinoid therapeutics.

From July 2018 through mid-2021, the Company focused on commercializing its own and licensed technologies worldwide for transmucosal and transdermal delivery of legal medical or recreational cannabis (other than in the field of oral care) and cannabinoids. The Company’s initial product was an oral transmucosal patch platform which for provides for loaded actives to be absorbed by the buccal mucosa into the body. Although the Company was able to launch the product and received some limited initial orders, the Company’s management ultimately elected to pursue other opportunities which they believed offered the Company greater potential for growth and ultimate profitability.

Principles of Consolidation

The consolidated financial statements include the accounts of The Greater Cannabis Company, Inc., and its wholly owned subsidiary Biocanrx, Inc. All intercompany balances and transactions have been eliminated in consolidation.

F-6

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Interim Financial Statements

The interim financial statements as of March 31, 2023 are unaudited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. These statements reflect all normal and recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the information contained herein. Operating results for the three months ended March 31, 2023 are not necessarily indicative of results that may be expected for the year ending December 31, 2023.

Certain information and finance disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the Securities and Exchange Commission’s rules and regulations. These unaudited financial statements should be read in conjunction with our audited financial statements and notes for the year ended December 31, 2022 as included in our report on Form 10-K.

Cash and Cash Equivalents

Investments having an original maturity of 90 days or less that are readily convertible into cash are considered to be cash equivalents. For the periods presented, the Company had no in cash equivalents.

Notes and Accounts Receivable

The Company maintains an allowance for doubtful accounts for estimated losses from the failure of its customers to make required payments for products and other consideration delivered. The Company estimates this allowance based on the age of the related receivable, knowledge of the financial condition of customers, review of historical receivables and reserve trends and other pertinent information. If the financial condition of customers deteriorates or an unfavorable trend in receivable collections is experienced in the future, additional allowances may be required. Historically, the Company’s reserves have approximated actual experience.

Income Taxes

In accordance with Accounting Standards Codification (ASC) 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The asset and liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.

We expect to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of March 31, 2023, we had no uncertain tax positions. We recognize interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. We currently have no foreign federal or state tax examinations nor have we had any foreign federal or state examinations since our inception. To date, we have not incurred any interest or tax penalties.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.

Financial Instruments and Fair Value of Financial Instruments

We follow ASC Topic 820, Fair Value Measurements and Disclosures, for assets and liabilities measured at fair value on a recurring basis. ASC Topic 820 establishes a common definition for fair value to be applied to existing US GAAP that requires the use of fair value measurements that establishes a framework for measuring fair value and expands disclosure about such fair value measurements.

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Topic 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

F-7

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Level 1:		Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level 2:		Observable market-based inputs or unobservable inputs that are corroborated by market data
Level 3:		Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. Except for derivative liabilities, we had no financial assets or liabilities carried and measured on a recurring or nonrecurring basis during the reporting periods.

Derivative Liabilities

We evaluate convertible notes payable, stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity.

The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date.

Long-lived Assets

Long-lived assets such as property and equipment and intangible assets are periodically reviewed for impairment. We test for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.

F-8

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Equity Instruments Issued to Non-Employees for Acquiring Goods or Services

Issuances of our common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete.

Although situations may arise in which counter performance may be required over a period of time, the equity award granted to the party performing the service may be fully vested and non-forfeitable on the date of the agreement. As a result, in this situation in which vesting periods do not exist if the instruments are fully vested on the date of agreement, we determine such date to be the measurement date and will record the estimated fair market value of the instruments granted as a prepaid expense and amortize such amount to expense over the contract period. When it is appropriate for us to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values.

Related Parties

A party is considered to be related to us if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with us. Related parties also include our principal owners, our management, members of the immediate families of our principal owners and our management and other parties with which we may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties, or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests, is also a related party.

F-9

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Revenue Recognition

Revenue recognition:

The Company adopted Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) on January 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services, in accordance with the following five-step process:

	●	Identify the contract(s) with a customer
	●	Identify the performance obligations
	●	Determine the transaction price
	●	Allocate the transaction price
	●	Recognize revenue when the performance obligations are met

During the periods presented, all revenue was from sales of cannabis products. The Company has determined the sole performance obligation to be the delivery of the purchased goods to the customers, and as such, recognizes revenue at the time the customer takes possession.

Advertising Costs

Advertising costs are expensed as incurred. For the periods presented, we had no advertising costs.

Loss per Share

We compute net loss per share in accordance with FASB ASC 260. The ASC specifies the computation, presentation and disclosure requirements for loss per share for entities with publicly held common stock.

Basic loss per share amounts is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options, warrants and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net loss per share are excluded from the calculation. For the periods presented, the Company excluded 470,599,900 shares relating to the Series A Convertible Preferred Stock (see Note H), shares relating to convertible notes payable to third parties (Please see NOTE E - NOTES PAYABLE TO THIRD PARTIES for further information) and shares relating to outstanding warrants (Please see NOTE G - CAPITAL STOCK AND WARRANTS for further information) from the calculation of diluted shares outstanding as the effect of their inclusion would be anti-dilutive.

F-10

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023and 2022

(Unaudited)

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Recently Enacted Accounting Standards

In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting models for convertible debt instruments and convertible preferred stock. As well as amend the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related EPS guidance. This standard is effective for us on July 1, 2024, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. We are currently evaluating the impact of the adoption of ASU 2020-06 on our financial statements.

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). Financial Instruments—Credit Losses (Topic 326) amends guideline on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available-for-sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. ASU 2016-13 affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this ASU will be effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We are currently evaluating the impact of the adoption of ASU 2016-13 on our financial statements.

Other standards not presented are not deemed to be material.

F-11

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

NOTE B - GOING CONCERN

Under ASC 205-40, we have the responsibility to evaluate whether conditions and/or events raise substantial doubt about our ability to meet our future obligations as they become due within one year after the date the financial statements are issued. As required by this standard, our evaluation shall initially not take into consideration the potential mitigating effects of our plans that have not been fully implemented as of the date the financial statements are issued.

In performing the first step of this assessment, we concluded that the following conditions raise substantial doubt about our ability to meet our financial obligations as they become due. As of March 31, 2023, the Company had cash of $251,553, total current liabilities of $848,618, and negative working capital of $597,065. For the three months ended March 31, 2023, we incurred a net loss of $43,068 and used $18,477 cash from operating activities. We expect to continue to incur negative cash flows until such time as our business generates sufficient cash inflows to finance our operations and debt service requirements.

In performing the second step of this assessment, we are required to evaluate whether our plans to mitigate the conditions above alleviate the substantial doubt about our ability to meet our obligations as they become due within one year after the date that the financial statements are issued. Our future plans include securing additional funding sources.

There is no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available through external sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material effect on the business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company’s existing shareholders. We have therefore concluded there is substantial doubt about our ability to continue as a going concern through March 2024.

The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of the uncertainty related to our ability to continue as a going concern.

F-12

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

NOTE C – RIGHT OF FIRST REFUSAL AGREEMENT

On January 30, 2020, the Company executed a Right of First Refusal Agreement with an entity engaged in the business of cosmetics, health, and well-being. The Agreement provided for the Company to pay Kol Tuv Ventures, LLC (“KTV”), $25,000 on January 30, 2020 (which was paid January 30,2020) and to make other investments in opportunities to be pursued by KTV and/or payments to KTV to enable KTV to pursue and secure Cannabidiol (“CBD”) opportunities. The Agreement provides the Company an exclusive right of first refusal to participate in all CBD opportunities to be pursued by KTV for a term of five years. The $25,000 cost for this Agreement is being amortized over the five year term of the Agreement.

NOTE D - LOANS PAYABLE TO RELATED PARTIES

Loans payable to related parties consist of:

	March 31, 2023		December 31, 2022

Loans from Elisha Kalfa and Yonah Kalfa, holders of a total of 2,966,666 shares of Series A Convertible Preferred stock	$	180,000	$	180,000

Loan from Fernando Bisker and Sigalush, LLC, holders of a total of 2,966,666 shares of Series A Convertible Preferred stock		80,000		80,000

Total	$	260,000	$	260,000

Pursuant to loan and contribution agreements dated July 31, 2018, the above loans are non-interest bearing and are to be repaid after the Company raises from investors no less than $1,500,000 or generates sufficient revenue to make repayments (each, a “Replacement Event”). If the First Replacement Event does not occur within 18 months from July 31, 2018, the loans are to be repaid immediately. In the event there is insufficient capital to repay the loans, the lenders have the option to convert all or part of the loans into shares at the Company common stock at the average trading price of the 10 days prior to the date of the conversion request.

F-13

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

NOTE E - NOTES PAYABLE TO THIRD PARTIES

Notes payable to third parties consist of:

	March 31, 2023		December 31, 2022

Promissory Note dated March 28, 2017 payable to John T. Root, Jr., interest at 4%, due September 28, 2017, convertible into shares of common stock at a conversion price of $.001 per share.	$	375	$	375
Convertible Promissory Note dated March 15, 2021 payable to FirstFire Global Opportunities Fund, LLC (“FF”), interest at 6%, due March 11, 2022-less unamortized debt discount of $0 and $0, respectively. ⁽ⁱ⁾		243,062		243,062
Total	$	243,437	$	243,437

(i) On March 15, 2021, we issued a 6% Convertible Promissory Note to FirstFire Global Opportunities Fund, LLC (“FF”), having a principal amount of $545,000 and an initial tranche principal amount of $272,500 of which $22,500 constituted an original issue discount (the “FF Note”). In connection with the FF Note, we and FF entered into a registration rights agreement, three warrant agreements and a securities purchase agreement. On June 30, 2021, we issued the final tranche principle amount of $272,500 of which $22,500 constituted an original issue discount (the “FF Note). The FF Note had an original maturity date of March 11, 2022, which was extended to April 30, 2023 by agreement between the parties dated May 1, 2022, which agreement also waiver certain defaults under the FF Note will mature on.

On June 1, 2022, the Company issued 25,000,000 shares for the conversion of $25,000 principal on the FirstFire note dated March 5, 2021 at a conversion price of $.001.

During the three months ended September 30, 2022, the Company issued 135,000,000 shares for the conversion of $135,000 principal on the FirstFire note dated March 5, 2021 at a conversion price of $.001.

During the three months ended December 31, 2022, the Company issued 64,000,000 shares for the conversion of $64,000 principal on the FirstFire note dated March 5, 2021 at a conversion price of $.001.

The FF Note may be pre-paid in whole or in part by paying FF the following premiums:

PREPAY DATE		PREPAY AMOUNT
≤ 30 days		105% * (Principal + Interest (“P+I”)
31- 60 days		110% * (P+I)
61-90 days		115% * (P+I)
91-120 days		120% * (P+I)
121-150 days		125% * (P+I)
151-180 days		130% * (P+I)

F-14

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

Any amount of principal or interest on the FF Note, which is not paid when due shall bear interest at the rate of twenty-four (24%) per annum from the due date thereof until the same is paid (“Default Interest”). FF has the right beginning on the date which is the earlier of (i) the date the Registration Statement (as defined below) covering the shares issuable upon conversion of the FFG Notes is declared effective by the Securities and Exchange Commission (the “SEC”) or (ii) one hundred eighty (180) days following the Issue Date to convert all or any part of the outstanding and unpaid principal amount of the FF Note into fully paid and non-assessable shares of our common stock at the conversion price (the “Conversion Price”). The Conversion Price shall be, equal to 70% of the average closing price of our common stock for the five prior trading days prior to the date that a registration statement in respect of the shares into which is the FF Note is convertible is declared effective. The FF Note contains other customary terms found in like instruments for conversion price adjustments. In the case of an Event of Default (as defined in the Note), the FF Note shall become immediately due and payable in an amount (the “Default Amount”) equal to the principal amount then outstanding plus accrued interest (including any Default Interest) through the date of full repayment multiplied by one hundred twenty-five percent (125%) and interest shall accrue at the rate of Default Interest. Certain events of default will result in further penalties. Default obligations have been waived.

Copies of Warrant A, Warrant B and Warrant C are attached as Exhibits 10.4, 10.5 and 10.6 to our current report on Form 8-K dated March 16, 2021.

The valuation of the above warrants issued and recorded during the three months ended June 30, 2021 was $262,429.

See NOTE -G WARRANTS

NOTE F - DERIVATIVE LIABILITY

The derivative liability consists of:

SCHEDULE OF DERIVATIVE LIABILITY

March 31,

2023

December 31,

2022

Convertible Promissory Note dated March 15, 2021 and June 30, 2021 payable to FirstFire Global Opportunities Fund, LLC, See Note E (i) Due March 11, 2022

Total derivative liability

The Convertible Promissory Notes (the “Notes”) contain a variable conversion feature based on the future trading price of the Company’s common stock. Therefore, the number of shares of common stock issuable upon conversion of the Notes is indeterminate.

The fair value of the derivative liability is measured at the respective issuance dates and quarterly thereafter using the Black Scholes option pricing model. Assumptions used for the calculation of the derivative liability of the Notes at December 31, 2020 were (1) stock price of $.003 per share, (2) conversion price of $.00169 per share, (3) term of 0 days, (4) expected volatility of 142.94%, and (5) risk free interest rate of 0%. Assumptions used for the calculation of the derivative liability of the Notes at March 31, 2021 were (1) stock price of $.0011 per share, (2) conversion price of $.0071 per share, (3) term of 345 days, (4) expected volatility of 142.94%, and (5) risk free interest rate of .07%. As of June 30, 2021, the note no longer carries variable conversion features and as such, the derivative was reduced to zero.

(i)As discussed in Note A above, warrants with “down round” features (and do not contain variable conversion features) are not subject to derivative liability treatment effective January 1, 2019.

F-15

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023nd 2022

(Unaudited)

NOTE G - CAPITAL STOCK AND WARRANTS

Preferred Stock

On July 31, 2018, The Greater Cannabis Company, Inc. (the “Company”) acquired 100% of the issued and outstanding shares of Class A common stock of Green C Corporation (“Green C”) in exchange for 9,411,998 newly issued shares of the Company’s Series A Convertible Preferred Stock (the Exchange”). Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to 50 votes on all matters as a class with the holders of common stock.

On February 14, 2019, the Company issued 9,000,000 shares of Series B Convertible Preferred Stock to Emet Capital Partners, LLC (“Emet”) in exchange for the surrender of all outstanding warrants held by Emet. Each share of Series B Convertible Preferred Stock was convertible into one share of Company common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company common stock was less than $0.075 per share. On October 18, 2019, this exchange agreement was reversed. (See Note E)

On September 21, 2021, 300,000 shares of Series A Preferred Shares were converted into 15,000,000 shares of common stock.

Common Stock

Effective March 10, 2017, in connection with a partial spin-off of the Company from Sylios Corp, the Company issued a total of 26,905,969 shares of its common stock. 5,378,476 shares were issued to Sylios Corp (representing 19.99% of the issued and outstanding shares of Company common stock after the spin-off) and 21,527,493 shares were issued to the stockholders of record of Sylios Corp on February 3, 2017 on the basis of one share of Company common stock for each 500 shares of Sylios Corp common stock held (representing 80.01% of the issued and outstanding shares of Company common stock after the spin-off).

On January 4, 2019, the Company issued 769,785 shares of its common stock pursuant to a conversion of $670 principal and $100 accrued interest of its convertible note dated May 25, 2018 by Emet Capital Partners, LLC (“Emet”). This conversion was based on a conversion price of $0.001 per share (rather than the Variable Conversion Price provided in the related note) submitted by Emet in its Conversion Notice. Emet asserted that the Company had committed a dilutive issuance, which triggered the “ratchet-down” provision of the related note which provides for a reduction of the conversion price. The $99,302 excess of the $100,072 fair value of the 769,785 shares over the $770 liability reduction was charged to Loss on Conversion of Debt in the three months ended March 31, 2019.

On January 4, 2019, the Company issued 695,129 shares of its common stock pursuant to an exercise of the equivalent of 1,400 warrants (of the 440,000 warrants issued to Emet Capital Partners, LLC on May 25, 2017) in a cashless exercise transaction based on a ratchet-down exercise price of $0.001 per share.

On April 16, 2019, the Company issued 1,384,600 shares of its common stock pursuant to conversions of $40,500 principal and $7,961 accrued interest of two convertible notes issued to by Emet Capital Partners, LLC (“Emet”). The $131,537 excess of the $179,998 fair value of the 1,384,600 shares over the $47,961 liability reduction was charged to Loss on Conversion of Debt in the three months ended June 30, 2019.

On May 29, 2019, the Company issued a total of 542,000 shares of its common stock to two consulting firm entities for certain specified investor relations and advisory services. The $75,880 fair value of the 542,000 shares was charged to Other Operating Expenses in the three months ended June 30, 2019.

F-16

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

On August 15, 2019, the Company issued 175,000 shares of its common stock to an entity consultant for accounting services rendered. The $12,250 fair value of the 175,000 shares was charged to Other Operating Expenses.

On October 18, 2019, the Company entered into two Exchange Agreements with Emet Capital Partners, LLC (“Emet”). The first Exchange Agreement provided for the exchange of three outstanding convertible notes payable to Emet with a total remaining principal balance of $20,399 and a total accrued interest balance of $5,189 for three new convertible notes payable to Emet in the total amount of $25,587. The new notes bear interest at 6%, are due on February 12, 2020 and are convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. The second Exchange Agreement provided for the reversal of the February 14, 2019 exchange agreement pursuant to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock (see Note G) and the exchange of such warrants for four new convertible notes payable to Emet in the total amount of $675,000. These new note bear interest at 2%, are due on October 18, 2020 and are convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date.

On November 11, 2019, the Company issued 1,748,363 shares of its common stock pursuant to a conversion of $53,705 principal and $2,680 accrued interest and fees of its convertible note dated October 18, 2019 by Emet.

On December 20, 2019, the Company issued 1,468,204 shares of its common stock pursuant to a conversion of $29,000 principal and $4,015 accrued interest and fees of its convertible note dated October 18, 2019 by Emet.

On December 24, 2019, the Company issued 637,273 shares of its common stock pursuant to a conversion of $10,000 principal and $515 accrued interest and fees of its convertible note dated October 18, 2019 by Emet.

During the three months ended March 31, 2020, the Company issued a total of 21,484,688 shares of common stock pursuant to conversions of an aggregate of $165,350 in principal and $11,793 in interest under our outstanding convertible notes. The $228,949 excess of the $406,093 fair value of the 21,484,688 shares of common stock at the respective dates of issuance over the $177,143 liability reduction was charged to Loss on Conversions of Notes Payable.

During the three months ended June 30, 2020, the Company issued a total of 27,563,525 shares of common stock pursuant to conversions of an aggregate of $67,082 in principal and $10,613 in interest under our outstanding convertible notes. The $132,838 excess of the $210,532 fair value of the 27,563,525 shares of common stock at the respective dates of issuance over the $77,695 liability reduction was charged to Loss on Conversions of Notes Payable.

During the three months ended September 30, 2020, the Company issued a total of 115,277,834 shares of common stock pursuant to conversions of an aggregate of $311,050 in principal and $18,462 in interest under our outstanding convertible notes. The $467,554 excess of the $797,067 fair value of the 115,277,834 shares of common stock at the respective dates of issuance over the $329,512 liability reduction was charged to Loss on Conversions of Notes Payable.

During the three months ended December 31, 2020, the Company issued a total of 261,215,948 shares of common stock pursuant to conversions of an aggregate of $325,212 in principal and $16,849 in interest under our outstanding convertible notes. The $462,263 excess of the $804,324 fair value of the 261,215,948 shares of common stock at the respective dates of issuance over the $342,061 liability reduction was charged to Loss on Conversions of Notes Payable.

During the three months ended March 31, 2021, the Company recorded the conversion of note payable ($22,500) and accrued interest ($814) into 13,795,118 shares of common stock (Fair Value of $45,525).

During the three months ended June 30, 2021, the Company recorded the value of the warrants at $262,429 and the conversion of the second FirstFire note tranche in the amount of $39,000.

On July 15, 2021, the Company issued 10,000,000 shares for the conversion of $52,080 principal on the FirstFire note dated March 5, 2021 at a conversion price of $.005208.

F-17

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

Warrants

On March 11, 2021, in connection with the issuance of a Convertible Promissory Note to FirstFire Global Opportunities Fund, LLC (“FF”) (see Note F), we issued three warrants (Warrant A, Warrant B and Warrant C) to purchase shares of our common stock, as follows:

Warrant A permits FF to purchase 25,000,000 shares of common stock at an exercise price of $0.025 per share through September 11, 2022.

Warrant B permits FF to purchase 15,000,000 shares of common stock at an exercise price of $0.05 per share through September 11, 2022.

Warrant C permits FF to purchase 10,000,000 shares of common stock at an exercise price of $0.075 per share. through September 11, 2022.

Each warrant has other customary terms found in like instruments, including, but not limited to, events of default.

In any event of default, the exercise price for each warrant automatically becomes $0.005 per share.

Copies of Warrant A, Warrant B and Warrant C are attached as Exhibits 10.4, 10.5 and 10.6 to our current report on Form 8-K dated March 16, 2021 and the above summary of the warrant terms are subject to full terms of the applicable warrants.

The valuation of the above warrants issued and recorded during the three months ended June 30, 2021 was $262,429.

NOTE H - INCOME TAXES

The Company and its United States subsidiaries file consolidated Federal income tax returns. Green C Corporation, its Ontario Canada subsidiary, files Canada and Ontario income tax returns.

At March 31, 2023 the Company has available for federal income tax purposes a net operating loss carry forward that may be used to offset future taxable income. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company, it is not more likely than not that the benefits will be realized. If there are significant changes in the Company’s ownership, the future use of its existing net operating losses will be limited.

All tax years of the Company and its United States subsidiaries remain subject to examination by the Internal Revenue Service.

F-18

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

NOTE I - COMMITMENTS AND CONTINGENCIES

Pharmedica Exclusive License Agreement

On June 21, 2018, Green C executed an Exclusive License Agreement with Pharmedica, Ltd. (“Pharmedica”), an Israeli company, to exploit certain Pharmedica intellectual property for the development and distribution of a certain Licensed Product involved in the transmucosal delivery of medicinal or recreational cannabis. The agreement provides for Green C payments to Pharmedica of a $100,000 license fee (which was paid by 2591028 Ontario Limited, an entity affiliated with Green C’s Chief Executive Officer, on June 26, 2018) and annual royalties at a rate of 5% of the Net Sales of the Licensed Product subject to a Minimum Annual Royalty of $50,000. The agreement also provides for certain milestones to be accomplished by Green C in order for Green C to retain the license. Green C and Pharmedica each may terminate the agreement upon the occurrence of a material breach by the other party of its obligations under the agreement and such other party’s failure to remedy such breach to the reasonable satisfaction of the other party within thirty (30) days after being requested in writing to do so.

The Company generated only minimal revenues from this asset through December 31, 2019 and did not pay the Year 1 Minimum Annual Royalty of $50,000 due Pharmedica. Accordingly, we recorded an impairment charge of $69,749 at December 31, 2019 and reduced the $69,749 remaining carrying value of this intangible asset to $0.

On September 2, 2020, Green C notified Pharmedica of Green C’s termination of the Exclusive License Agreement and Green C’s intention to wind up Green C.

On September 17, 2020, Pharmedica notified Green C of Pharmedica’s acceptance of Green C’s proposal to terminate the license agreement and Pharmedica’s intention not to burden Green C further. Accordingly, we recorded “Forgiveness of Royalty Payable” other income of $50,000 in the three months ended September 30, 2020 and reduced the $50,000 “Accrued Royalties” liability balance to $0.

Sub-License Agreement with Symtomax Unipessoal Lda

On July 15, 2019, the Company executed a Sub-License Agreement with Symtomax Unipessoal Lda (“Symtomax”).

The agreement provides for the Company’s grant to Symtomax of a non-exclusive right and sub-license to use certain Company technology and intellectual property to develop and commercialize products for sale in Europe, the Middle East, and Africa. The agreement provides for Symtomax payments of royalties to the Company (payable monthly) ranging from 10% to 17% of Symtomax sales of eluting patches developed from Company technology.

On May 27, 2020, the Company executed an amended and restated sub-license agreement with Symtomax (the “Amended License Agreement”). The term of the Amended License Agreement ends the earlier of (i) August 31, 2021 and (ii) the date that Symtomax is no longer commercializing any of the products. The term is extended for an additional year on each anniversary of the agreement for any country where the royalty payment in respect of such country was equal to or greater than $1,000,000 for the previous year.

To date, Symtomax has not made any sales requiring the payment of royalties to the Company.

Agreements

On July 31, 2018, the Company executed Services Agreements with its newly appointed Chief Executive Officer (the “CEO”), for terms of five years. The Agreement provides for a monthly base salary of $10,000 for the CEO. For the three months years ended March 31, 2023 and 2022 the Company expensed a total of $30,000, respectively.

NOTE J – SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date the financial statements were available to be issued. The Company had no subsequent events that require disclosure.

F-19

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Company Overview

From July 2018 through mid-2021, Greater Cannabis focused on commercializing its own and licensed technologies worldwide for transmucosal and transdermal delivery of legal medical or recreational cannabis (other than in the field of oral care) and cannabinoids (“CBD”) (. While part of the cannabis family, CBD, which contains less than 0.3% tetrahydrocannabinol (“THC”), the psychoactive compound that produces the “high” in marijuana, is distinguished from cannabis by its use, physical appearance and lower THC concentration (cannabis generally has a THC level of 10% or more). The Company’s initial product was an oral transmucosal patch platform which for provides for loaded actives to be absorbed by the buccal mucosa into the body. Although the Company was able to launch the product and received some limited initial orders, Greater Cannabis management ultimately elected to pursue other opportunities which they believed offered the Company greater potential for growth and ultimate profitability.

Accordingly, on October 19, 2021 the Company entered into a license agreement with Shaare Zedek Scientific Ltd. (“SZS”), the technology transfer arm of Jerusalem’s Shaare Zedek Medical Center (SZMC). The license agreement covers the license of SZS’s novel cannabinoid therapeutic focused on treatment of autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease and other neuropsychiatric disorders. Shaare Zedek Medical Center, founded in 1901, is one of the largest multidisciplinary research hospitals in Israel with 1,000 beds and over 850,000 patient visits a year. The SZMC Center for Research and Development has over 300 annual publications of investigator initiated studies in medical journals in addition to almost 160 clinical trials.

Accompanying the license agreement is a joint research and development agreement, which will focus on continuing the clinical program spearheaded by Dr. Adi Aran, M.D. Director of Pediatric Neurology at SZMC, Board Member of the Israeli Society for Pediatric Neurology, and co-inventor of the novel cannabinoid therapy. Dr. Aran is a world renowned expert in cannabis research and pediatric neurology and was the principal investigator of the first ever cannabis research study conducted on autistic children.

Dr. Aran’s pioneering study assessed safety, tolerability and efficacy of CBD based medical cannabis as an adjuvant therapy for refractory behavioral problems in children with ASD. The results provided very compelling evidence that medical cannabis is an effective therapy for children on the autism spectrum. Conditions in 80% of the children improved, with 62% of parents reporting substantial improvements. Half of the children had improved communication and 40% reported a decrease in anxiety. The same children had not shown improvement with conventional drug therapies. Dr. Aran and his team have now developed a novel combination therapy that is believed to be significantly more effective than the cannabis-only formulation that had been used in the aforementioned study. The Company plans to further develop this therapeutic and conduct clinical studies to further substantiate its safety and efficacy beginning in neuropsychiatric disorders.

The clinical studies of the therapeutic are expected to require an investment of up to $1,000,000 and up to two years to finalize.

The Company’s current business plan is to (i) conduct clinical studies on and commercialize the cannabinoid-based therapeutic and (ii) concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing agreements or acquisitions.

Results of operations

The Company had no revenue during each of the three months ended March 31, 2023 and 2022.

Our operating expenses in the three months ended March 31, 2023 decreased to $39,468, from $42,430 for the same period of 2022. Major operating expenses include officers compensation of $30,000, amortization expense, professional fees and research and development costs.

Other income and (expenses) was $(3,600) for the three months ended March 31, 2023, as compared to $(105,256) for the same quarter in 2022. The decrease is mainly due from the amortization of debt discounts from $ 98,342 to $0 for the three months ended March 31, 2023.

Our net loss for the three months ended March 31, 2023, was $42,068 as compared to the net loss of $147,868 during the same quarter in 2022.

Liquidity and Capital Resources

We had $251,553 cash at March 31, 2023, compared to $270,030 cash at December 31, 2022.

At March 31, 2023, we had $243,437 in principal amount of outstanding notes to third parties compared to $243,437 at December 31, 2022.

The following table provides detailed information about our net cash flows for the three months ended March 31, 2023 and 2022.

	March 31, 2023			March 31, 2022
Net cash used in operating activities	$	(18,477	)	$	(9,931	)
Net cash used in investing activities		-			-
Net cash provided by financing activities		-			-
Net decrease in cash	$	(18,477	)		(9,931	)

Critical Accounting Policies and Estimates

The SEC issued Financial Reporting Release No. 60, “Cautionary Advice Regarding Disclosure About Critical Accounting Policies” suggesting that companies provide additional disclosure and commentary on their most critical accounting policies. In Financial Reporting Release No. 60, the SEC has defined the most critical accounting policies as the ones that are most important to the portrayal of a company’s financial condition and operating results and require management to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition, we have identified the following significant policies as critical to the understanding of our financial statements. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make a variety of estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and (ii) the reported amounts of revenues and expenses during the reporting periods covered by the financial statements. Our management expects to make judgments and estimates about the effect of matters that are inherently uncertain. As the number of variables and assumptions affecting the future resolution of the uncertainties increase, these judgments become even more subjective and complex. Although we believe that our estimates and assumptions are reasonable, actual results may differ significantly from these estimates. Changes in estimates and assumptions based upon actual results may have a material impact on our results.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a “smaller reporting company,” we are not required to provide this information.

ITEM 4. CONTROLS AND PROCEDURES

Management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Rules 13a-15(f) under the Exchange Act, internal control over financial reporting is a process designed by, or under the supervision of, Aitan Zacharin, the Company’s Chief Executive Officer and Chief Financial Officer (principal executive, financial and accounting officer), and effected by the Company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.

The Company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records, that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company’s assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of the Company’s management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Our chief executive officer and acting chief financial officer (principal executive, financial and accounting officer, assessed the effectiveness of our internal control over financial reporting at March 21, 2022, 2021. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control—Integrated Framework (2013). Based on that assessment under those criteria, management has determined that, as of March 31, 2022, our internal controls over financial reporting was not effective for the reasons set forth in our Annual Report on Form 10-K for the year ended December 31, 2021.

As set forth in that Report the Company intends to take various remedial measures described therein as its capital resources permit.

Changes in Internal Controls

During the quarter ended March 31, 2023, there was no change in internal control over financial reporting that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

PART II- OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 1A. RISK FACTORS

As a “smaller reporting company” as defined in Rule 12b-2 under the Exchange Act, disclosure of this Item is not required.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit No.		Description
31.1		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13(a)-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended (filed herewith).
32.1		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	THE GREATER CANNABIS COMPANY, INC.

May 12, 2023	/s/ Aitan Zacharin
	Chief Executive Officer
	(Principal executive, financial and accounting officer).

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13(a)-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Aitan Zacharin, Chief Executive Officer and Chief Financial Officer of The Greater Cannabis Company, Inc., certify that:

	1.	I have reviewed this Form 10-Q for the quarter ended March 31, 2023 of The Greater Cannabis Company, Inc.;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	THE GREATER CANNABIS COMPANY, INC.

May 12, 2023	/s/ Aitan Zacharin
	Chief Executive Officer and Chief Financial Officer (Principal executive, financial and accounting officer)

EX-32.1 3 ex32-1.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of The Greater Cannabis Company, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Aitan Zacharin, Chief Executive Officer and Chief Financial Officer of The Greater Cannabis Company, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

	THE GREATER CANNABIS COMPANY, INC.

May 12, 2023	/s/ Aitan Zacharin
	Chief Executive Officer and Chief Financial Officer (Principal executive, financial and accounting officer)

GRAPHIC 4 form10-q_001.jpg begin 644 form10-q_001.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ I, MT'I5>XGBMX7EE;8BC+$GI0)M)78]Y%126( '4GC%M4#>W;'+73%5M?>91M]8U"V;,=Y+]';>/UK;L?&DB,JWD 9>[Q<$?@?\:R+ MGP]JEJ,O:,R^J$-_*LU@5.""#Z'@_E4NG1J[%QKXG#/6Z]3UBTO[>^A66WD# MH1V[59W<5Y-8ZAZYX;V->C:3JT&JVJS1D!A]]/[IK@KX>5+5:H M]_ YC#$>[+278TB<5C:MXDL]-/EDF2;_ )YIV^I[5D^)?$9B)LK&3$G_ "TD M7^'V!]:XYF+,6))8]3W/UJZ&$Y_>D1O11FM6+PIJT@!,"QY_ON/Z5V6HPT> MAY7^U5]=69\>I7L+!H[R<$=/WA(_(UKVGC#4(2!.L%]5B7<(%D M'^PXK*F@EMY#'-&T;_W7&*.6C4VU$I8K#ZZH]'TK7K+5/EC8I,.L;=?_ *]: M^[V->/I(\;AXV*,IR&'4?2NW\-Z_]N46EW)_I*_=;.-X_P :XZ^%<%S1V/9P M.9JLU3J?$:M_KEM8S"W*R37!Y$42[FQZU!!XCA:Z2WN+:XMG?[AE3 ;\:M7, MUG8YN9_+C+<;R/F;V]363<12Z[<5SQ46M4=E2PKL[J5;>VEF8_*B%C^ KR>69IYGF1R['W-=F#I\TFWT/&S?$.G34(O5C M.I]^O3O77Z!X84B.[O@&)^9(CSCW-9GA?2EU"_,LF3%;X;![MSBO154 <=JU MQE=Q?)$YPIPHKSCZ)*R&%,#@"L36?#T&IQEU C MN!]UU'7Z^M;M':JC)Q=T9U:,*L>6:NCS2S\-:AAZG^?Z5UTYR MKS2ELCQL30I8.DY0^)Z)]C%).#W]?>MG0] EU63S';9;(<%N[?2LVUMGO+N* MW09:1@!_C7J5C9QV5K'!&H"J,<5T8FM[./*MSCRW!K$3YY[(2ULH+&$1P1JB M#^Z.OUITEW;PMB2:-#Z,0*SO$>JG2-&FN%YDX5 1W/'_ ->O+;*"\U^\N&EE M:65(F?"#GJS[?!9_6"!#*DGW']O0^E=%HOAB.Q(GN<2S#[J_PI_B?>NEQTZ4N.E7/$ MSE'E/&I9;1I5/:+4.5AVQ':JCICW]ZV+;6WGN$C_ ++O M8PYQO>/ 7Z\ULE!Z?E2JN#WJ'-/H;PHSB_B_ /PKTWQ)'OT"\'HF[\CFO,L]SU_S_A7IX'X6 M?,YU_%2\OU.[\%1A=*>3^*24Y_ "NH'2N8\%2A])>/CU@+?5X6[#N:6BBLCL$HIK,%&2<"J\5Y;S?ZJ5'_ -TYIV)!7E& MI.9-2O'_ +TS_P S7JS-NC->4ZBABU.[1AC;,X'OR:[,$TI.YXF=7=.+6QK> M$(@^N;CUCC9E_' _K7H)( KS[PA((]BDNYD:XEEK4!T^9G"LX.]>BL.E8_AC0IM'U>^2=D=3$/+ M^TOU QR..HKP<)FTYI\]K?B? M32E.C!TX_"SE=#\.V]O;2:WJ2$P1,6@A!^]@X!/U.*[;1]C/$WDK;'@8[-ISKKF=UM8]:4AL'%.IB$X!]:DK8[$-(- %.HIC$I:** "BB MB@ HHHH JW<*W-K+"WW9$*GZ$5Y-+$T4KQ/PR-M;V(ZU[ V *X7Q;I/DS?;H M4^1SB4#LWK^-=F#J;ZGT*=UWK7 MK-Y;0WELT$Z!XVQES8]'.[^>:D;7KF1/])@M;@GJ9(1G],5ET5Z#I0L]#POK55. MW,S=MKRUCM)-0BLDAGMY$"LLC$'.<\'V!KN89(M2TY70@QRIFO.I?W7A^!>, MS7+/]0JX_P :L:%KTFER>5+E[5CRO=?<5PXC"^U@[:[_ ''K8/'JA449Z72^ M\WI]/N+9ROELR]%8#.:6/2)KR-P_[L;< NN>:W[6\M[N,2P2K(AYR#5GC&17 MS"R>$:CE)Z=CZAXQU*=EUZGE5SHVIVD[1O:S'' =%+!JU_#OAN>6ZCN[Q&B2 M-@51A\S$>M=Z0#Z53O-0M=/C,D\RQKZ9Y/TKTH8=)+VYOO-MYGAA3_5H.,CU([UK:1XNW[(+Z-C)G:)(QU^HKOGA: MD8\Q=/,J,ZGL[V.UHIBG.T^M/KG/3"BBB@ HHHH **** $;ITJMCS$TGHSS76]#ETJX9HPSV['Y'QG;[&L?&>,>Y&:]=:%9$ M*NH8'J".#7,:GX-BF8R64GE,>?*;[OX>E>A1Q:VF?.XS*IJ3G1U\CEK+5K_3 MTVV]PRKG.P\C\C6FOC#5 N"L!/J4/^-4[CP]JMNV&M6?WC^;/]:JG3+\'!L; MD'_KDW^%=#C1EKH<2EC*7NJY=NO$NJW2[3<>6IZB-0/_ *]9!)+$DG).>O>M M"+1-4F;:EC,#_M+M_G6O8^#;EV4WLRQIW1.6-'M*-)7T&J&+Q,E=/U9S(5F5 MF )5<9([9I*[;Q!I8M](2WTZV8@R#<(UR2 #U]><5R M)UN$B>*2-V8 !E([ MT4Z\9QN:CB^5\LMCU,5E;G'FIO6RT//[6\ MN+*7S+>9HF(P2O?Z^M;$7B[58EPQAD]W3_ TRZ\*ZI;G*1K,OK&W^-9[Z5J* M,0UC<_A&2/TKK?L*FNAYL5BZ.BNC1F\6:K*,*\46>Z)_B:R+BYFNI?,GE>1_ M[S-_G%3II.HR$!;&XS[QD?SK2M?">I3D&4) OJYR?P H3H4M583CB\1[K39A M*K.X5068\ #DFNV\-^'OLN+VZ3]^1\J'^#_Z]:6E^'K33%5E423=3(XY_#TK M8 [<5PXC%.:Y8['KX'+%2:G4W%4=,T^D[TM<9[04444 %%%% "$XI-WL:HW" MS&>$I*ST\Y[ MMSYLX16QMPFWIGZ]Z?<-(S+$DC1E@3N3&>.PSD=Z+ I)JY=S1UK)DFE98@LL MP&URQ55).T@!WP/TI2@]* MSI[F2*50IZ2M<1XN955@3M 0@XQZKF@+I]"]CVI,6&^[\FS^6[]:9:32F:-6>5MZ;SO50,8[%?:[PO(%6)7 7!SNZYY_*E8&T:97V MQ0!5&:65Q(D)P<*01C/).<9X[5-;LSP89F9E."7 R?KCBBPTTRSQ2YYX%9\< MDGEF?SV<%,B+ P./IG\S38GD$L1\\2+)_".B\9R._P"?K18.=(TMU&[VK+6Y MN/*CW##;DW/C@J2.![\TEF]Q(Y_3MG\Z+>XF9+9)6'F. 20.&&W/X46#G-+-%4+=I7F M(%)!AT5A[CI4E% N5$ A1?NHJCV Z=Q2FVC;;NC0[!\O'2IJ* MY41K$J@X51GK3B@R#@<=/:G44#Y40BWB$A<1H'/\6.33A$HVX4#;TQVJ2B@. M5$+P1R??1&QQR,TY8E4?*JKZX%244!RHB\E>/E4\;>?2E\E-NT*,8VXQV]*D MHH%RHA6%5Z!>@' ]*:;6$]88S@ ]2T4!RHB\I0!A5^7[HQT^GI2B) 5^5?EX7CI4E% ^5"!0"< # (/6BG44 ?_]D! end EX-101.SCH 5 gcan-20230331.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Stockholders Deficiency (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - RIGHT OF FIRST REFUSAL AGREEMENT link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - LOANS PAYABLE TO RELATED PARTIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - NOTES PAYABLE TO THIRD PARTIES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - DERIVATIVE LIABILITY link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - CAPITAL STOCK AND WARRANTS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - LOANS PAYABLE TO RELATED PARTIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - NOTES PAYABLE TO THIRD PARTIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - DERIVATIVE LIABILITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - RIGHT OF FIRST REFUSAL AGREEMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - LOANS PAYABLE TO RELATED PARTIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Schedule of Prepay Amount and Date Description (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - NOTES PAYABLE TO THIRD PARTIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SCHEDULE OF DERIVATIVE LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SCHEDULE OF DERIVATIVE LIABILITY (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - DERIVATIVE LIABILITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - CAPITAL STOCK AND WARRANTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 gcan-20230331_cal.xml INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 gcan-20230331_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 gcan-20230331_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Related and Nonrelated Party Status [Axis] Related Party [Member] Class of Stock [Axis] Series A Convertible Preferred Stock [Member] Product and Service [Axis] Product [Member] Consulting Fees [Member] Series A Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Business Acquisition [Axis] Green C Corporation [Member] Class A Common Stock [Member] Legal Entity [Axis] Title of Individual [Axis] Former Share Holders [Member] Antidilutive Securities [Axis] Related Party, Type [Axis] KTV [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Commitments [Member] CBD [Member] Elisha Kalfa And Yonah Kalfa [Member] Fernando Bisker And Sigalush LLC [Member] Statistical Measurement [Axis] Maximum [Member] Loan and Contribution Agreements [Member] Debt Instrument [Axis] Promissory Note [Member] Convertible Promissory Note [Member] John T. Root [Member] FirstFire Global Opportunities Fund, LLC [Member] Vesting [Axis] Share-Based Payment Arrangement, Tranche One [Member] FirstFire note [Member] FF Note [Member] Second FirstFire Note [Member] Scenario [Axis] Less than or Equal to 30 Days [Member] 31 - 60 Days [Member] 61 - 90 Days [Member] 91 - 120 Days [Member] 121 - 150 Days [Member] 151 - 180 Days [Member] Short-Term Debt, Type [Axis] Convertible Debt [Member] Measurement Input Type [Axis] Measurement Input, Share Price [Member] Measurement Input, Conversion Price [Member] Measurement Input, Expected Term [Member] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Series B Convertible Preferred Stock [Member] Emet Capital Partners, LLC [Member] Sylios Corp [Member] Two Consulting Firm Entities [Member] Convertible Warrant Note One [Member] Two Exchange Agreement [Member] Second Exchange Agreement [Member] Four New Convertible Warrant Notes [Member] Convertible Notes [Member] Notes Payable [Member] Warrant A [Member] Warrant B [Member] Warrant C [Member] Warrant [Member] Exclusive License Agreement [Member] Pharmedica Ltd [Member] Minimum [Member] Sub License Agreement [Member] Symtomax Unipessoal IDA [Member] Chief Executive Officer [Member] Services Agreements [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] ASSETS CURRENT ASSETS Cash Total current assets OTHER ASSETS Right of first refusal agreement cost (less accumulated amortization of $15,833 and $14,583) Total assets LIABILITIES AND STOCKHOLDERS’ DEFICIENCY CURRENT LIABILITIES Accounts payable Accrued interest Accrued officers’ compensation Loans payable to related parties Notes payable to third parties Total current liabilities and total liabilities STOCKHOLDERS’ (DEFICIENCY) Preferred stock; 19,000,000 shares authorized, $.001 par value: Series A Convertible Preferred-issued and outstanding 9,111,998 and 9,111,998 shares, respectively Common stock; 2,000,000,000 shares authorized, $.001 par value, as of March 31, 2023 and December 31, 2022, there are 732,638,436 shares outstanding, respectively Additional paid-in capital Accumulated deficit Total stockholders’ (deficiency) Total liabilities and stockholders’ (deficiency) Statement [Table] Statement [Line Items] Accumulated amortization Preferred stock, shares authorized Preferred stock, par value Preferred stock, shares issued Preferred stock, shares outstanding Common stock, shares authorized Common stock, par value Common stock, shares outstanding Revenue: Total revenue Cost of product sales EX-101.PRE 9 gcan-20230331_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2023	May 15, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	000-56027
Entity Registrant Name	THE GREATER CANNABIS COMPANY, INC.
Entity Central Index Key	0001695473
Entity Tax Identification Number	30-0842570
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	15 Walker Avenue Suite 101
Entity Address, City or Town	Baltimore
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	21208
City Area Code	(443)
Local Phone Number	738-4051
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		732,638,436

XML 11 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash	$ 251,553	$ 270,030
Total current assets	251,553	270,030
OTHER ASSETS
Right of first refusal agreement cost (less accumulated amortization of $15,833 and $14,583)	9,167	10,417
Total assets	260,720	280,447
CURRENT LIABILITIES
Accounts payable	5,993	16,251
Accrued interest	46,189	42,589
Accrued officers’ compensation	293,000	263,000
Notes payable to third parties	243,437	243,437
Total current liabilities and total liabilities	848,618	825,277
STOCKHOLDERS’ (DEFICIENCY)
Preferred stock; 19,000,000 shares authorized, $.001 par value: Series A Convertible Preferred-issued and outstanding 9,111,998 and 9,111,998 shares, respectively	9,112	9,112
Common stock; 2,000,000,000 shares authorized, $.001 par value, as of March 31, 2023 and December 31, 2022, there are 732,638,436 shares outstanding, respectively	732,639	732,639
Additional paid-in capital	3,006,321	3,006,321
Accumulated deficit	(4,335,970)	(4,292,902)
Total stockholders’ (deficiency)	(587,898)	(544,830)
Total liabilities and stockholders’ (deficiency)	260,720	280,447
Related Party [Member]
CURRENT LIABILITIES
Loans payable to related parties	$ 260,000	$ 260,000

XML 12 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Accumulated amortization	$ 15,833	$ 14,583
Preferred stock, shares authorized	19,000,000	19,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares outstanding	732,638,436	732,638,436
Series A Convertible Preferred Stock [Member]
Preferred stock, shares issued	9,111,998	9,111,998
Preferred stock, shares outstanding	9,111,998	9,111,998

XML 13 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Total revenue
Cost of product sales
Gross profit (loss)
Operating Expenses:
Officers compensation	30,000	30,000
Amortization of Right of First Refusal Agreement cost	1,250	1,250
Other operating expenses	8,218	11,180
Total operating expenses	39,468	42,430
Income (loss) from operations	(39,468)	(42,430)
Other income (expenses):
Interest expense	(3,600)	(6,914)
Amortization of debt discounts		(98,342)
Total other income (expenses)	(3,600)	(105,256)
Income (loss) before provision for income taxes	(43,068)	(147,686)
Provision for income taxes
Net loss	$ (43,068)	$ (147,686)
Basic and diluted income (loss) per common share	$ (0.00)	$ (0.00)
Weighted average common shares outstanding-basic and diluted	732,638,436	508,638,436
Product [Member]
Revenue:
Total revenue
Consulting Fees [Member]
Revenue:
Total revenue

XML 14 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders Deficiency (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Beginning balances, value	$ (544,830)	$ (469,062)
Net loss	(43,068)	(147,686)
Ending balances, value	(587,898)	(616,748)
Common Stock [Member]
Beginning balances, value	$ 732,639	$ 508,639
Beginning balances, shares	732,638,436	508,638,436
Net loss
Ending balances, value	$ 732,639	$ 508,639
Ending balances, shares	732,638,436	508,638,436
Additional Paid-in Capital [Member]
Beginning balances, value	$ 3,006,321	$ 2,945,821
Net loss
Ending balances, value	3,006,321	2,945,821
Retained Earnings [Member]
Beginning balances, value	(4,292,902)	(3,932,634)
Net loss	(43,068)	(147,686)
Ending balances, value	(4,335,970)	(4,080,320)
Series A Preferred Stock [Member] \| Preferred Stock [Member]
Beginning balances, value	$ 9,112	$ 9,112
Beginning balances, shares	9,111,998	9,111,998
Net loss
Ending balances, value	$ 9,112	$ 9,112
Ending balances, shares	9,111,998	9,111,998

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

XML 15 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
OPERATING ACTIVITIES
Net income (loss)	$ (43,068)	$ (147,686)
Adjustments to reconcile net income (loss) to net cash provided (used) in operating activities:
Amortization of Right of First Refusal Agreement cost	1,250	1,250
Amortization of debt discounts		98,342
Changes in operating assets and liabilities:
Accounts payable	(10,259)	1,250
Accrued interest	3,600	6,913
Accrued officers’ compensation	30,000	30,000
Net cash used in operating activities	(18,477)	(9,931)
INVESTING ACTIVITIES
Purchase of Right of First Refusal Agreement
Net cash used in investing activities
FINANCING ACTIVITIES
Proceeds from notes payable to third parties
Net cash provided by financing activities
NET INCREASE (DECREASE) IN CASH	(18,477)	(9,931)
CASH BALANCE, BEGINNING OF PERIOD	270,030	377,520
CASH BALANCE, END OF PERIOD	251,553	367,589
Supplemental Disclosures of Cash Flow Information:
Interest paid
Income tax paid

XML 16 R7.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations

Green C was incorporated on December 21, 2017 under the laws of the Province of Ontario Canada with its principal place of business in North York, Ontario.

Principles of Consolidation

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Interim Financial Statements

Cash and Cash Equivalents

Notes and Accounts Receivable

Income Taxes

Use of Estimates

Financial Instruments and Fair Value of Financial Instruments

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Level 1:		Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level 2:		Observable market-based inputs or unobservable inputs that are corroborated by market data
Level 3:		Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

Derivative Liabilities

Long-lived Assets

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Equity Instruments Issued to Non-Employees for Acquiring Goods or Services

Related Parties

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Revenue Recognition

Revenue recognition:

	●	Identify the contract(s) with a customer
	●	Identify the performance obligations
	●	Determine the transaction price
	●	Allocate the transaction price
	●	Recognize revenue when the performance obligations are met

Advertising Costs

Advertising costs are expensed as incurred. For the periods presented, we had no advertising costs.

Loss per Share

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023and 2022

(Unaudited)

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Recently Enacted Accounting Standards

Other standards not presented are not deemed to be material.

XML 17 R8.htm IDEA: XBRL DOCUMENT

GOING CONCERN

3 Months Ended

Mar. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN

NOTE B - GOING CONCERN

XML 18 R9.htm IDEA: XBRL DOCUMENT

RIGHT OF FIRST REFUSAL AGREEMENT

3 Months Ended

Mar. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

RIGHT OF FIRST REFUSAL AGREEMENT

NOTE C – RIGHT OF FIRST REFUSAL AGREEMENT

XML 19 R10.htm IDEA: XBRL DOCUMENT

LOANS PAYABLE TO RELATED PARTIES

3 Months Ended

Mar. 31, 2023

LOANS PAYABLE TO RELATED PARTIES

NOTE D - LOANS PAYABLE TO RELATED PARTIES

Loans payable to related parties consist of:

	March 31, 2023		December 31, 2022

Loans from Elisha Kalfa and Yonah Kalfa, holders of a total of 2,966,666 shares of Series A Convertible Preferred stock	$	180,000	$	180,000

Loan from Fernando Bisker and Sigalush, LLC, holders of a total of 2,966,666 shares of Series A Convertible Preferred stock		80,000		80,000

Total	$	260,000	$	260,000

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

XML 20 R11.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE TO THIRD PARTIES

3 Months Ended

Mar. 31, 2023

Debt Disclosure [Abstract]

NOTES PAYABLE TO THIRD PARTIES

NOTE E - NOTES PAYABLE TO THIRD PARTIES

Notes payable to third parties consist of:

	March 31, 2023		December 31, 2022

Promissory Note dated March 28, 2017 payable to John T. Root, Jr., interest at 4%, due September 28, 2017, convertible into shares of common stock at a conversion price of $.001 per share.	$	375	$	375
Convertible Promissory Note dated March 15, 2021 payable to FirstFire Global Opportunities Fund, LLC (“FF”), interest at 6%, due March 11, 2022-less unamortized debt discount of $0 and $0, respectively. ⁽ⁱ⁾		243,062		243,062
Total	$	243,437	$	243,437

On June 1, 2022, the Company issued 25,000,000 shares for the conversion of $25,000 principal on the FirstFire note dated March 5, 2021 at a conversion price of $.001.

During the three months ended December 31, 2022, the Company issued 64,000,000 shares for the conversion of $64,000 principal on the FirstFire note dated March 5, 2021 at a conversion price of $.001.

The FF Note may be pre-paid in whole or in part by paying FF the following premiums:

PREPAY DATE		PREPAY AMOUNT
≤ 30 days		105% * (Principal + Interest (“P+I”)
31- 60 days		110% * (P+I)
61-90 days		115% * (P+I)
91-120 days		120% * (P+I)
121-150 days		125% * (P+I)
151-180 days		130% * (P+I)

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

Copies of Warrant A, Warrant B and Warrant C are attached as Exhibits 10.4, 10.5 and 10.6 to our current report on Form 8-K dated March 16, 2021.

The valuation of the above warrants issued and recorded during the three months ended June 30, 2021 was $262,429.

See NOTE -G WARRANTS

XML 21 R12.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITY

3 Months Ended

Mar. 31, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE LIABILITY

NOTE F - DERIVATIVE LIABILITY

The derivative liability consists of:

SCHEDULE OF DERIVATIVE LIABILITY

March 31,

2023

December 31,

2022

Convertible Promissory Note dated March 15, 2021 and June 30, 2021 payable to FirstFire Global Opportunities Fund, LLC, See Note E (i) Due March 11, 2022

Total derivative liability

(i)As discussed in Note A above, warrants with “down round” features (and do not contain variable conversion features) are not subject to derivative liability treatment effective January 1, 2019.

XML 22 R13.htm IDEA: XBRL DOCUMENT

CAPITAL STOCK AND WARRANTS

3 Months Ended

Mar. 31, 2023

Equity [Abstract]

CAPITAL STOCK AND WARRANTS

NOTE G - CAPITAL STOCK AND WARRANTS

Preferred Stock

On September 21, 2021, 300,000 shares of Series A Preferred Shares were converted into 15,000,000 shares of common stock.

Common Stock

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

During the three months ended March 31, 2021, the Company recorded the conversion of note payable ($22,500) and accrued interest ($814) into 13,795,118 shares of common stock (Fair Value of $45,525).

During the three months ended June 30, 2021, the Company recorded the value of the warrants at $262,429 and the conversion of the second FirstFire note tranche in the amount of $39,000.

On July 15, 2021, the Company issued 10,000,000 shares for the conversion of $52,080 principal on the FirstFire note dated March 5, 2021 at a conversion price of $.005208.

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

Warrants

Warrant A permits FF to purchase 25,000,000 shares of common stock at an exercise price of $0.025 per share through September 11, 2022.

Warrant B permits FF to purchase 15,000,000 shares of common stock at an exercise price of $0.05 per share through September 11, 2022.

Warrant C permits FF to purchase 10,000,000 shares of common stock at an exercise price of $0.075 per share. through September 11, 2022.

Each warrant has other customary terms found in like instruments, including, but not limited to, events of default.

In any event of default, the exercise price for each warrant automatically becomes $0.005 per share.

The valuation of the above warrants issued and recorded during the three months ended June 30, 2021 was $262,429.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

XML 23 R14.htm IDEA: XBRL DOCUMENT

INCOME TAXES

3 Months Ended

Mar. 31, 2023

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE H - INCOME TAXES

The Company and its United States subsidiaries file consolidated Federal income tax returns. Green C Corporation, its Ontario Canada subsidiary, files Canada and Ontario income tax returns.

All tax years of the Company and its United States subsidiaries remain subject to examination by the Internal Revenue Service.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

XML 24 R15.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE I - COMMITMENTS AND CONTINGENCIES

Pharmedica Exclusive License Agreement

On September 2, 2020, Green C notified Pharmedica of Green C’s termination of the Exclusive License Agreement and Green C’s intention to wind up Green C.

Sub-License Agreement with Symtomax Unipessoal Lda

On July 15, 2019, the Company executed a Sub-License Agreement with Symtomax Unipessoal Lda (“Symtomax”).

To date, Symtomax has not made any sales requiring the payment of royalties to the Company.

Agreements

XML 25 R16.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2023

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE J – SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date the financial statements were available to be issued. The Company had no subsequent events that require disclosure.

XML 26 R17.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Nature of Operations

Nature of Operations

Green C was incorporated on December 21, 2017 under the laws of the Province of Ontario Canada with its principal place of business in North York, Ontario.

Principles of Consolidation

Principles of Consolidation

Interim Financial Statements

Interim Financial Statements

Cash and Cash Equivalents

Cash and Cash Equivalents

Notes and Accounts Receivable

Notes and Accounts Receivable

Income Taxes

Income Taxes

Use of Estimates

Use of Estimates

Financial Instruments and Fair Value of Financial Instruments

Financial Instruments and Fair Value of Financial Instruments

THE GREATER CANNABIS COMPANY, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2023 and 2022

(Unaudited)

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Level 1:		Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level 2:		Observable market-based inputs or unobservable inputs that are corroborated by market data
Level 3:		Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

Derivative Liabilities

Derivative Liabilities

Long-lived Assets

Long-lived Assets

Equity Instruments Issued to Non-Employees for Acquiring Goods or Services

Equity Instruments Issued to Non-Employees for Acquiring Goods or Services

Related Parties

Related Parties

Revenue Recognition

Revenue Recognition

Revenue recognition:

	●	Identify the contract(s) with a customer
	●	Identify the performance obligations
	●	Determine the transaction price
	●	Allocate the transaction price
	●	Recognize revenue when the performance obligations are met

Advertising Costs

Advertising Costs

Advertising costs are expensed as incurred. For the periods presented, we had no advertising costs.

Loss per Share

Loss per Share

Recently Enacted Accounting Standards

Recently Enacted Accounting Standards

Other standards not presented are not deemed to be material.

XML 27 R18.htm IDEA: XBRL DOCUMENT

LOANS PAYABLE TO RELATED PARTIES (Tables)

3 Months Ended

Mar. 31, 2023

SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES

Loans payable to related parties consist of:

	March 31, 2023		December 31, 2022

Loans from Elisha Kalfa and Yonah Kalfa, holders of a total of 2,966,666 shares of Series A Convertible Preferred stock	$	180,000	$	180,000

Loan from Fernando Bisker and Sigalush, LLC, holders of a total of 2,966,666 shares of Series A Convertible Preferred stock		80,000		80,000

Total	$	260,000	$	260,000

XML 28 R19.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE TO THIRD PARTIES (Tables)

3 Months Ended

Mar. 31, 2023

Debt Disclosure [Abstract]

SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES

Notes payable to third parties consist of:

	March 31, 2023		December 31, 2022

Promissory Note dated March 28, 2017 payable to John T. Root, Jr., interest at 4%, due September 28, 2017, convertible into shares of common stock at a conversion price of $.001 per share.	$	375	$	375
Convertible Promissory Note dated March 15, 2021 payable to FirstFire Global Opportunities Fund, LLC (“FF”), interest at 6%, due March 11, 2022-less unamortized debt discount of $0 and $0, respectively. ⁽ⁱ⁾		243,062		243,062
Total	$	243,437	$	243,437

Schedule of Prepay Amount and Date Description

The FF Note may be pre-paid in whole or in part by paying FF the following premiums:

PREPAY DATE		PREPAY AMOUNT
≤ 30 days		105% * (Principal + Interest (“P+I”)
31- 60 days		110% * (P+I)
61-90 days		115% * (P+I)
91-120 days		120% * (P+I)
121-150 days		125% * (P+I)
151-180 days		130% * (P+I)

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482949/835-30-55-8

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480848/942-470-50-3

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-8

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-6

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-7

+ Details

XML 29 R20.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITY (Tables)

3 Months Ended

Mar. 31, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

SCHEDULE OF DERIVATIVE LIABILITY

The derivative liability consists of:

SCHEDULE OF DERIVATIVE LIABILITY

March 31,

2023

December 31,

2022

Convertible Promissory Note dated March 15, 2021 and June 30, 2021 payable to FirstFire Global Opportunities Fund, LLC, See Note E (i) Due March 11, 2022

Total derivative liability

XML 30 R21.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)			3 Months Ended
	Jul. 31, 2018	Mar. 10, 2017	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Number of shares issued		26,905,969
Cash equivalents			$ 0		$ 0
Series A Convertible Preferred Stock [Member]
Anti-dilutive shares excluded from computation			470,599,900	470,599,900
Series A Convertible Preferred Stock [Member] \| Green C Corporation [Member]
Number of shares issued	9,411,998
Common stock, voting rights	Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock
Conversion of convertible preferred stock	50
Green C Corporation [Member] \| Former Share Holders [Member]
Percentage of issued and outstanding shares acquired	94.00%
Green C Corporation [Member] \| Class A Common Stock [Member]
Percentage of issued and outstanding shares acquired	100.00%
Green C Corporation [Member] \| Series A Convertible Preferred Stock [Member]
Number of shares issued	9,411,998

XML 31 R22.htm IDEA: XBRL DOCUMENT

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended
GOING CONCERN (Details Narrative) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 251,553		$ 270,030
Liabilities, current	848,618
Working capital deficit	597,065
Net loss	43,068	$ 147,686
Cash used from operating activities	$ 18,477	$ 9,931

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-25

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483467/210-10-45-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7

Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 32 R23.htm IDEA: XBRL DOCUMENT

RIGHT OF FIRST REFUSAL AGREEMENT (Details Narrative) - KTV [Member] - Commitments [Member] - CBD [Member]	Jan. 30, 2020 USD ($)
Product Liability Contingency [Line Items]
Payment for other invetsment opportunities	$ 25,000
Opportunities term	5 years
Amortization cost	$ 25,000

XML 33 R24.htm IDEA: XBRL DOCUMENT

SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES (Details)	Dec. 31, 2022 USD ($)
Related Party Transaction [Line Items]
Total	$ 260,000
Elisha Kalfa And Yonah Kalfa [Member]
Related Party Transaction [Line Items]
Total	180,000
Fernando Bisker And Sigalush LLC [Member]
Related Party Transaction [Line Items]
Total	$ 80,000

XML 34 R25.htm IDEA: XBRL DOCUMENT

SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES (Details) (Parenthetical) - Series A Convertible Preferred Stock [Member] - shares	Mar. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Preferred stock, shares issued	9,111,998	9,111,998
Elisha Kalfa And Yonah Kalfa [Member]
Related Party Transaction [Line Items]
Preferred stock, shares issued	2,966,666	2,966,666
Fernando Bisker And Sigalush LLC [Member]
Related Party Transaction [Line Items]
Preferred stock, shares issued	2,966,666	2,966,666

XML 35 R26.htm IDEA: XBRL DOCUMENT

LOANS PAYABLE TO RELATED PARTIES (Details Narrative)	Jul. 31, 2018 USD ($)
Maximum [Member] \| Loan and Contribution Agreements [Member]
Repayments of related party debt	$ 1,500,000

XML 36 R27.htm IDEA: XBRL DOCUMENT

SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Short-Term Debt [Line Items]
Total	$ 243,437	$ 243,437
Promissory Note [Member]
Short-Term Debt [Line Items]
Total	375	375
Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Total	$ 243,062	$ 243,062

XML 37 R28.htm IDEA: XBRL DOCUMENT

SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES (Details) (Parenthetical) - USD ($)	Jun. 30, 2021	Mar. 15, 2021	Mar. 28, 2017	Mar. 31, 2023	Dec. 31, 2022	Dec. 24, 2019	Dec. 20, 2019	Nov. 11, 2019
Short-Term Debt [Line Items]
Debt instrument, principal amount						$ 10,000	$ 29,000	$ 53,705
Promissory Note [Member] \| John T. Root [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate			4.00%
Debt instrument, maturity date			Sep. 28, 2017
Conversion price			$ 0.001
Convertible Promissory Note [Member] \| FirstFire Global Opportunities Fund, LLC [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate		6.00%
Debt instrument, maturity date		Mar. 11, 2022
Debt Instrument, Unamortized Discount				$ 0	$ 0
Debt instrument, principal amount		$ 545,000
Proceeds from issuance of convertible debt		272,500
Debt conversion, original issue discount		$ 22,500
Maturity date description		The FF Note had an original maturity date of March 11, 2022, which was extended to April 30, 2023 by agreement between the parties dated May 1, 2022, which agreement also waiver certain defaults under the FF Note
Convertible Promissory Note [Member] \| FirstFire Global Opportunities Fund, LLC [Member] \| Share-Based Payment Arrangement, Tranche One [Member]
Short-Term Debt [Line Items]
Proceeds from issuance of convertible debt	$ 272,500
Debt conversion, original issue discount	$ 22,500

XML 38 R29.htm IDEA: XBRL DOCUMENT

Schedule of Prepay Amount and Date Description (Details) - FF Note [Member]	Mar. 15, 2021
Less than or Equal to 30 Days [Member]
Short-Term Debt [Line Items]
Debt prepay amount, description	105% * (Principal + Interest (“P+I”)
31 - 60 Days [Member]
Short-Term Debt [Line Items]
Debt prepay amount, description	110% * (P+I)
61 - 90 Days [Member]
Short-Term Debt [Line Items]
Debt prepay amount, description	115% * (P+I)
91 - 120 Days [Member]
Short-Term Debt [Line Items]
Debt prepay amount, description	120% * (P+I)
121 - 150 Days [Member]
Short-Term Debt [Line Items]
Debt prepay amount, description	125% * (P+I)
151 - 180 Days [Member]
Short-Term Debt [Line Items]
Debt prepay amount, description	130% * (P+I)

- Definition

Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.

+ References + Details

XML 39 R30.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE TO THIRD PARTIES (Details Narrative) - USD ($)						3 Months Ended
	Jun. 01, 2022	Jul. 15, 2021	Dec. 24, 2019	Dec. 20, 2019	Nov. 11, 2019	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Mar. 15, 2021	Mar. 05, 2021
Short-Term Debt [Line Items]
Shares issued in conversion			637,273	1,468,204	1,748,363					261,215,948	115,277,834	27,563,525	21,484,688
Principal amount										$ 804,324	$ 797,067	$ 210,532	$ 406,093
Debt instrument, debt notice of default, description						the date the Registration Statement (as defined below) covering the shares issuable upon conversion of the FFG Notes is declared effective by the Securities and Exchange Commission (the “SEC”) or (ii) one hundred eighty (180) days following the Issue Date to convert all or any part of the outstanding and unpaid principal amount of the FF Note into fully paid and non-assessable shares of our common stock at the conversion price (the “Conversion Price”). The Conversion Price shall be, equal to 70% of the average closing price of our common stock for the five prior trading days prior to the date that a registration statement in respect of the shares into which is the FF Note is convertible is declared effective.
Debt instrument event of default, description						In the case of an Event of Default (as defined in the Note), the FF Note shall become immediately due and payable in an amount (the “Default Amount”) equal to the principal amount then outstanding plus accrued interest (including any Default Interest) through the date of full repayment multiplied by one hundred twenty-five percent (125%) and interest shall accrue at the rate of Default Interest.
FirstFire note [Member]
Short-Term Debt [Line Items]
Shares issued in conversion	25,000,000	10,000,000					64,000,000	135,000,000
Principal amount	$ 25,000						$ 64,000	$ 135,000
Conversion price	$ 0.001						$ 0.001	$ 0.001							$ 0.005208
FF Note [Member] \| FirstFire Global Opportunities Fund, LLC [Member]
Short-Term Debt [Line Items]
Debt repayment percentage														125.00%
Second FirstFire Note [Member]
Short-Term Debt [Line Items]
Issuance of warrants									$ 262,429

XML 40 R31.htm IDEA: XBRL DOCUMENT

SCHEDULE OF DERIVATIVE LIABILITY (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Short-Term Debt [Line Items]
Total derivative liability
Convertible Debt [Member]
Short-Term Debt [Line Items]
Total derivative liability

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column G)(Footnote 8))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column G))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5A
-Subparagraph (SX 210.12-13A(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483466/210-20-50-3

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483444/210-20-55-22

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483444/210-20-55-10

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-10

+ Details

XML 41 R32.htm IDEA: XBRL DOCUMENT

SCHEDULE OF DERIVATIVE LIABILITY (Details) (Parenthetical)	3 Months Ended
	Mar. 31, 2023
Convertible Debt [Member] \| FirstFire Global Opportunities Fund, LLC [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Mar. 11, 2022

XML 42 R33.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITY (Details Narrative) - Convertible Promissory Note [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2021 $ / shares	Dec. 31, 2020 $ / shares
Measurement Input, Share Price [Member]
Short-Term Debt [Line Items]
Derivative liability measurement input	0.0011	0.003
Measurement Input, Conversion Price [Member]
Short-Term Debt [Line Items]
Derivative liability measurement input	0.0071	0.00169
Measurement Input, Expected Term [Member]
Short-Term Debt [Line Items]
Derivative liability, measurement input, term	345 days	0 days
Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Derivative liability measurement input	142.94	142.94
Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Derivative liability measurement input	0.07	0

XML 43 R34.htm IDEA: XBRL DOCUMENT

CAPITAL STOCK AND WARRANTS (Details Narrative)																3 Months Ended
CAPITAL STOCK AND WARRANTS (Details Narrative)	Jun. 01, 2022 USD ($) $ / shares shares	Sep. 21, 2021 USD ($) shares	Jul. 15, 2021 USD ($) shares	Dec. 24, 2019 USD ($) shares	Dec. 20, 2019 USD ($) shares	Nov. 11, 2019 USD ($) shares	Oct. 18, 2019 USD ($) Integer	Aug. 15, 2019 USD ($) shares	May 29, 2019 shares	Apr. 16, 2019 USD ($) shares	Feb. 14, 2019 $ / shares shares	Jan. 04, 2019 USD ($) $ / shares shares	Jul. 31, 2018 shares	Mar. 10, 2017 shares	Feb. 03, 2017 shares	Dec. 31, 2022 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares	Sep. 30, 2020 USD ($) shares	Jun. 30, 2020 USD ($) shares	Mar. 31, 2020 USD ($) shares	Jun. 30, 2019 USD ($) shares	Mar. 31, 2019 USD ($) shares	Mar. 11, 2021 $ / shares shares	Mar. 05, 2021 $ / shares	May 25, 2017 shares
Class of Stock [Line Items]
Stock issued new issues \| shares														26,905,969
Debt conversion, converted instrument, shares issued \| shares				637,273	1,468,204	1,748,363														261,215,948	115,277,834	27,563,525	21,484,688
Debt instrument, face amount				$ 10,000	$ 29,000	$ 53,705
Interest payable				$ 515	$ 4,015	$ 2,680
Fair value of common stock								$ 12,250
Number of shares issued for services \| shares								175,000
Value of shares issued for services								$ 175,000																$ 75,880
Number of shares issued for other operating expenses \| shares																								542,000
Excess of fair value																				$ 462,263	$ 467,554	$ 132,838	$ 228,949
Debt conversion, converted instrument, amount																				804,324	797,067	210,532	406,093
Liability reduction																				$ 342,061	$ 329,512	$ 77,695	$ 177,143
Convertible Notes [Member]
Class of Stock [Line Items]
Debt conversion, converted instrument, shares issued \| shares																				261,215,948	115,277,834	27,563,525	21,484,688
Debt instrument, face amount																				$ 325,212	$ 311,050	$ 67,082	$ 165,350
Interest payable																				$ 16,849	$ 18,462	$ 10,613	$ 11,793
Notes Payable [Member]
Class of Stock [Line Items]
Debt conversion, converted instrument, shares issued \| shares																			13,795,118
Interest payable																			$ 814
Debt conversion, converted instrument, amount																			45,525
Notes payable																			$ 22,500
Second FirstFire Note [Member]
Class of Stock [Line Items]
Issuance of warrants																		$ 262,429
Debt conversion, original debt, amount																		$ 39,000
FirstFire note [Member]
Class of Stock [Line Items]
Debt instrument, convertible, conversion price \| $ / shares	$ 0.001															$ 0.001	$ 0.001										$ 0.005208
Debt conversion, converted instrument, shares issued \| shares	25,000,000		10,000,000													64,000,000	135,000,000
Debt instrument, face amount			$ 52,080
Debt conversion, converted instrument, amount	$ 25,000															$ 64,000	$ 135,000
Two Consulting Firm Entities [Member]
Class of Stock [Line Items]
Number of shares issued for services \| shares									542,000
Emet Capital Partners, LLC [Member] \| Convertible Warrant Note One [Member] \| Two Exchange Agreement [Member]
Class of Stock [Line Items]
Debt instrument, face amount							$ 20,399
Interest payable							5,189
Debt instrument, periodic payment							$ 25,587
Debt instrument, interest rate, percentage							6.00%
Debt instrument, maturity date							Feb. 12, 2020
Debt convertible threshold percentage							75.00%
Debt convertible threshold trading days \| Integer							15
Emet Capital Partners, LLC [Member] \| Four New Convertible Warrant Notes [Member] \| Second Exchange Agreement [Member]
Class of Stock [Line Items]
Debt instrument, periodic payment							$ 675,000
Debt instrument, interest rate, percentage							2.00%
Debt convertible threshold percentage							75.00%
Debt convertible threshold trading days \| Integer							15
Common Stock [Member]
Class of Stock [Line Items]
Conversion of stock, shares issued \| shares		15,000,000
Emet Capital Partners, LLC [Member]
Class of Stock [Line Items]
Stock issued new issues \| shares										1,384,600		695,129												1,384,600
Debt instrument, convertible, conversion price \| $ / shares												$ 0.001
Debt conversion, converted instrument, shares issued \| shares												769,785													769,785
Debt instrument, face amount										$ 40,500		$ 670
Interest payable										$ 7,961		$ 100
Excess of common stock value																								$ 131,537	$ 99,302
Fair value of common stock																								179,998	100,072
Loss on conversion of debt																								$ 47,961	$ 770
Number of warrant issued \| shares												1,400																440,000
Exercise price of warrants \| $ / shares												$ 0.001
FirstFire Global Opportunities Fund, LLC [Member] \| Warrant A [Member]
Class of Stock [Line Items]
Exercise price of warrants \| $ / shares																										$ 0.025
Warrant purchase of common stock \| shares																										25,000,000
FirstFire Global Opportunities Fund, LLC [Member] \| Warrant B [Member]
Class of Stock [Line Items]
Exercise price of warrants \| $ / shares																										$ 0.05
Warrant purchase of common stock \| shares																										15,000,000
FirstFire Global Opportunities Fund, LLC [Member] \| Warrant C [Member]
Class of Stock [Line Items]
Exercise price of warrants \| $ / shares																										$ 0.075
Warrant purchase of common stock \| shares																										10,000,000
FirstFire Global Opportunities Fund, LLC [Member] \| Warrant [Member]
Class of Stock [Line Items]
Exercise price of warrants \| $ / shares																										$ 0.005
Series A Convertible Preferred Stock [Member] \| Green C Corporation [Member]
Class of Stock [Line Items]
Stock issued new issues \| shares													9,411,998
Conversion of stock, shares converted \| shares													50
Series B Convertible Preferred Stock [Member] \| Emet Capital Partners, LLC [Member]
Class of Stock [Line Items]
Stock issued new issues \| shares											9,000,000
Preferred stock, conversion basis											Each share of Series B Convertible Preferred Stock was convertible into one share of Company common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company common stock was less than $0.075 per share.
Debt instrument, convertible, conversion price \| $ / shares											$ 0.075
Series B Convertible Preferred Stock [Member] \| Emet Capital Partners, LLC [Member] \| Second Exchange Agreement [Member]
Class of Stock [Line Items]
Stock issued new issues \| shares											9,000,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of stock, shares converted		$ 300,000
Green C Corporation [Member] \| Class A Common Stock [Member]
Class of Stock [Line Items]
Business acquisition, percentage of voting interests acquired													100.00%
Green C Corporation [Member] \| Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock issued new issues \| shares													9,411,998
Preferred stock, conversion basis													Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to 50 votes on all matters as a class with the holders of common stock.
Sylios Corp [Member]
Class of Stock [Line Items]
Business acquisition, percentage of voting interests acquired														19.99%	80.01%
Stock issued new issues \| shares														5,378,476	21,527,493
Common stock, shares held \| shares															500

XML 44 R35.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)					3 Months Ended			12 Months Ended
	May 27, 2020	Jul. 15, 2019	Jul. 31, 2018	Jun. 21, 2018	Mar. 31, 2023	Mar. 31, 2022	Sep. 30, 2020	Dec. 31, 2019
Loss Contingencies [Line Items]
Officers compensation					$ 30,000	$ 30,000
Pharmedica Ltd [Member]
Loss Contingencies [Line Items]
Royalty expense								$ 50,000
Asset impairment charges								69,749
Reduction of carrying value of assets								69,749
Intangible assets, net								$ 0
Sub License Agreement [Member] \| Symtomax Unipessoal IDA [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Annual royalties rate		10.00%
Sub License Agreement [Member] \| Symtomax Unipessoal IDA [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Annual royalties rate		17.00%
Payments for royalties	$ 1,000,000
Services Agreements [Member]
Loss Contingencies [Line Items]
Officers compensation					$ 30,000	$ 30,000
Services Agreements [Member] \| Chief Executive Officer [Member]
Loss Contingencies [Line Items]
Officers compensation			$ 10,000
Green C Corporation [Member] \| Exclusive License Agreement [Member]
Loss Contingencies [Line Items]
Cost, direct tax and license				$ 100,000
Annual royalties rate				5.00%
Royalty expense				$ 50,000
Forgiveness of royalty payable							$ 50,000
Reduction of accrued royalties							50,000
Accrued royalties							$ 0

XML 45 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001695473 2023-01-01 2023-03-31 0001695473 2023-05-15 0001695473 2023-03-31 0001695473 2022-12-31 0001695473 us-gaap:RelatedPartyMember 2023-03-31 0001695473 us-gaap:RelatedPartyMember 2022-12-31 0001695473 GCAN:SeriesAConvertiblePreferredStockMember 2023-03-31 0001695473 GCAN:SeriesAConvertiblePreferredStockMember 2022-12-31 0001695473 2022-01-01 2022-03-31 0001695473 us-gaap:ProductMember 2023-01-01 2023-03-31 0001695473 us-gaap:ProductMember 2022-01-01 2022-03-31 0001695473 GCAN:ConsultingFeesMember 2023-01-01 2023-03-31 0001695473 GCAN:ConsultingFeesMember 2022-01-01 2022-03-31 0001695473 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001695473 us-gaap:CommonStockMember 2021-12-31 0001695473 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001695473 us-gaap:RetainedEarningsMember 2021-12-31 0001695473 2021-12-31 0001695473 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001695473 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001695473 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001695473 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001695473 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001695473 us-gaap:CommonStockMember 2022-03-31 0001695473 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001695473 us-gaap:RetainedEarningsMember 2022-03-31 0001695473 2022-03-31 0001695473 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001695473 us-gaap:CommonStockMember 2022-12-31 0001695473 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001695473 us-gaap:RetainedEarningsMember 2022-12-31 0001695473 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001695473 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001695473 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001695473 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001695473 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001695473 us-gaap:CommonStockMember 2023-03-31 0001695473 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001695473 us-gaap:RetainedEarningsMember 2023-03-31 0001695473 GCAN:GreenCCorporationMember GCAN:ClassACommonStockMember 2018-07-31 0001695473 GCAN:SeriesAConvertiblePreferredStockMember GCAN:GreenCCorporationMember 2018-07-30 2018-07-31 0001695473 GCAN:FormerShareHoldersMember GCAN:GreenCCorporationMember 2018-07-31 0001695473 GCAN:SeriesAConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001695473 GCAN:SeriesAConvertiblePreferredStockMember 2022-01-01 2022-03-31 0001695473 GCAN:CBDMember GCAN:KTVMember us-gaap:CommitmentsMember 2020-01-29 2020-01-30 0001695473 GCAN:ElishaKalfaAndYonahKalfaMember 2022-12-31 0001695473 GCAN:FernandoBiskerAndSigalushLLCMember 2022-12-31 0001695473 GCAN:ElishaKalfaAndYonahKalfaMember GCAN:SeriesAConvertiblePreferredStockMember 2023-03-31 0001695473 GCAN:ElishaKalfaAndYonahKalfaMember GCAN:SeriesAConvertiblePreferredStockMember 2022-12-31 0001695473 GCAN:FernandoBiskerAndSigalushLLCMember GCAN:SeriesAConvertiblePreferredStockMember 2022-12-31 0001695473 GCAN:FernandoBiskerAndSigalushLLCMember GCAN:SeriesAConvertiblePreferredStockMember 2023-03-31 0001695473 srt:MaximumMember GCAN:LoanAndContributionAgreementsMember 2018-07-30 2018-07-31 0001695473 GCAN:PromissoryNoteMember 2023-03-31 0001695473 GCAN:PromissoryNoteMember 2022-12-31 0001695473 GCAN:ConvertiblePromissoryNoteMember 2023-03-31 0001695473 GCAN:ConvertiblePromissoryNoteMember 2022-12-31 0001695473 GCAN:PromissoryNoteMember GCAN:JohnT.RootMember 2017-03-28 0001695473 GCAN:PromissoryNoteMember GCAN:JohnT.RootMember 2017-03-27 2017-03-28 0001695473 GCAN:ConvertiblePromissoryNoteMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember 2021-03-15 0001695473 GCAN:ConvertiblePromissoryNoteMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember 2021-03-10 2021-03-15 0001695473 GCAN:ConvertiblePromissoryNoteMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember 2023-03-31 0001695473 GCAN:ConvertiblePromissoryNoteMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember 2022-12-31 0001695473 GCAN:ConvertiblePromissoryNoteMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-06-29 2021-06-30 0001695473 GCAN:ConvertiblePromissoryNoteMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-06-30 0001695473 GCAN:FirstFireNoteMember 2022-05-28 2022-06-01 0001695473 GCAN:FirstFireNoteMember 2022-06-01 0001695473 GCAN:FirstFireNoteMember 2022-07-01 2022-09-30 0001695473 GCAN:FirstFireNoteMember 2022-09-30 0001695473 GCAN:FirstFireNoteMember 2022-10-01 2022-12-31 0001695473 GCAN:FirstFireNoteMember 2022-12-31 0001695473 GCAN:FFNoteMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember 2021-03-15 0001695473 GCAN:SecondFirstFireNoteMember 2021-04-01 2021-06-30 0001695473 GCAN:LessThanOrEqualsToThirtyDaysMember GCAN:FFNoteMember 2021-03-10 2021-03-15 0001695473 GCAN:ThirtyOneToSixtyDaysMember GCAN:FFNoteMember 2021-03-10 2021-03-15 0001695473 GCAN:SixtyOneToNinetyDaysMember GCAN:FFNoteMember 2021-03-10 2021-03-15 0001695473 GCAN:NinetyOneToHundredAndTwentyMember GCAN:FFNoteMember 2021-03-10 2021-03-15 0001695473 GCAN:OnehundredAndTwentyOneToOneHundredFiftyDaysMember GCAN:FFNoteMember 2021-03-10 2021-03-15 0001695473 GCAN:OneHundredAndFiftyOneToOneHundredAndEightyMember GCAN:FFNoteMember 2021-03-10 2021-03-15 0001695473 us-gaap:ConvertibleDebtMember 2023-03-31 0001695473 us-gaap:ConvertibleDebtMember 2022-12-31 0001695473 GCAN:FirstFireGlobalOpportunitiesFundLLCMember us-gaap:ConvertibleDebtMember 2023-01-01 2023-03-31 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputSharePriceMember 2020-12-31 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputConversionPriceMember 2020-12-31 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputExpectedTermMember 2020-01-01 2020-12-31 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputSharePriceMember 2021-03-31 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputConversionPriceMember 2021-03-31 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-03-31 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2021-03-31 0001695473 GCAN:ConvertiblePromissoryNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-03-31 0001695473 GCAN:GreenCCorporationMember GCAN:SeriesAConvertiblePreferredStockMember 2018-07-30 2018-07-31 0001695473 GCAN:SeriesBConvertiblePreferredStockMember GCAN:EmetCapitalPartnersLLCMember 2019-02-11 2019-02-14 0001695473 GCAN:SeriesBConvertiblePreferredStockMember GCAN:EmetCapitalPartnersLLCMember 2019-02-14 0001695473 us-gaap:SeriesAPreferredStockMember 2021-09-20 2021-09-21 0001695473 us-gaap:CommonStockMember 2021-09-20 2021-09-21 0001695473 2017-03-09 2017-03-10 0001695473 GCAN:SyliosCorpMember 2017-03-09 2017-03-10 0001695473 GCAN:SyliosCorpMember 2017-03-10 0001695473 GCAN:SyliosCorpMember 2017-02-02 2017-02-03 0001695473 GCAN:SyliosCorpMember 2017-02-03 0001695473 GCAN:EmetCapitalPartnersLLCMember 2019-01-03 2019-01-04 0001695473 GCAN:EmetCapitalPartnersLLCMember 2019-01-04 0001695473 GCAN:EmetCapitalPartnersLLCMember 2019-01-01 2019-03-31 0001695473 GCAN:EmetCapitalPartnersLLCMember 2017-05-25 0001695473 GCAN:EmetCapitalPartnersLLCMember 2019-04-15 2019-04-16 0001695473 GCAN:EmetCapitalPartnersLLCMember 2019-04-16 0001695473 GCAN:EmetCapitalPartnersLLCMember 2019-04-01 2019-06-30 0001695473 GCAN:TwoConsultingFirmEntitiesMember 2019-05-28 2019-05-29 0001695473 2019-04-01 2019-06-30 0001695473 2019-08-14 2019-08-15 0001695473 GCAN:ConvertibleWarrantNoteOneMember GCAN:EmetCapitalPartnersLLCMember GCAN:TwoExchangeAgreementMember 2019-10-18 0001695473 GCAN:ConvertibleWarrantNoteOneMember GCAN:EmetCapitalPartnersLLCMember GCAN:TwoExchangeAgreementMember 2019-10-17 2019-10-18 0001695473 GCAN:SeriesBConvertiblePreferredStockMember GCAN:SecondExchangeAgreementMember GCAN:EmetCapitalPartnersLLCMember 2019-02-11 2019-02-14 0001695473 GCAN:FourNewConvertibleWarrantNotesMember GCAN:EmetCapitalPartnersLLCMember GCAN:SecondExchangeAgreementMember 2019-10-17 2019-10-18 0001695473 GCAN:FourNewConvertibleWarrantNotesMember GCAN:EmetCapitalPartnersLLCMember GCAN:SecondExchangeAgreementMember 2019-10-18 0001695473 2019-11-10 2019-11-11 0001695473 2019-11-11 0001695473 2019-12-19 2019-12-20 0001695473 2019-12-20 0001695473 2019-12-23 2019-12-24 0001695473 2019-12-24 0001695473 GCAN:ConvertibleNotesMember 2020-01-01 2020-03-31 0001695473 GCAN:ConvertibleNotesMember 2020-03-31 0001695473 2020-01-01 2020-03-31 0001695473 2020-03-31 0001695473 GCAN:ConvertibleNotesMember 2020-04-01 2020-06-30 0001695473 GCAN:ConvertibleNotesMember 2020-06-30 0001695473 2020-04-01 2020-06-30 0001695473 2020-06-30 0001695473 GCAN:ConvertibleNotesMember 2020-07-01 2020-09-30 0001695473 GCAN:ConvertibleNotesMember 2020-09-30 0001695473 2020-07-01 2020-09-30 0001695473 2020-09-30 0001695473 GCAN:ConvertibleNotesMember 2020-10-01 2020-12-31 0001695473 GCAN:ConvertibleNotesMember 2020-12-31 0001695473 2020-10-01 2020-12-31 0001695473 2020-12-31 0001695473 GCAN:NotesPayableMember 2021-03-31 0001695473 GCAN:NotesPayableMember 2021-01-01 2021-03-31 0001695473 GCAN:FirstFireNoteMember 2021-07-14 2021-07-15 0001695473 GCAN:FirstFireNoteMember 2021-07-15 0001695473 GCAN:FirstFireNoteMember 2021-03-05 0001695473 GCAN:WarrantAMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember 2021-03-11 0001695473 GCAN:WarrantBMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember 2021-03-11 0001695473 GCAN:WarrantCMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember 2021-03-11 0001695473 us-gaap:WarrantMember GCAN:FirstFireGlobalOpportunitiesFundLLCMember 2021-03-11 0001695473 GCAN:GreenCCorporationMember GCAN:ExclusiveLicenseAgreementMember 2018-06-20 2018-06-21 0001695473 GCAN:PharmedicaLtdMember 2019-01-01 2019-12-31 0001695473 GCAN:PharmedicaLtdMember 2019-12-31 0001695473 GCAN:GreenCCorporationMember GCAN:ExclusiveLicenseAgreementMember 2020-07-01 2020-09-30 0001695473 GCAN:GreenCCorporationMember GCAN:ExclusiveLicenseAgreementMember 2020-09-30 0001695473 srt:MinimumMember GCAN:SubLicenseAgreementMember GCAN:SymtomaxUnipessoalLdaMember 2019-07-14 2019-07-15 0001695473 srt:MaximumMember GCAN:SubLicenseAgreementMember GCAN:SymtomaxUnipessoalLdaMember 2019-07-14 2019-07-15 0001695473 srt:MaximumMember GCAN:SubLicenseAgreementMember GCAN:SymtomaxUnipessoalLdaMember 2020-05-25 2020-05-27 0001695473 srt:ChiefExecutiveOfficerMember GCAN:ServicesAgreementsMember 2018-07-30 2018-07-31 0001695473 GCAN:ServicesAgreementsMember 2023-01-01 2023-03-31 0001695473 GCAN:ServicesAgreementsMember 2022-01-01 2022-03-31 iso4217:USD shares iso4217:USD shares GCAN:Integer pure 0001695473 false --12-31 Q1

10-Q true 2023-03-31 2023 false 000-56027 THE GREATER CANNABIS COMPANY, INC. FL 30-0842570 15 Walker Avenue Suite 101 Baltimore MD 21208 (443) 738-4051 Yes Yes Non-accelerated Filer true false false 732638436

251553

270030

251553

270030

15833

14583

9167

10417

260720

280447

5993

16251

46189

42589

293000

263000

260000

243437

848618

825277

19000000

0.001

9111998

9112

2000000000

0.001

732638436

732639

3006321

-4335970

-4292902

-587898

-544830

260720

280447

30000

1250

8218

11180

39468

42430

-39468

-42430

3600

6914

98342

-3600

-105256

-43068

-147686

-43068

-147686

-0.00

732638436

508638436

9111998

9112

508638436

508639

2945821

-3932634

-469062

-147686

9111998

9112

508638436

508639

2945821

-4080320

-616748

9111998

9112

732638436

732639

3006321

-4292902

-544830

9112

732639

3006321

-4292902

-544830

-43068

9111998

9112

732638436

732639

3006321

-4335970

-587898

9112

732639

3006321

-4335970

-587898

-43068

-147686

1250

98342

-10259

1250

3600

6913

30000

-18477

-9931

-18477

-9931

270030

377520

251553

367589

<p id="xdx_804_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zukYrJ5EVih" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations The Greater Cannabis Company, Inc. (the “Company”) was formed in March 2014 as a limited liability company under the name, The Greater Cannabis Company, LLC. The Company was a wholly owned subsidiary of Sylios Corp (“Sylios”) until March 10, 2017. On July 31, 2018, the Company acquired <span id="xdx_909_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20180731__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember__us-gaap--StatementClassOfStockAxis__custom--ClassACommonStockMember_z1RFuLrG7c5d" title="Percentage of issued and outstanding shares acquired">100% of the issued and outstanding shares of Class A common stock of Green C Corporation (“Green C”) in exchange for <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180730__20180731__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__dei--LegalEntityAxis__custom--GreenCCorporationMember_z8QzwdW57eFk" title="Number of shares issued">9,411,998 newly issued shares of the Company’s Series A Convertible Preferred Stock (the “Exchange”). <span id="xdx_90B_eus-gaap--CommonStockVotingRights_c20180730__20180731__dei--LegalEntityAxis__custom--GreenCCorporationMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zEPWgUUz39c6" title="Common stock, voting rights">Each share of Series A Convertible Preferred Stock is convertible into <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20180730__20180731__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__dei--LegalEntityAxis__custom--GreenCCorporationMember_zjvY4VlS3Hm6" title="Conversion of convertible preferred stock">50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock. Since after the Exchange was consummated, the former shareholders of Green C and their designees owned approximately <span id="xdx_904_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20180731__srt--TitleOfIndividualAxis__custom--FormerShareHoldersMember__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember_ztb8sFJtcfJa" title="Percentage of issued and outstanding shares acquired">94% of the issued and outstanding voting shares of the Company, Green C is the acquirer for accounting purposes. Prior to the Exchange, the Company had no assets and nominal business operations. Accordingly, the Exchange has been treated for accounting purposes as a recapitalization by the accounting acquirer, Green C, and the accompanying consolidated financial statements of the Company reflect the assets, liabilities and operations of Green C from its inception on December 21, 2017 to July 31, 2018 and combined with the Company thereafter. Green C was incorporated on December 21, 2017 under the laws of the Province of Ontario Canada with its principal place of business in North York, Ontario. Green C was the owner of an exclusive, worldwide license for an eluting transmucosal patch platform (“ETP”) for non-invasive drug delivery in the cannabis field as further described in the exclusive license agreement dated June 21, 2018 with Pharmedica Ltd. (see Note J). After the consummation of the above-described transactions, the Company switched its business model in fiscal 2018 and no longer intended to pursue E-commerce, advertising, licensing (except as specified below) or direct investment operations. Instead, the Company is now engaged in the development and commercialization of innovative cannabinoid therapeutics. From July 2018 through mid-2021, the Company focused on commercializing its own and licensed technologies worldwide for transmucosal and transdermal delivery of legal medical or recreational cannabis (other than in the field of oral care) and cannabinoids. The Company’s initial product was an oral transmucosal patch platform which for provides for loaded actives to be absorbed by the buccal mucosa into the body. Although the Company was able to launch the product and received some limited initial orders, the Company’s management ultimately elected to pursue other opportunities which they believed offered the Company greater potential for growth and ultimate profitability. Accordingly, on October 19, 2021 the Company entered into a license agreement with Shaare Zedek Scientific Ltd. (“SZS”), the technology transfer arm of Jerusalem’s Shaare Zedek Medical Center (SZMC). The license agreement covers the license of SZS’s novel cannabinoid therapeutic focused on treatment of autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease and other neuropsychiatric disorders. Accompanying the license agreement is a joint research and development agreement, which will focus on continuing the clinical program spearheaded by Dr. Adi Aran, M.D. Director of Pediatric Neurology at SZMC, Board Member of the Israeli Society for Pediatric Neurology, and co-inventor of the novel cannabinoid therapy. Principles of Consolidation The consolidated financial statements include the accounts of The Greater Cannabis Company, Inc., and its wholly owned subsidiary Biocanrx, Inc. All intercompany balances and transactions have been eliminated in consolidation. THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Three Months Ended March 31, 2023 and 2022 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Interim Financial Statements The interim financial statements as of March 31, 2023 are unaudited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. These statements reflect all normal and recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the information contained herein. Operating results for the three months ended March 31, 2023 are not necessarily indicative of results that may be expected for the year ending December 31, 2023. Certain information and finance disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the Securities and Exchange Commission’s rules and regulations. These unaudited financial statements should be read in conjunction with our audited financial statements and notes for the year ended December 31, 2022 as included in our report on Form 10-K. Cash and Cash Equivalents Investments having an original maturity of 90 days or less that are readily convertible into cash are considered to be cash equivalents. For the periods presented, the Company had no in cash equivalents. Notes and Accounts Receivable The Company maintains an allowance for doubtful accounts for estimated losses from the failure of its customers to make required payments for products and other consideration delivered. The Company estimates this allowance based on the age of the related receivable, knowledge of the financial condition of customers, review of historical receivables and reserve trends and other pertinent information. If the financial condition of customers deteriorates or an unfavorable trend in receivable collections is experienced in the future, additional allowances may be required. Historically, the Company’s reserves have approximated actual experience. Income Taxes In accordance with Accounting Standards Codification (ASC) 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The asset and liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. We expect to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of March 31, 2023, we had no uncertain tax positions. We recognize interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. We currently have no foreign federal or state tax examinations nor have we had any foreign federal or state examinations since our inception. To date, we have not incurred any interest or tax penalties. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Financial Instruments and Fair Value of Financial Instruments We follow ASC Topic 820, Fair Value Measurements and Disclosures, for assets and liabilities measured at fair value on a recurring basis. ASC Topic 820 establishes a common definition for fair value to be applied to existing US GAAP that requires the use of fair value measurements that establishes a framework for measuring fair value and expands disclosure about such fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Topic 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Three Months Ended March 31, 2023 and 2022 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">Level 1:</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Observable inputs such as quoted market prices in active markets for identical assets or liabilities</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Observable market-based inputs or unobservable inputs that are corroborated by market data</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.</td></tr> </table> The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. Except for derivative liabilities, we had no financial assets or liabilities carried and measured on a recurring or nonrecurring basis during the reporting periods. Derivative Liabilities We evaluate convertible notes payable, stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. <p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zu2E66Grb5Ub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Long-lived Assets Long-lived assets such as property and equipment and intangible assets are periodically reviewed for impairment. We test for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Three Months Ended March 31, 2023 and 2022 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Equity Instruments Issued to Non-Employees for Acquiring Goods or Services Issuances of our common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. Although situations may arise in which counter performance may be required over a period of time, the equity award granted to the party performing the service may be fully vested and non-forfeitable on the date of the agreement. As a result, in this situation in which vesting periods do not exist if the instruments are fully vested on the date of agreement, we determine such date to be the measurement date and will record the estimated fair market value of the instruments granted as a prepaid expense and amortize such amount to expense over the contract period. When it is appropriate for us to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values. Related Parties A party is considered to be related to us if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with us. Related parties also include our principal owners, our management, members of the immediate families of our principal owners and our management and other parties with which we may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties, or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests, is also a related party. THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Three Months Ended March 31, 2023 and 2022 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) <p id="xdx_845_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zhuoafoJG3qi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Revenue Recognition Revenue recognition: The Company adopted Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) on January 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services, in accordance with the following five-step process: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Identify the contract(s) with a customer</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Identify the performance obligations</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Determine the transaction price</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Allocate the transaction price</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Recognize revenue when the performance obligations are met</td></tr> </table> During the periods presented, all revenue was from sales of cannabis products. The Company has determined the sole performance obligation to be the delivery of the purchased goods to the customers, and as such, recognizes revenue at the time the customer takes possession. Advertising Costs Advertising costs are expensed as incurred. For the periods presented, we had no advertising costs. Loss per Share We compute net loss per share in accordance with FASB ASC 260. The ASC specifies the computation, presentation and disclosure requirements for loss per share for entities with publicly held common stock. Basic loss per share amounts is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options, warrants and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net loss per share are excluded from the calculation. For the periods presented, the Company excluded <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zyu2Yb2jDcy6" title="Anti-dilutive shares excluded from computation"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zvKbErj0MMd4" title="Anti-dilutive shares excluded from computation">470,599,900 shares relating to the Series A Convertible Preferred Stock (see Note H), shares relating to convertible notes payable to third parties (Please see NOTE E - NOTES PAYABLE TO THIRD PARTIES for further information) and shares relating to outstanding warrants (Please see NOTE G - CAPITAL STOCK AND WARRANTS for further information) from the calculation of diluted shares outstanding as the effect of their inclusion would be anti-dilutive. THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Three Months Ended March 31, 2023and 2022 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) <p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zz8AD8Tu41rj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Recently Enacted Accounting Standards In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting models for convertible debt instruments and convertible preferred stock. As well as amend the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related EPS guidance. This standard is effective for us on July 1, 2024, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. We are currently evaluating the impact of the adoption of ASU 2020-06 on our financial statements. In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). Financial Instruments—Credit Losses (Topic 326) amends guideline on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available-for-sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. ASU 2016-13 affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this ASU will be effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We are currently evaluating the impact of the adoption of ASU 2016-13 on our financial statements. Other standards not presented are not deemed to be material.

Nature of Operations The Greater Cannabis Company, Inc. (the “Company”) was formed in March 2014 as a limited liability company under the name, The Greater Cannabis Company, LLC. The Company was a wholly owned subsidiary of Sylios Corp (“Sylios”) until March 10, 2017. On July 31, 2018, the Company acquired <span id="xdx_909_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20180731__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember__us-gaap--StatementClassOfStockAxis__custom--ClassACommonStockMember_z1RFuLrG7c5d" title="Percentage of issued and outstanding shares acquired">100% of the issued and outstanding shares of Class A common stock of Green C Corporation (“Green C”) in exchange for <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180730__20180731__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__dei--LegalEntityAxis__custom--GreenCCorporationMember_z8QzwdW57eFk" title="Number of shares issued">9,411,998 newly issued shares of the Company’s Series A Convertible Preferred Stock (the “Exchange”). <span id="xdx_90B_eus-gaap--CommonStockVotingRights_c20180730__20180731__dei--LegalEntityAxis__custom--GreenCCorporationMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zEPWgUUz39c6" title="Common stock, voting rights">Each share of Series A Convertible Preferred Stock is convertible into <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20180730__20180731__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__dei--LegalEntityAxis__custom--GreenCCorporationMember_zjvY4VlS3Hm6" title="Conversion of convertible preferred stock">50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock. Since after the Exchange was consummated, the former shareholders of Green C and their designees owned approximately <span id="xdx_904_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20180731__srt--TitleOfIndividualAxis__custom--FormerShareHoldersMember__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember_ztb8sFJtcfJa" title="Percentage of issued and outstanding shares acquired">94% of the issued and outstanding voting shares of the Company, Green C is the acquirer for accounting purposes. Prior to the Exchange, the Company had no assets and nominal business operations. Accordingly, the Exchange has been treated for accounting purposes as a recapitalization by the accounting acquirer, Green C, and the accompanying consolidated financial statements of the Company reflect the assets, liabilities and operations of Green C from its inception on December 21, 2017 to July 31, 2018 and combined with the Company thereafter. Green C was incorporated on December 21, 2017 under the laws of the Province of Ontario Canada with its principal place of business in North York, Ontario. Green C was the owner of an exclusive, worldwide license for an eluting transmucosal patch platform (“ETP”) for non-invasive drug delivery in the cannabis field as further described in the exclusive license agreement dated June 21, 2018 with Pharmedica Ltd. (see Note J). After the consummation of the above-described transactions, the Company switched its business model in fiscal 2018 and no longer intended to pursue E-commerce, advertising, licensing (except as specified below) or direct investment operations. Instead, the Company is now engaged in the development and commercialization of innovative cannabinoid therapeutics. From July 2018 through mid-2021, the Company focused on commercializing its own and licensed technologies worldwide for transmucosal and transdermal delivery of legal medical or recreational cannabis (other than in the field of oral care) and cannabinoids. The Company’s initial product was an oral transmucosal patch platform which for provides for loaded actives to be absorbed by the buccal mucosa into the body. Although the Company was able to launch the product and received some limited initial orders, the Company’s management ultimately elected to pursue other opportunities which they believed offered the Company greater potential for growth and ultimate profitability. Accordingly, on October 19, 2021 the Company entered into a license agreement with Shaare Zedek Scientific Ltd. (“SZS”), the technology transfer arm of Jerusalem’s Shaare Zedek Medical Center (SZMC). The license agreement covers the license of SZS’s novel cannabinoid therapeutic focused on treatment of autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease and other neuropsychiatric disorders. Accompanying the license agreement is a joint research and development agreement, which will focus on continuing the clinical program spearheaded by Dr. Adi Aran, M.D. Director of Pediatric Neurology at SZMC, Board Member of the Israeli Society for Pediatric Neurology, and co-inventor of the novel cannabinoid therapy.

9411998

Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock

0.94

Principles of Consolidation The consolidated financial statements include the accounts of The Greater Cannabis Company, Inc., and its wholly owned subsidiary Biocanrx, Inc. All intercompany balances and transactions have been eliminated in consolidation.

Interim Financial Statements The interim financial statements as of March 31, 2023 are unaudited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. These statements reflect all normal and recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the information contained herein. Operating results for the three months ended March 31, 2023 are not necessarily indicative of results that may be expected for the year ending December 31, 2023. Certain information and finance disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the Securities and Exchange Commission’s rules and regulations. These unaudited financial statements should be read in conjunction with our audited financial statements and notes for the year ended December 31, 2022 as included in our report on Form 10-K.

Cash and Cash Equivalents Investments having an original maturity of 90 days or less that are readily convertible into cash are considered to be cash equivalents. For the periods presented, the Company had no in cash equivalents.

Notes and Accounts Receivable The Company maintains an allowance for doubtful accounts for estimated losses from the failure of its customers to make required payments for products and other consideration delivered. The Company estimates this allowance based on the age of the related receivable, knowledge of the financial condition of customers, review of historical receivables and reserve trends and other pertinent information. If the financial condition of customers deteriorates or an unfavorable trend in receivable collections is experienced in the future, additional allowances may be required. Historically, the Company’s reserves have approximated actual experience.

Income Taxes In accordance with Accounting Standards Codification (ASC) 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The asset and liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. We expect to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of March 31, 2023, we had no uncertain tax positions. We recognize interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. We currently have no foreign federal or state tax examinations nor have we had any foreign federal or state examinations since our inception. To date, we have not incurred any interest or tax penalties.

Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.

Financial Instruments and Fair Value of Financial Instruments We follow ASC Topic 820, Fair Value Measurements and Disclosures, for assets and liabilities measured at fair value on a recurring basis. ASC Topic 820 establishes a common definition for fair value to be applied to existing US GAAP that requires the use of fair value measurements that establishes a framework for measuring fair value and expands disclosure about such fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Topic 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Three Months Ended March 31, 2023 and 2022 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">Level 1:</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Observable inputs such as quoted market prices in active markets for identical assets or liabilities</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Observable market-based inputs or unobservable inputs that are corroborated by market data</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.</td></tr> </table> The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. Except for derivative liabilities, we had no financial assets or liabilities carried and measured on a recurring or nonrecurring basis during the reporting periods.

Derivative Liabilities We evaluate convertible notes payable, stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date.

<p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zu2E66Grb5Ub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Long-lived Assets Long-lived assets such as property and equipment and intangible assets are periodically reviewed for impairment. We test for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.

Equity Instruments Issued to Non-Employees for Acquiring Goods or Services Issuances of our common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. Although situations may arise in which counter performance may be required over a period of time, the equity award granted to the party performing the service may be fully vested and non-forfeitable on the date of the agreement. As a result, in this situation in which vesting periods do not exist if the instruments are fully vested on the date of agreement, we determine such date to be the measurement date and will record the estimated fair market value of the instruments granted as a prepaid expense and amortize such amount to expense over the contract period. When it is appropriate for us to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values.

Related Parties A party is considered to be related to us if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with us. Related parties also include our principal owners, our management, members of the immediate families of our principal owners and our management and other parties with which we may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties, or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests, is also a related party.

<p id="xdx_845_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zhuoafoJG3qi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Revenue Recognition Revenue recognition: The Company adopted Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) on January 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services, in accordance with the following five-step process: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Identify the contract(s) with a customer</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Identify the performance obligations</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Determine the transaction price</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Allocate the transaction price</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Recognize revenue when the performance obligations are met</td></tr> </table> During the periods presented, all revenue was from sales of cannabis products. The Company has determined the sole performance obligation to be the delivery of the purchased goods to the customers, and as such, recognizes revenue at the time the customer takes possession.

Advertising Costs Advertising costs are expensed as incurred. For the periods presented, we had no advertising costs.

Loss per Share We compute net loss per share in accordance with FASB ASC 260. The ASC specifies the computation, presentation and disclosure requirements for loss per share for entities with publicly held common stock. Basic loss per share amounts is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options, warrants and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net loss per share are excluded from the calculation. For the periods presented, the Company excluded <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zyu2Yb2jDcy6" title="Anti-dilutive shares excluded from computation"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zvKbErj0MMd4" title="Anti-dilutive shares excluded from computation">470,599,900 shares relating to the Series A Convertible Preferred Stock (see Note H), shares relating to convertible notes payable to third parties (Please see NOTE E - NOTES PAYABLE TO THIRD PARTIES for further information) and shares relating to outstanding warrants (Please see NOTE G - CAPITAL STOCK AND WARRANTS for further information) from the calculation of diluted shares outstanding as the effect of their inclusion would be anti-dilutive.

470599900

<p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zz8AD8Tu41rj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Recently Enacted Accounting Standards In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting models for convertible debt instruments and convertible preferred stock. As well as amend the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related EPS guidance. This standard is effective for us on July 1, 2024, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. We are currently evaluating the impact of the adoption of ASU 2020-06 on our financial statements. In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). Financial Instruments—Credit Losses (Topic 326) amends guideline on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available-for-sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. ASU 2016-13 affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this ASU will be effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We are currently evaluating the impact of the adoption of ASU 2016-13 on our financial statements. Other standards not presented are not deemed to be material.

<p id="xdx_80E_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z8TMTVDaaY14" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">NOTE B - GOING CONCERN Under ASC 205-40, we have the responsibility to evaluate whether conditions and/or events raise substantial doubt about our ability to meet our future obligations as they become due within one year after the date the financial statements are issued. As required by this standard, our evaluation shall initially not take into consideration the potential mitigating effects of our plans that have not been fully implemented as of the date the financial statements are issued. In performing the first step of this assessment, we concluded that the following conditions raise substantial doubt about our ability to meet our financial obligations as they become due. As of March 31, 2023, the Company had cash of $251,553, total current liabilities of $848,618, and negative working capital of $597,065. For the three months ended March 31, 2023, we incurred a net loss of $43,068 and used $18,477 cash from operating activities. We expect to continue to incur negative cash flows until such time as our business generates sufficient cash inflows to finance our operations and debt service requirements. In performing the second step of this assessment, we are required to evaluate whether our plans to mitigate the conditions above alleviate the substantial doubt about our ability to meet our obligations as they become due within one year after the date that the financial statements are issued. Our future plans include securing additional funding sources. There is no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available through external sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material effect on the business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company’s existing shareholders. We have therefore concluded there is substantial doubt about our ability to continue as a going concern through March 2024. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of the uncertainty related to our ability to continue as a going concern.

251553

848618

-597065

-43068

-18477

NOTE C – RIGHT OF FIRST REFUSAL AGREEMENT On January 30, 2020, the Company executed a Right of First Refusal Agreement with an entity engaged in the business of cosmetics, health, and well-being. The Agreement provided for the Company to pay Kol Tuv Ventures, LLC (“KTV”), $<span id="xdx_907_eus-gaap--PaymentsForProceedsFromOtherInvestingActivities_c20200129__20200130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KTVMember__us-gaap--TypeOfArrangementAxis__us-gaap--CommitmentsMember__srt--ProductOrServiceAxis__custom--CBDMember_z1ovShaJCRYj" title="Payment for other invetsment opportunities">25,000 on January 30, 2020 (which was paid January 30,2020) and to make other investments in opportunities to be pursued by KTV and/or payments to KTV to enable KTV to pursue and secure Cannabidiol (“CBD”) opportunities. The Agreement provides the Company an exclusive right of first refusal to participate in all CBD opportunities to be pursued by KTV for a term of <span id="xdx_900_ecustom--OpportunitiesTerm_dc_c20200129__20200130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KTVMember__us-gaap--TypeOfArrangementAxis__us-gaap--CommitmentsMember__srt--ProductOrServiceAxis__custom--CBDMember_z1ATLUZiODQc" title="Opportunities term">five years. The $<span id="xdx_909_eus-gaap--CostOfGoodsAndServicesSoldAmortization_c20200129__20200130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KTVMember__us-gaap--TypeOfArrangementAxis__us-gaap--CommitmentsMember__srt--ProductOrServiceAxis__custom--CBDMember_zP5nRo756Fgj" title="Amortization cost">25,000 cost for this Agreement is being amortized over the five year term of the Agreement.

25000

P5Y

25000

<p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zwwlavnpES1e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">NOTE D - LOANS PAYABLE TO RELATED PARTIES <p id="xdx_89E_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zilXG9SBiKFa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Loans payable to related parties consist of: SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20221231_znpnrduJFA5e" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20221231_zm2cK3CKKe6g" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElishaKalfaAndYonahKalfaMember_zxwtOjhQYg6l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Loans from Elisha Kalfa and Yonah Kalfa, holders of a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_c20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElishaKalfaAndYonahKalfaMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zV222a72adNk" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElishaKalfaAndYonahKalfaMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zAMY1ycVR8F7" title="Preferred stock, shares issued">2,966,666 shares of Series A Convertible Preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">180,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">180,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FernandoBiskerAndSigalushLLCMember_zRK03ht61LIg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Loan from Fernando Bisker and Sigalush, LLC, holders of a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FernandoBiskerAndSigalushLLCMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zcz4XqGrDijd" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FernandoBiskerAndSigalushLLCMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zKvj8RZNidR7" title="Preferred stock, shares issued">2,966,666 shares of Series A Convertible Preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">80,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">80,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LoansPayableCurrent_iI_z68wkBcOuFv8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">260,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">260,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> Pursuant to loan and contribution agreements dated July 31, 2018, the above loans are non-interest bearing and are to be repaid after the Company raises from investors no less than $<span id="xdx_906_eus-gaap--RepaymentsOfRelatedPartyDebt_c20180730__20180731__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LoanAndContributionAgreementsMember_zJpqbmcrrqa6" title="Repayments of related party debt">1,500,000 or generates sufficient revenue to make repayments (each, a “Replacement Event”). If the First Replacement Event does not occur within 18 months from July 31, 2018, the loans are to be repaid immediately. In the event there is insufficient capital to repay the loans, the lenders have the option to convert all or part of the loans into shares at the Company common stock at the average trading price of the 10 days prior to the date of the conversion request.

<p id="xdx_89E_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zilXG9SBiKFa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Loans payable to related parties consist of: SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20221231_znpnrduJFA5e" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20221231_zm2cK3CKKe6g" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElishaKalfaAndYonahKalfaMember_zxwtOjhQYg6l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Loans from Elisha Kalfa and Yonah Kalfa, holders of a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_c20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElishaKalfaAndYonahKalfaMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zV222a72adNk" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElishaKalfaAndYonahKalfaMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zAMY1ycVR8F7" title="Preferred stock, shares issued">2,966,666 shares of Series A Convertible Preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">180,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">180,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FernandoBiskerAndSigalushLLCMember_zRK03ht61LIg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Loan from Fernando Bisker and Sigalush, LLC, holders of a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FernandoBiskerAndSigalushLLCMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zcz4XqGrDijd" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FernandoBiskerAndSigalushLLCMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zKvj8RZNidR7" title="Preferred stock, shares issued">2,966,666 shares of Series A Convertible Preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">80,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">80,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LoansPayableCurrent_iI_z68wkBcOuFv8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">260,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">260,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>

2966666

180000

2966666

80000

260000

1500000

NOTE E - NOTES PAYABLE TO THIRD PARTIES Notes payable to third parties consist of: SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230331_zDscSgfWp1W2" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20221231_zGZ7TCZkYQL9" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--NotesPayableCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zy1pJS03fo5k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Promissory Note dated March 28, 2017 payable to John T. Root, Jr., interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20170328__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnT.RootMember_zE2GfaWShBQ9" title="Debt instrument, interest rate">4%, due <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20170327__20170328__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnT.RootMember_zffJI8BntLLc" title="Debt instrument, maturity date">September 28, 2017, convertible into shares of common stock at a conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20170328__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnT.RootMember_ziihQHqBGM55" title="Conversion price">.001 per share.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">375</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">375</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NotesPayableCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zLzBds5GHWM" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Convertible Promissory Note dated March 15, 2021 payable to FirstFire Global Opportunities Fund, LLC (“FF”), interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zeXdAWZlyjf8">6%, due <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20210310__20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zoKrxycJ5XO6">March 11, 2022-less unamortized debt discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zxQr9h89SQ0f">0 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zGUPN00zyNAd">0, respectively. (i)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">243,062</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">243,062</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NotesPayableCurrent_iI_zIZJx6Oxh82h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">243,437</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">243,437</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> (i) On March 15, 2021, we issued a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_z2VSBNfI31Pd" title="Debt instrument, interest rate">6% Convertible Promissory Note to FirstFire Global Opportunities Fund, LLC (“FF”), having a principal amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zybrXi218JDa" title="Debt instrument, principal amount">545,000 and an initial tranche principal amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--ProceedsFromConvertibleDebt_c20210310__20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zKMrkWNUNgp1" title="Proceeds from issuance of convertible debt">272,500 of which $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_z4QUUpq2Zy23" title="Debt conversion, original issue discount">22,500 constituted an original issue discount (the “FF Note”). In connection with the FF Note, we and FF entered into a registration rights agreement, three warrant agreements and a securities purchase agreement. On June 30, 2021, we issued the final tranche principle amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--ProceedsFromConvertibleDebt_c20210629__20210630__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zYgPgcMZ9VKf" title="Proceeds from issuance of convertible debt">272,500 of which $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20210630__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zetqHcl3hvc1" title="Debt conversion, original issue discount">22,500 constituted an original issue discount (the “FF Note).<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--DebtInstrumentMaturityDateDescription_c20210310__20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zFSQc4qes6jb" title="Maturity date description"> The FF Note had an original maturity date of March 11, 2022, which was extended to April 30, 2023 by agreement between the parties dated May 1, 2022, which agreement also waiver certain defaults under the FF Note will mature on. On June 1, 2022, the Company issued 25,000,000 shares for the conversion of $25,000 principal on the FirstFire note dated March 5, 2021 at a conversion price of $.001. During the three months ended September 30, 2022, the Company issued 135,000,000 shares for the conversion of $135,000 principal on the FirstFire note dated March 5, 2021 at a conversion price of $.001. During the three months ended December 31, 2022, the Company issued 64,000,000 shares for the conversion of $64,000 principal on the FirstFire note dated March 5, 2021 at a conversion price of $.001. The FF Note may be pre-paid in whole or in part by paying FF the following premiums: Schedule of Prepay Amount and Date Description <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify">PREPAY DATE</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify">PREPAY AMOUNT</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">≤ 30 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_901_eus-gaap--DebtInstrumentDescription_c20210310__20210315__srt--StatementScenarioAxis__custom--LessThanOrEqualsToThirtyDaysMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zELpoTpoKRqk" title="Debt Instrument, Description">105% * (Principal + Interest (“P+I”)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">31- 60 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_904_eus-gaap--DebtInstrumentDescription_c20210310__20210315__srt--StatementScenarioAxis__custom--ThirtyOneToSixtyDaysMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zxGuEMpDdKgk" title="Debt Instrument, Description">110% * (P+I)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">61-90 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90A_eus-gaap--DebtInstrumentDescription_c20210310__20210315__srt--StatementScenarioAxis__custom--SixtyOneToNinetyDaysMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zVHNPNGuFSxc" title="Debt Instrument, Description">115% * (P+I)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">91-120 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_908_eus-gaap--DebtInstrumentDescription_c20210310__20210315__srt--StatementScenarioAxis__custom--NinetyOneToHundredAndTwentyMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zDELGTdDQgv3" title="Debt Instrument, Description">120% * (P+I)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">121-150 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_908_eus-gaap--DebtInstrumentDescription_c20210310__20210315__srt--StatementScenarioAxis__custom--OnehundredAndTwentyOneToOneHundredFiftyDaysMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zkEpy5GubN35" title="Debt Instrument, Description">125% * (P+I)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">151-180 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_903_eus-gaap--DebtInstrumentDescription_c20210310__20210315__srt--StatementScenarioAxis__custom--OneHundredAndFiftyOneToOneHundredAndEightyMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zZEZKnq4eWx2" title="Debt prepay amount, description">130% * (P+I)</td></tr> </table> THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Three Months Ended March 31, 2023 and 2022 (Unaudited) Any amount of principal or interest on the FF Note, which is not paid when due shall bear interest at the rate of twenty-four (24%) per annum from the due date thereof until the same is paid (“Default Interest”). FF has the right beginning on the date which is the earlier of (i) the date the Registration Statement (as defined below) covering the shares issuable upon conversion of the FFG Notes is declared effective by the Securities and Exchange Commission (the “SEC”) or (ii) one hundred eighty (180) days following the Issue Date to convert all or any part of the outstanding and unpaid principal amount of the FF Note into fully paid and non-assessable shares of our common stock at the conversion price (the “Conversion Price”). The Conversion Price shall be, equal to 70% of the average closing price of our common stock for the five prior trading days prior to the date that a registration statement in respect of the shares into which is the FF Note is convertible is declared effective. The FF Note contains other customary terms found in like instruments for conversion price adjustments. In the case of an Event of Default (as defined in the Note), the FF Note shall become immediately due and payable in an amount (the “Default Amount”) equal to the principal amount then outstanding plus accrued interest (including any Default Interest) through the date of full repayment multiplied by one hundred twenty-five percent (<span id="xdx_908_ecustom--DebtRepaymentPercentage_iI_pid_dp_c20210315__us-gaap--DebtInstrumentAxis__custom--FFNoteMember__dei--LegalEntityAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zmO72nYm0ouj">125%) and interest shall accrue at the rate of Default Interest. Certain events of default will result in further penalties. Default obligations have been waived. Copies of Warrant A, Warrant B and Warrant C are attached as Exhibits 10.4, 10.5 and 10.6 to our current report on Form 8-K dated March 16, 2021. The valuation of the above warrants issued and recorded during the three months ended June 30, 2021 was $262,429. See NOTE -G WARRANTS

Notes payable to third parties consist of: SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230331_zDscSgfWp1W2" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20221231_zGZ7TCZkYQL9" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--NotesPayableCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zy1pJS03fo5k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Promissory Note dated March 28, 2017 payable to John T. Root, Jr., interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20170328__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnT.RootMember_zE2GfaWShBQ9" title="Debt instrument, interest rate">4%, due <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20170327__20170328__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnT.RootMember_zffJI8BntLLc" title="Debt instrument, maturity date">September 28, 2017, convertible into shares of common stock at a conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20170328__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnT.RootMember_ziihQHqBGM55" title="Conversion price">.001 per share.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">375</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">375</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NotesPayableCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zLzBds5GHWM" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Convertible Promissory Note dated March 15, 2021 payable to FirstFire Global Opportunities Fund, LLC (“FF”), interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zeXdAWZlyjf8">6%, due <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20210310__20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zoKrxycJ5XO6">March 11, 2022-less unamortized debt discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zxQr9h89SQ0f">0 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zGUPN00zyNAd">0, respectively. (i)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">243,062</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">243,062</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NotesPayableCurrent_iI_zIZJx6Oxh82h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">243,437</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">243,437</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> (i) On March 15, 2021, we issued a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_z2VSBNfI31Pd" title="Debt instrument, interest rate">6% Convertible Promissory Note to FirstFire Global Opportunities Fund, LLC (“FF”), having a principal amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zybrXi218JDa" title="Debt instrument, principal amount">545,000 and an initial tranche principal amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--ProceedsFromConvertibleDebt_c20210310__20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zKMrkWNUNgp1" title="Proceeds from issuance of convertible debt">272,500 of which $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_z4QUUpq2Zy23" title="Debt conversion, original issue discount">22,500 constituted an original issue discount (the “FF Note”). In connection with the FF Note, we and FF entered into a registration rights agreement, three warrant agreements and a securities purchase agreement. On June 30, 2021, we issued the final tranche principle amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--ProceedsFromConvertibleDebt_c20210629__20210630__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zYgPgcMZ9VKf" title="Proceeds from issuance of convertible debt">272,500 of which $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20210630__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zetqHcl3hvc1" title="Debt conversion, original issue discount">22,500 constituted an original issue discount (the “FF Note).<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gVEhJUkQgUEFSVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--DebtInstrumentMaturityDateDescription_c20210310__20210315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zFSQc4qes6jb" title="Maturity date description"> The FF Note had an original maturity date of March 11, 2022, which was extended to April 30, 2023 by agreement between the parties dated May 1, 2022, which agreement also waiver certain defaults under the FF Note will mature on.

0.04

2017-09-28

0.001

375

0.06

2022-03-11

243062

243437

0.06

545000

272500

22500

272500

22500

The FF Note had an original maturity date of March 11, 2022, which was extended to April 30, 2023 by agreement between the parties dated May 1, 2022, which agreement also waiver certain defaults under the FF Note

25000000

25000

0.001

135000000

135000

0.001

64000000

64000

0.001

The FF Note may be pre-paid in whole or in part by paying FF the following premiums: Schedule of Prepay Amount and Date Description <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify">PREPAY DATE</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify">PREPAY AMOUNT</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">≤ 30 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_901_eus-gaap--DebtInstrumentDescription_c20210310__20210315__srt--StatementScenarioAxis__custom--LessThanOrEqualsToThirtyDaysMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zELpoTpoKRqk" title="Debt Instrument, Description">105% * (Principal + Interest (“P+I”)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">31- 60 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_904_eus-gaap--DebtInstrumentDescription_c20210310__20210315__srt--StatementScenarioAxis__custom--ThirtyOneToSixtyDaysMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zxGuEMpDdKgk" title="Debt Instrument, Description">110% * (P+I)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">61-90 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90A_eus-gaap--DebtInstrumentDescription_c20210310__20210315__srt--StatementScenarioAxis__custom--SixtyOneToNinetyDaysMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zVHNPNGuFSxc" title="Debt Instrument, Description">115% * (P+I)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">91-120 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_908_eus-gaap--DebtInstrumentDescription_c20210310__20210315__srt--StatementScenarioAxis__custom--NinetyOneToHundredAndTwentyMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zDELGTdDQgv3" title="Debt Instrument, Description">120% * (P+I)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">121-150 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_908_eus-gaap--DebtInstrumentDescription_c20210310__20210315__srt--StatementScenarioAxis__custom--OnehundredAndTwentyOneToOneHundredFiftyDaysMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zkEpy5GubN35" title="Debt Instrument, Description">125% * (P+I)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">151-180 days</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_903_eus-gaap--DebtInstrumentDescription_c20210310__20210315__srt--StatementScenarioAxis__custom--OneHundredAndFiftyOneToOneHundredAndEightyMember__us-gaap--DebtInstrumentAxis__custom--FFNoteMember_zZEZKnq4eWx2" title="Debt prepay amount, description">130% * (P+I)</td></tr> </table>

105% * (Principal + Interest (“P+I”)

110% * (P+I)

115% * (P+I)

120% * (P+I)

125% * (P+I)

130% * (P+I)

the date the Registration Statement (as defined below) covering the shares issuable upon conversion of the FFG Notes is declared effective by the Securities and Exchange Commission (the “SEC”) or (ii) one hundred eighty (180) days following the Issue Date to convert all or any part of the outstanding and unpaid principal amount of the FF Note into fully paid and non-assessable shares of our common stock at the conversion price (the “Conversion Price”). The Conversion Price shall be, equal to 70% of the average closing price of our common stock for the five prior trading days prior to the date that a registration statement in respect of the shares into which is the FF Note is convertible is declared effective.

In the case of an Event of Default (as defined in the Note), the FF Note shall become immediately due and payable in an amount (the “Default Amount”) equal to the principal amount then outstanding plus accrued interest (including any Default Interest) through the date of full repayment multiplied by one hundred twenty-five percent (125%) and interest shall accrue at the rate of Default Interest.

1.25

262429

<p id="xdx_804_eus-gaap--DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_zNNpnVE2A5y8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">NOTE F - DERIVATIVE LIABILITY <p id="xdx_896_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_z3MSSQBaV91j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The derivative liability consists of: SCHEDULE OF DERIVATIVE LIABILITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_490_20230331_zMrmoFTOdHb5" style="border-bottom: Black 1.5pt solid; text-align: right">March 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_492_20221231_z9jsgzbTGkPj" style="border-bottom: Black 1.5pt solid; text-align: right">December 31, 2022</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DerivativeLiabilities_iI_hus-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zObd4pOsW4e2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Convertible Promissory Note dated March 15, 2021 and June 30, 2021 payable to FirstFire Global Opportunities Fund, LLC, See Note E (i) Due <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIERFUklWQVRJVkUgTElBQklMSVRZIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230331__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zAVp3m13mxcl" title="Debt instrument, maturity date">March 11, 2022</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DerivativeLiabilities_iI_zixf6yvEcDFg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total derivative liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> The Convertible Promissory Notes (the “Notes”) contain a variable conversion feature based on the future trading price of the Company’s common stock. Therefore, the number of shares of common stock issuable upon conversion of the Notes is indeterminate. The fair value of the derivative liability is measured at the respective issuance dates and quarterly thereafter using the Black Scholes option pricing model. Assumptions used for the calculation of the derivative liability of the Notes at December 31, 2020 were (1) stock price of $<span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zgtGeq0AyAh5" title="Derivative liability measurement input">.003 per share, (2) conversion price of $<span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember_z4PFiDummAz6" title="Derivative liability measurement input">.00169 per share, (3) term of <span id="xdx_90E_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm_dtD_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_za3I9Uv9wEka" title="Derivative liability, measurement input, term">0 days, (4) expected volatility of <span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zpGKf7d6AhNc" title="Derivative liability measurement input">142.94%, and (5) risk free interest rate of <span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_ztWLOjna33Rl" title="Derivative liability measurement input">0%. Assumptions used for the calculation of the derivative liability of the Notes at March 31, 2021 were (1) stock price of $<span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20210331__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zqFKVishJZq7" title="Derivative liability measurement input">.0011 per share, (2) conversion price of $<span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20210331__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember_zMQ0xi4Q9Jn4" title="Derivative liability measurement input">.0071 per share, (3) term of <span id="xdx_900_ecustom--DerivativeLiabilityFairValueAssumptionsExpectedTerm_dtD_c20210101__20210331__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zRyrP8g3THHl" title="Derivative liability, measurement input, term">345 days, (4) expected volatility of <span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20210331__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zEw6y3hRiGpa" title="Derivative liability measurement input">142.94%, and (5) risk free interest rate of <span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20210331__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zNZU4plh72ui" title="Derivative liability measurement input">.07%. As of June 30, 2021, the note no longer carries variable conversion features and as such, the derivative was reduced to zero. (i)As discussed in Note A above, warrants with “down round” features (and do not contain variable conversion features) are not subject to derivative liability treatment effective January 1, 2019.

<p id="xdx_896_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_z3MSSQBaV91j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The derivative liability consists of: SCHEDULE OF DERIVATIVE LIABILITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_490_20230331_zMrmoFTOdHb5" style="border-bottom: Black 1.5pt solid; text-align: right">March 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_492_20221231_z9jsgzbTGkPj" style="border-bottom: Black 1.5pt solid; text-align: right">December 31, 2022</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DerivativeLiabilities_iI_hus-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zObd4pOsW4e2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Convertible Promissory Note dated March 15, 2021 and June 30, 2021 payable to FirstFire Global Opportunities Fund, LLC, See Note E (i) Due <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIERFUklWQVRJVkUgTElBQklMSVRZIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230331__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zAVp3m13mxcl" title="Debt instrument, maturity date">March 11, 2022</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DerivativeLiabilities_iI_zixf6yvEcDFg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total derivative liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>

2022-03-11

0.003

0.00169

P0D

142.94

0.0011

0.0071

P345D

142.94

0.07

NOTE G - CAPITAL STOCK AND WARRANTS Preferred Stock On July 31, 2018, The Greater Cannabis Company, Inc. (the “Company”) acquired <span id="xdx_90E_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20180731__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember__us-gaap--StatementClassOfStockAxis__custom--ClassACommonStockMember_zQDS7aHyhuA5" title="Percentage of issued and outstanding shares acquired">100% of the issued and outstanding shares of Class A common stock of Green C Corporation (“Green C”) in exchange for <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180730__20180731__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember_zdwxzk4H7Dj1" title="Shares issued in acquisition">9,411,998 newly issued shares of the Company’s Series A Convertible Preferred Stock (the Exchange”). <span id="xdx_903_eus-gaap--PreferredStockConversionBasis_c20180730__20180731__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--GreenCCorporationMember_zjsyhArVMMU2" title="Preferred stock, conversion basis">Each share of Series A Convertible Preferred Stock is convertible into <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_c20180730__20180731__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__dei--LegalEntityAxis__custom--GreenCCorporationMember_zXHkAqZjTKsg" title="Conversion of stock, shares converted">50 shares of common stock and is entitled to 50 votes on all matters as a class with the holders of common stock. On February 14, 2019, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190211__20190214__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__dei--LegalEntityAxis__custom--EmetCapitalPartnersLLCMember_zvotgCEMxF54" title="Stock issued new issues">9,000,000 shares of Series B Convertible Preferred Stock to Emet Capital Partners, LLC (“Emet”) in exchange for the surrender of all outstanding warrants held by Emet. <span id="xdx_906_eus-gaap--PreferredStockConversionBasis_c20190211__20190214__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__dei--LegalEntityAxis__custom--EmetCapitalPartnersLLCMember_z0he6oqUrh0h" title="Preferred stock, conversion basis">Each share of Series B Convertible Preferred Stock was convertible into one share of Company common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company common stock was less than $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20190214__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__dei--LegalEntityAxis__custom--EmetCapitalPartnersLLCMember_zNq4Vk7KVkI" title="Debt instrument, convertible, conversion price">0.075 per share. On October 18, 2019, this exchange agreement was reversed. (See Note E) On September 21, 2021, <span id="xdx_901_eus-gaap--ConversionOfStockAmountConverted1_c20210920__20210921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zur3iLfsPF2a" title="Conversion of stock, shares converted">300,000 shares of Series A Preferred Shares were converted into 15,000,000 shares of common stock. Common Stock Effective March 10, 2017, in connection with a partial spin-off of the Company from Sylios Corp, the Company issued a total of 26,905,969 shares of its common stock. 5,378,476 shares were issued to Sylios Corp (representing <span id="xdx_908_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_c20170310__us-gaap--BusinessAcquisitionAxis__custom--SyliosCorpMember_z7ztg00ygA37" title="Business acquisition, percentage of voting interests acquired">19.99% of the issued and outstanding shares of Company common stock after the spin-off) and 21,527,493 shares were issued to the stockholders of record of Sylios Corp on February 3, 2017 on the basis of one share of Company common stock for each 500 shares of Sylios Corp common stock held (representing <span id="xdx_90E_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_c20170203__us-gaap--BusinessAcquisitionAxis__custom--SyliosCorpMember_zPJ6U34PYSmk" title="Business acquisition, percentage of voting interests acquired">80.01% of the issued and outstanding shares of Company common stock after the spin-off). On January 4, 2019, the Company issued <span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20190103__20190104__dei--LegalEntityAxis__custom--EmetCapitalPartnersLLCMember_zVJndykDrbbk" title="Debt conversion, converted instrument, shares issued">769,785 shares of its common stock pursuant to a conversion of $670 principal and $100 accrued interest of its convertible note dated May 25, 2018 by Emet Capital Partners, LLC (“Emet”). This conversion was based on a conversion price of $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20190104__dei--LegalEntityAxis__custom--EmetCapitalPartnersLLCMember_zICCj7030BYi" title="Debt instrument, convertible, conversion price">0.001 per share (rather than the Variable Conversion Price provided in the related note) submitted by Emet in its Conversion Notice. Emet asserted that the Company had committed a dilutive issuance, which triggered the “ratchet-down” provision of the related note which provides for a reduction of the conversion price. The $99,302 excess of the $100,072 fair value of the <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20190101__20190331__dei--LegalEntityAxis__custom--EmetCapitalPartnersLLCMember_pdd" title="Debt conversion, converted instrument, shares issued">769,785 shares over the $<span id="xdx_906_ecustom--LossOnConversionOfNotePayableAndAccruedInterestToCommonStock_c20190101__20190331__dei--LegalEntityAxis__custom--EmetCapitalPartnersLLCMember_pp0p0" title="Loss on conversion of debt">770 liability reduction was charged to Loss on Conversion of Debt in the three months ended March 31, 2019. On January 4, 2019, the Company issued 695,129 shares of its common stock pursuant to an exercise of the equivalent of 1,400 warrants (of the 440,000 warrants issued to Emet Capital Partners, LLC on May 25, 2017) in a cashless exercise transaction based on a ratchet-down exercise price of $0.001 per share. On April 16, 2019, the Company issued 1,384,600 shares of its common stock pursuant to conversions of $40,500 principal and $7,961 accrued interest of two convertible notes issued to by Emet Capital Partners, LLC (“Emet”). The $131,537 excess of the $179,998 fair value of the 1,384,600 shares over the $<span id="xdx_906_ecustom--LossOnConversionOfNotePayableAndAccruedInterestToCommonStock_c20190401__20190630__dei--LegalEntityAxis__custom--EmetCapitalPartnersLLCMember_z0g1WR8YIola" title="Loss on conversion of debt">47,961 liability reduction was charged to Loss on Conversion of Debt in the three months ended June 30, 2019. On May 29, 2019, the Company issued a total of <span id="xdx_909_ecustom--NumberOfSharesIssuedForServices_c20190528__20190529__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoConsultingFirmEntitiesMember_zDat97Eh1mGd" title="Number of shares issued for services">542,000 shares of its common stock to two consulting firm entities for certain specified investor relations and advisory services. The $75,880 fair value of the 542,000 shares was charged to Other Operating Expenses in the three months ended June 30, 2019. THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Three Months Ended March 31, 2023 and 2022 (Unaudited) On August 15, 2019, the Company issued 175,000 shares of its common stock to an entity consultant for accounting services rendered. The $12,250 fair value of the 175,000 shares was charged to Other Operating Expenses. On October 18, 2019, the Company entered into two Exchange Agreements with Emet Capital Partners, LLC (“Emet”). The first Exchange Agreement provided for the exchange of three outstanding convertible notes payable to Emet with a total remaining principal balance of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20191018__us-gaap--DebtInstrumentAxis__custom--ConvertibleWarrantNoteOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--TwoExchangeAgreementMember_zK78VaqyGZgf" title="Debt instrument, face amount">20,399 and a total accrued interest balance of $<span id="xdx_906_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20191018__us-gaap--DebtInstrumentAxis__custom--ConvertibleWarrantNoteOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--TwoExchangeAgreementMember_zWh95H4hiIg7" title="Interest payable">5,189 for three new convertible notes payable to Emet in the total amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_c20191017__20191018__us-gaap--DebtInstrumentAxis__custom--ConvertibleWarrantNoteOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--TwoExchangeAgreementMember_zFWnA9stbi27" title="Debt instrument, periodic payment">25,587. The new notes bear interest at <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20191018__us-gaap--DebtInstrumentAxis__custom--ConvertibleWarrantNoteOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--TwoExchangeAgreementMember_zzgYBpPH4nF9" title="Debt instrument, interest rate, percentage">6%, are due on<span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20191017__20191018__us-gaap--DebtInstrumentAxis__custom--ConvertibleWarrantNoteOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--TwoExchangeAgreementMember_zpRrhePaktS8" title="Debt instrument, maturity date"> February 12, 2020 and are convertible into common stock at a conversion price equal to <span id="xdx_905_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_c20191017__20191018__us-gaap--DebtInstrumentAxis__custom--ConvertibleWarrantNoteOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--TwoExchangeAgreementMember_zMSb6SIGl7Rd" title="Debt convertible threshold percentage">75% of the lowest Trading Price during the <span id="xdx_901_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_dtD_uInteger_c20191017__20191018__us-gaap--DebtInstrumentAxis__custom--ConvertibleWarrantNoteOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--TwoExchangeAgreementMember_zLaWr16xjB82" title="Debt convertible threshold trading days">15 Trading Day Period prior to the Conversion Date. The second Exchange Agreement provided for the reversal of the February 14, 2019 exchange agreement pursuant to which certain warrants then held by Emet were exchanged for <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190211__20190214__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecondExchangeAgreementMember__dei--LegalEntityAxis__custom--EmetCapitalPartnersLLCMember_zFmdGazDiAT3" title="Stock issued new issues">9,000,000 shares of Series B Convertible Preferred Stock (see Note G) and the exchange of such warrants for four new convertible notes payable to Emet in the total amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPayment_c20191017__20191018__us-gaap--DebtInstrumentAxis__custom--FourNewConvertibleWarrantNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecondExchangeAgreementMember_zPOPUIBaZmdf" title="Debt instrument, periodic payment">675,000. These new note bear interest at <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20191018__us-gaap--DebtInstrumentAxis__custom--FourNewConvertibleWarrantNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecondExchangeAgreementMember_zrfXRwvJFrE2" title="Debt instrument, interest rate, percentage">2%, are due on October 18, 2020 and are convertible into common stock at a conversion price equal to <span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_c20191017__20191018__us-gaap--DebtInstrumentAxis__custom--FourNewConvertibleWarrantNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecondExchangeAgreementMember_zu3U2NIg8c14" title="Debt convertible threshold percentage">75% of the lowest Trading Price during the <span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_pid_uInteger_c20191017__20191018__us-gaap--DebtInstrumentAxis__custom--FourNewConvertibleWarrantNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmetCapitalPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecondExchangeAgreementMember_zW5jK7TU5S5a" title="Debt convertible threshold trading days">15 Trading Day Period prior to the Conversion Date. On November 11, 2019, the Company issued 1,748,363 shares of its common stock pursuant to a conversion of $53,705 principal and $2,680 accrued interest and fees of its convertible note dated October 18, 2019 by Emet. On December 20, 2019, the Company issued 1,468,204 shares of its common stock pursuant to a conversion of $29,000 principal and $4,015 accrued interest and fees of its convertible note dated October 18, 2019 by Emet. On December 24, 2019, the Company issued 637,273 shares of its common stock pursuant to a conversion of $10,000 principal and $515 accrued interest and fees of its convertible note dated October 18, 2019 by Emet. During the three months ended March 31, 2020, the Company issued a total of <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20200101__20200331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_pdd" title="Debt conversion, converted instrument, shares issued">21,484,688 shares of common stock pursuant to conversions of an aggregate of $165,350 in principal and $11,793 in interest under our outstanding convertible notes. The $228,949 excess of the $406,093 fair value of the 21,484,688 shares of common stock at the respective dates of issuance over the $177,143 liability reduction was charged to Loss on Conversions of Notes Payable. During the three months ended June 30, 2020, the Company issued a total of <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20200401__20200630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zyvuHjjKaeTb" title="Debt conversion, converted instrument, shares issued">27,563,525 shares of common stock pursuant to conversions of an aggregate of $67,082 in principal and $10,613 in interest under our outstanding convertible notes. The $132,838 excess of the $210,532 fair value of the 27,563,525 shares of common stock at the respective dates of issuance over the $77,695 liability reduction was charged to Loss on Conversions of Notes Payable. During the three months ended September 30, 2020, the Company issued a total of <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20200701__20200930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zzQIZovNLUX1" title="Debt conversion, converted instrument, shares issued">115,277,834 shares of common stock pursuant to conversions of an aggregate of $311,050 in principal and $18,462 in interest under our outstanding convertible notes. The $467,554 excess of the $797,067 fair value of the 115,277,834 shares of common stock at the respective dates of issuance over the $329,512 liability reduction was charged to Loss on Conversions of Notes Payable. During the three months ended December 31, 2020, the Company issued a total of <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20201001__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zZvoZDONkM68" title="Debt conversion, converted instrument, shares issued">261,215,948 shares of common stock pursuant to conversions of an aggregate of $325,212 in principal and $16,849 in interest under our outstanding convertible notes. The $462,263 excess of the $804,324 fair value of the 261,215,948 shares of common stock at the respective dates of issuance over the $342,061 liability reduction was charged to Loss on Conversions of Notes Payable. During the three months ended March 31, 2021, the Company recorded the conversion of note payable ($22,500) and accrued interest ($814) into <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210101__20210331__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zrsBOGJlHEra" title="Debt conversion, converted instrument, shares issued">13,795,118 shares of common stock (Fair Value of $45,525). During the three months ended June 30, 2021, the Company recorded the value of the warrants at $262,429 and the conversion of the second FirstFire note tranche in the amount of $<span id="xdx_90F_eus-gaap--DebtConversionOriginalDebtAmount1_pp0p0_c20210401__20210630__us-gaap--DebtInstrumentAxis__custom--SecondFirstFireNoteMember_zWJbAXb6WdLd" title="Debt conversion, original debt, amount">39,000. On July 15, 2021, the Company issued <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210714__20210715__us-gaap--DebtInstrumentAxis__custom--FirstFireNoteMember_zaLfCfHU8zni" title="Debt conversion, converted instrument, shares issued">10,000,000 shares for the conversion of $52,080 principal on the FirstFire note dated March 5, 2021 at a conversion price of $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20210305__us-gaap--DebtInstrumentAxis__custom--FirstFireNoteMember_zmr0Cc0T2Ym2" title="Debt instrument, convertible, conversion price">.005208. THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Three Months Ended March 31, 2023 and 2022 (Unaudited) Warrants On March 11, 2021, in connection with the issuance of a Convertible Promissory Note to FirstFire Global Opportunities Fund, LLC (“FF”) (see Note F), we issued three warrants (Warrant A, Warrant B and Warrant C) to purchase shares of our common stock, as follows: Warrant A permits FF to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210311__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember__dei--LegalEntityAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zoxPSiPtPDRb" title="Warrant purchase of common stock">25,000,000 shares of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210311__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember__dei--LegalEntityAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zE7GVNbzPsD4" title="Exercise price of warrants">0.025 per share through September 11, 2022. Warrant B permits FF to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210311__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember__dei--LegalEntityAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zALxd8Z2nPvl" title="Warrant purchase of common stock">15,000,000 shares of common stock at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210311__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember__dei--LegalEntityAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zFTy3VtvQKO6" title="Exercise price of warrants">0.05 per share through September 11, 2022. Warrant C permits FF to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210311__us-gaap--StatementEquityComponentsAxis__custom--WarrantCMember__dei--LegalEntityAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zYcsIclQVVPh" title="Warrant purchase of common stock">10,000,000 shares of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210311__us-gaap--StatementEquityComponentsAxis__custom--WarrantCMember__dei--LegalEntityAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_z7h7N7RCsNfd" title="Exercise price of warrants">0.075 per share. through September 11, 2022. Each warrant has other customary terms found in like instruments, including, but not limited to, events of default. In any event of default, the exercise price for each warrant automatically becomes $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210311__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--FirstFireGlobalOpportunitiesFundLLCMember_zUvPqHLLxyzh" title="Exercise price of warrants">0.005 per share. Copies of Warrant A, Warrant B and Warrant C are attached as Exhibits 10.4, 10.5 and 10.6 to our current report on Form 8-K dated March 16, 2021 and the above summary of the warrant terms are subject to full terms of the applicable warrants. The valuation of the above warrants issued and recorded during the three months ended June 30, 2021 was $262,429.

9411998

Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to 50 votes on all matters as a class with the holders of common stock.

9000000

Each share of Series B Convertible Preferred Stock was convertible into one share of Company common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company common stock was less than $0.075 per share.

0.075

300000

15000000

26905969

5378476

0.1999

21527493

500

0.8001

769785

670

100

0.001

99302 100072

769785

770

695129

1400 440000

0.001

1384600

40500

7961

131537 179998

1384600

47961 542000 75880 542000 175000 12250 175000

20399

5189

25587

0.06

2020-02-12

0.75

9000000

675000

0.02

0.75

1748363

53705

2680

1468204

29000

4015

637273

10000

515

21484688

165350

11793

228949

406093

21484688

177143

27563525

67082

10613

132838

210532

27563525

77695

115277834

311050

18462

467554

797067

115277834

329512

261215948

325212

16849

462263

804324

261215948

342061

22500

814

13795118

45525

262429

39000

10000000

52080

0.005208

25000000

0.025

15000000

0.05

10000000

0.075

0.005

262429

NOTE H - INCOME TAXES The Company and its United States subsidiaries file consolidated Federal income tax returns. Green C Corporation, its Ontario Canada subsidiary, files Canada and Ontario income tax returns. At March 31, 2023 the Company has available for federal income tax purposes a net operating loss carry forward that may be used to offset future taxable income. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company, it is not more likely than not that the benefits will be realized. If there are significant changes in the Company’s ownership, the future use of its existing net operating losses will be limited. All tax years of the Company and its United States subsidiaries remain subject to examination by the Internal Revenue Service.

<p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zI2QS1binzg1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">NOTE I - COMMITMENTS AND CONTINGENCIES Pharmedica Exclusive License Agreement On June 21, 2018, Green C executed an Exclusive License Agreement with Pharmedica, Ltd. (“Pharmedica”), an Israeli company, to exploit certain Pharmedica intellectual property for the development and distribution of a certain Licensed Product involved in the transmucosal delivery of medicinal or recreational cannabis. The agreement provides for Green C payments to Pharmedica of a $<span id="xdx_90A_eus-gaap--DirectTaxesAndLicensesCosts_c20180620__20180621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenCCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zUzGdr2crlk8" title="Cost, direct tax and license">100,000 license fee (which was paid by 2591028 Ontario Limited, an entity affiliated with Green C’s Chief Executive Officer, on June 26, 2018) and annual royalties at a rate of <span id="xdx_902_ecustom--AnnualRoyaltiesRate_pid_dp_c20180620__20180621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenCCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_z9pblEmTPZd4" title="Annual royalties rate">5% of the Net Sales of the Licensed Product subject to a Minimum Annual Royalty of $<span id="xdx_907_eus-gaap--RoyaltyExpense_c20180620__20180621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenCCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zTX1egpY2jy5" title="Royalty expense">50,000. The agreement also provides for certain milestones to be accomplished by Green C in order for Green C to retain the license. Green C and Pharmedica each may terminate the agreement upon the occurrence of a material breach by the other party of its obligations under the agreement and such other party’s failure to remedy such breach to the reasonable satisfaction of the other party within thirty (30) days after being requested in writing to do so. The Company generated only minimal revenues from this asset through December 31, 2019 and did not pay the Year 1 Minimum Annual Royalty of $50,000 due Pharmedica. Accordingly, we recorded an impairment charge of $69,749 at December 31, 2019 and reduced the $69,749 remaining carrying value of this intangible asset to $0. On September 2, 2020, Green C notified Pharmedica of Green C’s termination of the Exclusive License Agreement and Green C’s intention to wind up Green C. On September 17, 2020, Pharmedica notified Green C of Pharmedica’s acceptance of Green C’s proposal to terminate the license agreement and Pharmedica’s intention not to burden Green C further. Accordingly, we recorded “Forgiveness of Royalty Payable” other income of $<span id="xdx_907_ecustom--ForgivenessOfRoyaltyPayable_c20200701__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenCCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zzdidrpth2Eh" title="Forgiveness of royalty payable">50,000 in the three months ended September 30, 2020 and reduced the $<span id="xdx_90A_ecustom--ReductionOfAccruedRoyalties_c20200701__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenCCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zRRoVwCu2yhd" title="Reduction of accrued royalties">50,000 “Accrued Royalties” liability balance to $<span id="xdx_900_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_c20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenCCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zR7HtwbNoScb" title="Accrued royalties">0. Sub-License Agreement with Symtomax Unipessoal Lda On July 15, 2019, the Company executed a Sub-License Agreement with Symtomax Unipessoal Lda (“Symtomax”). The agreement provides for the Company’s grant to Symtomax of a non-exclusive right and sub-license to use certain Company technology and intellectual property to develop and commercialize products for sale in Europe, the Middle East, and Africa. The agreement provides for Symtomax payments of royalties to the Company (payable monthly) ranging from <span id="xdx_904_ecustom--AnnualRoyaltiesRate_pid_dp_c20190714__20190715__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--SubLicenseAgreementMember__dei--LegalEntityAxis__custom--SymtomaxUnipessoalLdaMember_z3FT6DR4JmUb" title="Annual royalties rate">10% to <span id="xdx_90E_ecustom--AnnualRoyaltiesRate_pid_dp_c20190714__20190715__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SubLicenseAgreementMember__dei--LegalEntityAxis__custom--SymtomaxUnipessoalLdaMember_zj3UXWGN2NNh" title="Annual royalties rate">17% of Symtomax sales of eluting patches developed from Company technology. On May 27, 2020, the Company executed an amended and restated sub-license agreement with Symtomax (the “Amended License Agreement”). The term of the Amended License Agreement ends the earlier of (i) August 31, 2021 and (ii) the date that Symtomax is no longer commercializing any of the products. The term is extended for an additional year on each anniversary of the agreement for any country where the royalty payment in respect of such country was equal to or greater than $<span id="xdx_90A_eus-gaap--PaymentsForRoyalties_c20200525__20200527__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SubLicenseAgreementMember__dei--LegalEntityAxis__custom--SymtomaxUnipessoalLdaMember_zCgCZO9Nl5Ed" title="Payments for royalties">1,000,000 for the previous year. To date, Symtomax has not made any sales requiring the payment of royalties to the Company. Agreements On July 31, 2018, the Company executed Services Agreements with its newly appointed Chief Executive Officer (the “CEO”), for terms of five years. The Agreement provides for a monthly base salary of $<span id="xdx_906_eus-gaap--OfficersCompensation_c20180730__20180731__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementsMember_z76ixTYSTvPf" title="Officers compensation">10,000 for the CEO. For the three months years ended March 31, 2023 and 2022 the Company expensed a total of $30,000, respectively.

100000

0.05

50000

69749

50000 50000

0.10 0.17

1000000

10000

30000

NOTE J – SUBSEQUENT EVENTS The Company has evaluated subsequent events through the date the financial statements were available to be issued. The Company had no subsequent events that require disclosure.

EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,^+K%8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #/BZQ6%TFG@^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)TEQ#Z&;B^))07!!\1:2V=U@TX1DI-VWMZV[740?P&-F_GSS M#4QKD[(QXW.."3-Y+#=CZ/JB;-JR(U%2 ,4>,9A23XE^:NYC#H:F9SY ,O;# M'! DYQL(2,89,C #J[02F6Z=53:CH9C/>&=7?/K,W0)S%K##@#T5$+4 IN>) MZ31V+5P!,XPPA_)=0+<2E^J?V*4#[)P621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M ,^+K%:,D18"9 4 !X< 8 >&PO=V]R:W-H965T&UL MM9GO;^(V',;?WU]A,6G:I-+$#K]ZHT@TU]ZAM926;J?;M!=N8B!J$C/;@?:_ MW]<))%QE#(N.-VU^/0_^Y&L[3^+^FHL7N6!,H="T3 7);%#7+?C)#1*&X-^?FPB!GV>J3A*V40@F24) M%6]7+.;KRP9N; \\1O.%T@><07])YVS*U!_+B8 ]IW0)HX2E,N(I$FQVV1CB MCSZYT(+\BC\CMI8[VTBC/'/^HG=&X67#U2UB,0N4MJ#P;\5\%L?:"=KQ[\:T M4?ZF%NYN;]UO::2^3S^&H5J<=GH-5#(9C2+U2-??V$;H+;V"W@L\[]H M75S;:C50D$G%DXT86I!$:?&?OFYNQ([ :^\1D(V O!-@;X_ VPB\'+1H68[U MB2HZZ N^1D)?#6YZ([\WN1IHHE27<:H$G(U IP8^7S&!FD@NJ&"R[RCPU&>< M8*._*O1DC]Y#=SQ5"XFNTY"%W^L=:$O9(+)MT!6Q&MY1<8X\?(:(2SQ#>_Q# M\C>$VR;U=ZWQRMOCY7:>]?;\/7R62D"/^\=T@PJ'EME!#\./?<,?]S43W@\R^@VV5L"V;^^ 3#S(8H0H]O2V9B=0NQV[SP81D5=5$ M:I=(;6N;AL 3YDPW,9V;F.SZ&8VEZ5;X5EE-J$X)U3FN3@\9%8J)^ T]LB47 MRL1GMU(B,^)9537QNB5>]\AN*"@\+O+9?C^?W6MO_:RRFH"]$K!W'."$B8B' M>NI$,'D;AYS=J9PL]\Z65GU-SHN2\^(XSIM(!C3>XM[ 8>.3QN[V@$U\5DU- M/NQ6#T_W?Q%^8U3LYSM@MJ^$=EE=QIV @*W-\C,AWB/:>NP!NV83DZ9GK*5= M61>45*#$VK+K5$7J#3ACAL99\LR$$<]NXKINL]UQ2=<(:-76!:RR#+:FARW@ M(YM'.LY 3<"(N/.1;O5-8_74P0>7"4> M;(\L&\XG^HI&( M;3?0+5R'[E,SI]T2MS]\I?$+O.P,5RS-&)IF$=Q [)IGZE/$)USE)VR//>_Y M?;T'M7[BZ]3(;K>[HK&*$BZ,0=&NK8M:12AL3SWO4X?N 4>"B=LS?D$X1: B5: B!P)5SBD8 MW0]F-_BEU?)^-8*=(D"1*D 1>_:YY7G*7_#4%J .F'2]7K/EMHW3CEU:EZ_* M3^2H_+0-Q,4[:93.\T%ICOP''+\9/[GY=E5=SBHID:.2TBA53!2?6778IUMP M(Z?=<1_G*9(2J9(2.2HIZ< /.0'FU3D7QCAXP&?,TR8- @8V8!(6AD;>4R0E M4B4EA^-[+*Z>%4J(D>EHNN$B;D>E9_!02U@DDV6 M-#77M>;'([NN+F@5?\A1\6>Z8%!'&Y[=9C_>*2(/J2(/.2KR %@"+RU3Q8,7 MR#WY^@2ZSQ3$@C2$^AJ)?U"&V=R'PJV=N^GUL!4\G4C'Z[6\3M]9[4(Z.RLP MNO_E"U,2!?KEHUB,*8^6BU_#?,G'J2XO5L[NJ.Z^$L5L!E+WO N_+XK%J&)' M\66^GO/,E>))OKE@-&1"7P#G9YRK[8[^@7))&PO=V]R:W-H965T&ULM5AM;^(X M$/XK%KM:]21:8N>%I"](+66UZ+J[%= [G4[WP4U,L3:)6=NTV_WU-PXT$&(" M>^(^M.1E9O+,BV<>^_)%R&]JQIA&/[(T5U>MF=;S\TY'Q3.6474FYBR'-U,A M,ZKA5CYUU%PRFA1*6=HACA-T,LKS5N^R>'8O>Y=BH5.>LWN)U"++J'R]8:EX MN6KAUMN#$7^::?.@T[NU<8V,*X]"?#,WP^2JY1A$+&6Q-B8H_#RS/DM38PEP?%\9;97?-(J; MUV_6/Q;.@S./5+&^2/_DB9Y=M<(62MB4+E(]$B^?V,HAW]B+1:J*_^AE)>NT M4+Q06F0K94"0\7SY2W^L K&A@+T="F2E0 Y5<%<*1>0Z2V2%6[=4T]ZE%"]( M&FFP9BZ*V!3:X W/31K'6L);#GJZUQ>Y$BE/J&8)NJ$IS6.&QL:<0J?H87R+ M3M[_=MG1\"FCT(E79F^69LD.LY^I/$,N;B/B$->BWF]6OV5QJ4ZJZAUPL/22 ME%Z2PIZ[R\N'T6CP98*NQ^/!9&QS9ZGOV?7-6CI7(ZB)T#2% M9(NT: \T$U+SG[3HOZ#^'OOMT'41S1.X]MI^Z%I;15!+5X2#[E9.ZT+8\7#7 MGM)NZ6GW@+K;76_=>B$%3I3O A26X\*"F=#>\OAG>#2?#@;7L MPF.6W9&,5?R-2G^CQF1:@??:.O6] (?1%D*;&/$WQ*H0-X8U/@BBF$YYS*3Z M\"XDN'L!"S8#7J>*E6F%C>L5'+F.LUWH-KF@(E<%OIZ_N''F];X(SPUMICQY&O_]T]?[VX'H_%;K9S<#CX. M^\/!E_Y?=F+7.,I_M>$\>AAN##"8(F'3\[0+AJ WE;/Z0 MFE%ILKG0,R'Y3Y:TT?LSQ\&F*M$S31?L'(V9-!F_1L"3GQD4JRG?TN@I5\HL M1U,0L$52&BYX_H2B-L:X'45A\69]M_QB&R:NFK-B_Y*^6E/@6R8F)MM5LT>J M&K(U.<#-[* OL@SF^RI>Y"UF2R)?1NZ M '1:!#91UR7MP W;GAN\?64CH@>$K,X?P&3@UCKS7KEJV-9, S=3C>LDX:;] M0E>84PZED:.8SCET"2O<.J6 -ANX!&_CW2]8!;QF'[AQV)M94C([V/?RF-LG M7E@#<.JYKA]U:\/#)DDB$CF[:G+-'' S=5CVXJ(D9R)--B;?R1(ZR^-7>S>K MDX53/^R&4:T'VP0]+]RUJR!K7D&:><5D>U04J^&_.$/JM,+*5VUR#825K/D' M:>8?([:LEWN8VZ_H[\_%>O['"K71T"]OJ(]DK>KVQNG!8<<'>Y@Z.>XAPO]Q MBD#6](0+ G00J:6:MHM*J*C;Q;0+DQR(52=F MM@-=?_V.DY 2F@*ME@N(D_.^?LZ)XY/11L@'E0!H\ICR3(VM1.O5I6VK*(&4 MJHY8089W%D*F5.-0+FVUDD#C0I1RVW.WR">'Y3<0U7*O M*;YKQ(FJ9":O9$S:IJ2ZQT"@HG\U*L0[XI$%*A,1U$#U<$)7@$U&$YCH1DCU!W 9<>O9V M489.<>PQGQ#8P.[6V-VW8:^H)&O*%-KB#FCMX _?!Z@8G5?=85(.R7U/VWUY=["1* MTRQFV;(-M_^B9GW?"_Q!UP_VD$^);& /:NS!0>P92(:@5P2WQC7@UC#G0)Z7 M],RD0W[=0CH'^;LMAX/VIBU?JA6-8&QAWU4@UV"%GSZX@?.E;5_\3V:-2@SK M2@S?M?TPI?+VMV/XXJ$,7=<=#@=[#^]X7 /8=9Z[F?,NY"/+KG(]#GY"8$EN M[[1D\SV$#7#),D4X+%#I=/IH(<7IPE^EH$T 7A_(83> M#DSCKS_TPG]02P,$% @ SXNL5JRS&>3_! B1@ !@ !X;"]W;W)K MRC8U!*"$X#\$R]QZ?8^GJ2&*X8?R[6 )(])K$ MJ1AUEE*NKAU'S):04''%5I"J;^:,)U2J)E\X8L6!AGE2$CO$=0,GH5':&0_S M>X]\/&29C*,4'CD269)0_N\MQ&PSZN#.]L93M%A*?<,9#U=T <\@7U:/7+6< M"B6,$DA%Q%+$83[JW.#K">GIA#SBSP@V8N<::2E3QK[KQGTXZKB:$<0PDQJ" MJH\U3"".-9+B\4\)VJF>J1-WK[?H=[EX)69*!4Q8_"T*Y7+4Z7=0"'.:Q?*) M;7Z#4E!7X\U8+/+_:%/$!NJ)LTQ(EI3)JIU$:?%)7\L7L9.@<,P)I$P@^PG^ MD02O3/!RH06S7-9G*NEXR-D&<1VMT/1%_F[R;*4F2G4W/DNNOHU4GAQ/6"I8 M'(540HB>I?I0?20%8G/T=06?Z,+G[\-'2D(J!A MG%GYL-OB8>3(PSSTP%*Y%.A+&D+8S'<4\8H]V;*_)5; !\JOD(=_1L0EGH'/ MY/WIQ$+'JUZFE^-Y1_">8 UI!M>F-U-D^N9,7:S78D5G,.JH:A3 U] 9__0# M#MQ?3+): FN(]"N1O@U]_ >3-%85G$LU*;6FF\DAD\CS<1KZNI6^KE7?A FI MA_^*LS";221H#,*DTPIS@L[S<1HZ@TIG8-7Y*V=":)7S2**+6#6,%6T%.4'E M^3@-E;U*9<]:DN4DEB[0EU=E?0*$L3I[;59G2V -O?U*;]_:JU_G\V@&7* 9 M2[3>? (W*2Y@NCF,]OKUV'/5W]!9[TIY*ZK!<5!Q'%@YWB2,R^B_G)JNM'SM MH"_N(JYJ[PGFF2HZ=+/@D+N1TB*D2B"X?8[IC\/@=\_4[F>+#_A[XP0'5PS"?^-XQ MJJ2F2JQ4[U,U:J&C8-_0.\'!'&,*"P;8/](WM8]C MNY'O3S,A3"4*(S%CF5KA&@FW9>DE4$/2H._YY(BFVK.QW;3+8C:/.J.DX'U] M8 C#;I=T@R.,:__%5KO;J^DIJ)TGZ%7'.LIW@JJY%2+IZY%9J6>H7L\]K')# M'/9[0?^8B-I4L=U5'T_C:P4[91B=#]047#LTMEOT[R"1[C&CO"(U>+,[#'&V M[B"U^1*[^=Y2$";R^[P7[ M<@Y#NVY_+[0IJW9N8G?NQW*S]-<#)%/@?QNI6B%.];^VT)J":^,G']_JDU:- MOBVTIM#:Z,F9VWU[_@FS70M 38WU2H&\M>5/11;GJ^,[4%5H'<4?6"-8.KCE!@H^/X@_LV"U"6T)K"JU7(<2^"GE[%']@TVX>Q><#%1J=G4/=!/@B M/^O6^WJU>BU.2*N[U7GZ37Z*O'?_%E]/BE/Q&J8XI'^@?!&E L4P5Y#N54^- M1EZ<>Q<-R5;YT?&42:%<00 '05 8 >&PO=V]R:W-H965T&UL MK5C;;N,V$/T50BV*76 3B=3%4FH;2)PMVH;DF*^2W= MD4R^65.68B&;;&/R'2,X*IS2Q$26Y9DICC-C/BWZEFP^I7N1Q!E9,L#W:8K9 MMP>2T./,@,9[QW.\V8J\PYQ/=WA#5D2\[)9,MLP:)8I3DO&89H"1] M,W=L/[^C_U8$+X-YQ9PL:/)7'(GMS/ -$)$UWB?BF1Y_)U5 !<&0)KSX!Q=/@(;L#+ZA%\^/GCU!2238YIAM7( M#^7(Z,S(-GBBF=AR\#F+2-3U-V44=2CH/90'I 5\PNP6V/ 30!:R%7P6U[LC M#1V[GEF[P'/.X#V039QE<;:1:9;@+"3\$SC@9$]44U5">054OO,.\QO7<7S; MFIJ'=@@*.\<++ _5=AVN3LW5T7+](L^+A'*NHE9ZNITA;=!;^+X:J)>3=33$EW0-)7'4K%IP-]/ M)'TE[!\53RU,?FK?\1T.RR=L^Y8%VXYE MAW!0$PY^>#]J/=5+#E2I\_]Q.J%!JU$<:Z0M70%=S!J%G2YM8$LG*020OA 8M#[HM+5EVF30& ] 7 L%JW G.[ M)�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�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end XML 47 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 48 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 158 172 1 false 65 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://gcanrx.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://gcanrx.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://gcanrx.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://gcanrx.com/role/StatementsOfOperations Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Stockholders Deficiency (Unaudited) Sheet http://gcanrx.com/role/StatementsOfStockholdersDeficiency Consolidated Statements of Stockholders Deficiency (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://gcanrx.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 00000008 - Disclosure - GOING CONCERN Sheet http://gcanrx.com/role/GoingConcern GOING CONCERN Notes 8 false false R9.htm 00000009 - Disclosure - RIGHT OF FIRST REFUSAL AGREEMENT Sheet http://gcanrx.com/role/RightOfFirstRefusalAgreement RIGHT OF FIRST REFUSAL AGREEMENT Notes 9 false false R10.htm 00000010 - Disclosure - LOANS PAYABLE TO RELATED PARTIES Sheet http://gcanrx.com/role/LoansPayableToRelatedParties LOANS PAYABLE TO RELATED PARTIES Notes 10 false false R11.htm 00000011 - Disclosure - NOTES PAYABLE TO THIRD PARTIES Notes http://gcanrx.com/role/NotesPayableToThirdParties NOTES PAYABLE TO THIRD PARTIES Notes 11 false false R12.htm 00000012 - Disclosure - DERIVATIVE LIABILITY Sheet http://gcanrx.com/role/DerivativeLiability DERIVATIVE LIABILITY Notes 12 false false R13.htm 00000013 - Disclosure - CAPITAL STOCK AND WARRANTS Sheet http://gcanrx.com/role/CapitalStockAndWarrants CAPITAL STOCK AND WARRANTS Notes 13 false false R14.htm 00000014 - Disclosure - INCOME TAXES Sheet http://gcanrx.com/role/IncomeTaxes INCOME TAXES Notes 14 false false R15.htm 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://gcanrx.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 15 false false R16.htm 00000016 - Disclosure - SUBSEQUENT EVENTS Sheet http://gcanrx.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 16 false false R17.htm 00000017 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 00000018 - Disclosure - LOANS PAYABLE TO RELATED PARTIES (Tables) Sheet http://gcanrx.com/role/LoansPayableToRelatedPartiesTables LOANS PAYABLE TO RELATED PARTIES (Tables) Tables http://gcanrx.com/role/LoansPayableToRelatedParties 18 false false R19.htm 00000019 - Disclosure - NOTES PAYABLE TO THIRD PARTIES (Tables) Notes http://gcanrx.com/role/NotesPayableToThirdPartiesTables NOTES PAYABLE TO THIRD PARTIES (Tables) Tables http://gcanrx.com/role/NotesPayableToThirdParties 19 false false R20.htm 00000020 - Disclosure - DERIVATIVE LIABILITY (Tables) Sheet http://gcanrx.com/role/DerivativeLiabilityTables DERIVATIVE LIABILITY (Tables) Tables http://gcanrx.com/role/DerivativeLiability 20 false false R21.htm 00000021 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies 21 false false R22.htm 00000022 - Disclosure - GOING CONCERN (Details Narrative) Sheet http://gcanrx.com/role/GoingConcernDetailsNarrative GOING CONCERN (Details Narrative) Details http://gcanrx.com/role/GoingConcern 22 false false R23.htm 00000023 - Disclosure - RIGHT OF FIRST REFUSAL AGREEMENT (Details Narrative) Sheet http://gcanrx.com/role/RightOfFirstRefusalAgreementDetailsNarrative RIGHT OF FIRST REFUSAL AGREEMENT (Details Narrative) Details http://gcanrx.com/role/RightOfFirstRefusalAgreement 23 false false R24.htm 00000024 - Disclosure - SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES (Details) Sheet http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetails SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES (Details) Details 24 false false R25.htm 00000025 - Disclosure - SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES (Details) (Parenthetical) Sheet http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetailsParenthetical SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES (Details) (Parenthetical) Details 25 false false R26.htm 00000026 - Disclosure - LOANS PAYABLE TO RELATED PARTIES (Details Narrative) Sheet http://gcanrx.com/role/LoansPayableToRelatedPartiesDetailsNarrative LOANS PAYABLE TO RELATED PARTIES (Details Narrative) Details http://gcanrx.com/role/LoansPayableToRelatedPartiesTables 26 false false R27.htm 00000027 - Disclosure - SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES (Details) Notes http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetails SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES (Details) Details 27 false false R28.htm 00000028 - Disclosure - SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES (Details) (Parenthetical) Notes http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES (Details) (Parenthetical) Details 28 false false R29.htm 00000029 - Disclosure - Schedule of Prepay Amount and Date Description (Details) Sheet http://gcanrx.com/role/ScheduleOfPrepayAmountAndDateDescriptionDetails Schedule of Prepay Amount and Date Description (Details) Details 29 false false R30.htm 00000030 - Disclosure - NOTES PAYABLE TO THIRD PARTIES (Details Narrative) Notes http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative NOTES PAYABLE TO THIRD PARTIES (Details Narrative) Details http://gcanrx.com/role/NotesPayableToThirdPartiesTables 30 false false R31.htm 00000031 - Disclosure - SCHEDULE OF DERIVATIVE LIABILITY (Details) Sheet http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetails SCHEDULE OF DERIVATIVE LIABILITY (Details) Details 31 false false R32.htm 00000032 - Disclosure - SCHEDULE OF DERIVATIVE LIABILITY (Details) (Parenthetical) Sheet http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetailsParenthetical SCHEDULE OF DERIVATIVE LIABILITY (Details) (Parenthetical) Details 32 false false R33.htm 00000033 - Disclosure - DERIVATIVE LIABILITY (Details Narrative) Sheet http://gcanrx.com/role/DerivativeLiabilityDetailsNarrative DERIVATIVE LIABILITY (Details Narrative) Details http://gcanrx.com/role/DerivativeLiabilityTables 33 false false R34.htm 00000034 - Disclosure - CAPITAL STOCK AND WARRANTS (Details Narrative) Sheet http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative CAPITAL STOCK AND WARRANTS (Details Narrative) Details http://gcanrx.com/role/CapitalStockAndWarrants 34 false false R35.htm 00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://gcanrx.com/role/CommitmentsAndContingencies 35 false false All Reports Book All Reports form10-q.htm ex31-1.htm ex32-1.htm gcan-20230331.xsd gcan-20230331_cal.xml gcan-20230331_def.xml gcan-20230331_lab.xml gcan-20230331_pre.xml form10-q_001.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 51 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 16, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 365, "http://xbrl.sec.gov/dei/2023": 26 }, "contextCount": 158, "dts": { "calculationLink": { "local": [ "gcan-20230331_cal.xml" ] }, "definitionLink": { "local": [ "gcan-20230331_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "gcan-20230331_lab.xml" ] }, "presentationLink": { "local": [ "gcan-20230331_pre.xml" ] }, "schema": { "local": [ "gcan-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 336, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 39, "http://xbrl.sec.gov/dei/2023": 4, "total": 43 }, "keyCustom": 22, "keyStandard": 150, "memberCustom": 41, "memberStandard": 19, "nsprefix": "GCAN", "nsuri": "http://gcanrx.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://gcanrx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - LOANS PAYABLE TO RELATED PARTIES", "menuCat": "Notes", "order": "10", "role": "http://gcanrx.com/role/LoansPayableToRelatedParties", "shortName": "LOANS PAYABLE TO RELATED PARTIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - NOTES PAYABLE TO THIRD PARTIES", "menuCat": "Notes", "order": "11", "role": "http://gcanrx.com/role/NotesPayableToThirdParties", "shortName": "NOTES PAYABLE TO THIRD PARTIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - DERIVATIVE LIABILITY", "menuCat": "Notes", "order": "12", "role": "http://gcanrx.com/role/DerivativeLiability", "shortName": "DERIVATIVE LIABILITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - CAPITAL STOCK AND WARRANTS", "menuCat": "Notes", "order": "13", "role": "http://gcanrx.com/role/CapitalStockAndWarrants", "shortName": "CAPITAL STOCK AND WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "14", "role": "http://gcanrx.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "15", "role": "http://gcanrx.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "16", "role": "http://gcanrx.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "GCAN:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "17", "role": "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "GCAN:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - LOANS PAYABLE TO RELATED PARTIES (Tables)", "menuCat": "Tables", "order": "18", "role": "http://gcanrx.com/role/LoansPayableToRelatedPartiesTables", "shortName": "LOANS PAYABLE TO RELATED PARTIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "GCAN:NotePayableDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - NOTES PAYABLE TO THIRD PARTIES (Tables)", "menuCat": "Tables", "order": "19", "role": "http://gcanrx.com/role/NotesPayableToThirdPartiesTables", "shortName": "NOTES PAYABLE TO THIRD PARTIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "GCAN:NotePayableDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://gcanrx.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - DERIVATIVE LIABILITY (Tables)", "menuCat": "Tables", "order": "20", "role": "http://gcanrx.com/role/DerivativeLiabilityTables", "shortName": "DERIVATIVE LIABILITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2017-03-092017-03-10", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "21", "role": "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - GOING CONCERN (Details Narrative)", "menuCat": "Details", "order": "22", "role": "http://gcanrx.com/role/GoingConcernDetailsNarrative", "shortName": "GOING CONCERN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:LiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-01-292020-01-30_custom_KTVMember_us-gaap_CommitmentsMember_custom_CBDMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForProceedsFromOtherInvestingActivities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - RIGHT OF FIRST REFUSAL AGREEMENT (Details Narrative)", "menuCat": "Details", "order": "23", "role": "http://gcanrx.com/role/RightOfFirstRefusalAgreementDetailsNarrative", "shortName": "RIGHT OF FIRST REFUSAL AGREEMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-01-292020-01-30_custom_KTVMember_us-gaap_CommitmentsMember_custom_CBDMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForProceedsFromOtherInvestingActivities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LoansPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES (Details)", "menuCat": "Details", "order": "24", "role": "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetails", "shortName": "SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LoansPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_custom_SeriesAConvertiblePreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES (Details) (Parenthetical)", "menuCat": "Details", "order": "25", "role": "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetailsParenthetical", "shortName": "SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_custom_ElishaKalfaAndYonahKalfaMember_custom_SeriesAConvertiblePreferredStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2018-07-302018-07-31_srt_MaximumMember_custom_LoanAndContributionAgreementsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfRelatedPartyDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - LOANS PAYABLE TO RELATED PARTIES (Details Narrative)", "menuCat": "Details", "order": "26", "role": "http://gcanrx.com/role/LoansPayableToRelatedPartiesDetailsNarrative", "shortName": "LOANS PAYABLE TO RELATED PARTIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2018-07-302018-07-31_srt_MaximumMember_custom_LoanAndContributionAgreementsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfRelatedPartyDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "GCAN:NotePayableDebtTableTextBlock", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES (Details)", "menuCat": "Details", "order": "27", "role": "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetails", "shortName": "SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "GCAN:NotePayableDebtTableTextBlock", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2019-12-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES (Details) (Parenthetical)", "menuCat": "Details", "order": "28", "role": "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical", "shortName": "SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "GCAN:NotePayableDebtTableTextBlock", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2017-03-28_custom_PromissoryNoteMember_custom_JohnT.RootMember", "decimals": "INF", "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-03-102021-03-15_custom_LessThanOrEqualsToThirtyDaysMember_custom_FFNoteMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Schedule of Prepay Amount and Date Description (Details)", "menuCat": "Details", "order": "29", "role": "http://gcanrx.com/role/ScheduleOfPrepayAmountAndDateDescriptionDetails", "shortName": "Schedule of Prepay Amount and Date Description (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-03-102021-03-15_custom_LessThanOrEqualsToThirtyDaysMember_custom_FFNoteMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://gcanrx.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2019-12-232019-12-24", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - NOTES PAYABLE TO THIRD PARTIES (Details Narrative)", "menuCat": "Details", "order": "30", "role": "http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative", "shortName": "NOTES PAYABLE TO THIRD PARTIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "lang": "en-US", "name": "us-gaap:DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SCHEDULE OF DERIVATIVE LIABILITY (Details)", "menuCat": "Details", "order": "31", "role": "http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetails", "shortName": "SCHEDULE OF DERIVATIVE LIABILITY (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-03-31_us-gaap_ConvertibleDebtMember_custom_FirstFireGlobalOpportunitiesFundLLCMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - SCHEDULE OF DERIVATIVE LIABILITY (Details) (Parenthetical)", "menuCat": "Details", "order": "32", "role": "http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetailsParenthetical", "shortName": "SCHEDULE OF DERIVATIVE LIABILITY (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-03-31_us-gaap_ConvertibleDebtMember_custom_FirstFireGlobalOpportunitiesFundLLCMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-03-31_custom_ConvertiblePromissoryNoteMember_us-gaap_MeasurementInputSharePriceMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - DERIVATIVE LIABILITY (Details Narrative)", "menuCat": "Details", "order": "33", "role": "http://gcanrx.com/role/DerivativeLiabilityDetailsNarrative", "shortName": "DERIVATIVE LIABILITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-03-31_custom_ConvertiblePromissoryNoteMember_us-gaap_MeasurementInputSharePriceMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2017-03-092017-03-10", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - CAPITAL STOCK AND WARRANTS (Details Narrative)", "menuCat": "Details", "order": "34", "role": "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "shortName": "CAPITAL STOCK AND WARRANTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2019-12-24", "decimals": "0", "lang": null, "name": "us-gaap:InterestPayableCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OfficersCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "menuCat": "Details", "order": "35", "role": "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2019-01-012019-12-31_custom_PharmedicaLtdMember", "decimals": "0", "lang": null, "name": "us-gaap:RoyaltyExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OfficersCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://gcanrx.com/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:OtherCostAndExpenseOperating", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Stockholders Deficiency (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://gcanrx.com/role/StatementsOfStockholdersDeficiency", "shortName": "Consolidated Statements of Stockholders Deficiency (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://gcanrx.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:IncreaseDecreaseInAccountsPayableTrade", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "7", "role": "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies", "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - GOING CONCERN", "menuCat": "Notes", "order": "8", "role": "http://gcanrx.com/role/GoingConcern", "shortName": "GOING CONCERN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - RIGHT OF FIRST REFUSAL AGREEMENT", "menuCat": "Notes", "order": "9", "role": "http://gcanrx.com/role/RightOfFirstRefusalAgreement", "shortName": "RIGHT OF FIRST REFUSAL AGREEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 65, "tag": { "GCAN_AnnualRoyaltiesRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual royalties rate.", "label": "Annual royalties rate" } } }, "localname": "AnnualRoyaltiesRate", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "GCAN_CBDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CBD [Member]", "label": "CBD [Member]" } } }, "localname": "CBDMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/RightOfFirstRefusalAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_ClassACommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class A Common Stock [Member]", "label": "Class A Common Stock [Member]" } } }, "localname": "ClassACommonStockMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_CommonStockSharesHeld": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock, shares held.", "label": "Common stock, shares held" } } }, "localname": "CommonStockSharesHeld", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "GCAN_ConsultingFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting Fees [Member]", "label": "Consulting Fees [Member]" } } }, "localname": "ConsultingFeesMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "domainItemType" }, "GCAN_ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Notes [Member]", "label": "Convertible Notes [Member]" } } }, "localname": "ConvertibleNotesMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_ConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Promissory Note [Member]", "label": "Convertible Promissory Note [Member]" } } }, "localname": "ConvertiblePromissoryNoteMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/DerivativeLiabilityDetailsNarrative", "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetails", "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "GCAN_ConvertibleWarrantNoteOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Warrant Note One [Member]", "label": "Convertible Warrant Note One [Member]" } } }, "localname": "ConvertibleWarrantNoteOneMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_DebtRepaymentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt repayment percentage.", "label": "Debt repayment percentage" } } }, "localname": "DebtRepaymentPercentage", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "GCAN_DerivativeLiabilityFairValueAssumptionsExpectedTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative liability fair value assumptions expected term.", "label": "Derivative liability, measurement input, term" } } }, "localname": "DerivativeLiabilityFairValueAssumptionsExpectedTerm", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/DerivativeLiabilityDetailsNarrative" ], "xbrltype": "durationItemType" }, "GCAN_ElishaKalfaAndYonahKalfaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Elisha Kalfa And Yonah Kalfa [Member]", "label": "Elisha Kalfa And Yonah Kalfa [Member]" } } }, "localname": "ElishaKalfaAndYonahKalfaMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetails", "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "GCAN_EmetCapitalPartnersLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emet Capital Partners, LLC [Member]", "label": "Emet Capital Partners, LLC [Member]" } } }, "localname": "EmetCapitalPartnersLLCMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_ExcessOfCommonStockValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of common stock value.", "label": "Excess of common stock value" } } }, "localname": "ExcessOfCommonStockValue", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "GCAN_ExcessOfFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Excess of fair value.", "label": "Excess of fair value" } } }, "localname": "ExcessOfFairValue", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "GCAN_ExclusiveLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exclusive License Agreement [Member]", "label": "Exclusive License Agreement [Member]" } } }, "localname": "ExclusiveLicenseAgreementMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_FFNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "FF Note [Member]", "label": "FF Note [Member]" } } }, "localname": "FFNoteMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative", "http://gcanrx.com/role/ScheduleOfPrepayAmountAndDateDescriptionDetails" ], "xbrltype": "domainItemType" }, "GCAN_FairValueOfCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of common stock.", "label": "Fair value of common stock" } } }, "localname": "FairValueOfCommonStock", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "GCAN_FairValueOfSharesChargedToOtherOperatingExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued for services.", "label": "Value of shares issued for services" } } }, "localname": "FairValueOfSharesChargedToOtherOperatingExpenses", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "GCAN_FernandoBiskerAndSigalushLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fernando Bisker And Sigalush LLC [Member]", "label": "Fernando Bisker And Sigalush LLC [Member]" } } }, "localname": "FernandoBiskerAndSigalushLLCMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetails", "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "GCAN_FirstFireGlobalOpportunitiesFundLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "FirstFire Global Opportunities Fund, LLC [Member]", "label": "FirstFire Global Opportunities Fund, LLC [Member]" } } }, "localname": "FirstFireGlobalOpportunitiesFundLLCMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative", "http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetailsParenthetical", "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "GCAN_FirstFireNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "FirstFire note [Member]", "label": "FirstFire note [Member]" } } }, "localname": "FirstFireNoteMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_ForgivenessOfRoyaltyPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Forgiveness of royalty payable.", "label": "Forgiveness of royalty payable" } } }, "localname": "ForgivenessOfRoyaltyPayable", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "GCAN_FormerShareHoldersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Share Holders [Member]", "label": "Former Share Holders [Member]" } } }, "localname": "FormerShareHoldersMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_FourNewConvertibleWarrantNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four New Convertible Warrant Notes [Member]", "label": "Four New Convertible Warrant Notes [Member]" } } }, "localname": "FourNewConvertibleWarrantNotesMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_GreenCCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Green C Corporation [Member]", "label": "Green C Corporation [Member]" } } }, "localname": "GreenCCorporationMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_InterimFinancialStatementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interim financial statements [Policy Text Block]", "label": "Interim Financial Statements" } } }, "localname": "InterimFinancialStatementsPolicyTextBlock", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "GCAN_JohnT.RootMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "John T. Root [Member]", "label": "John T. Root [Member]" } } }, "localname": "JohnT.RootMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "GCAN_KTVMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "KTV [Member]", "label": "KTV [Member]" } } }, "localname": "KTVMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/RightOfFirstRefusalAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_LessThanOrEqualsToThirtyDaysMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "= 30 days [Member]", "label": "Less than or Equal to 30 Days [Member]" } } }, "localname": "LessThanOrEqualsToThirtyDaysMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/ScheduleOfPrepayAmountAndDateDescriptionDetails" ], "xbrltype": "domainItemType" }, "GCAN_LiabilityReduction": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability reduction.", "label": "Liability reduction" } } }, "localname": "LiabilityReduction", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "GCAN_LoanAndContributionAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan and Contribution Agreements [Member]", "label": "Loan and Contribution Agreements [Member]" } } }, "localname": "LoanAndContributionAgreementsMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/LoansPayableToRelatedPartiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_LossOnConversionOfNotePayableAndAccruedInterestToCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss on conversion of note payable and accrued interest to common stock.", "label": "Loss on conversion of debt" } } }, "localname": "LossOnConversionOfNotePayableAndAccruedInterestToCommonStock", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "GCAN_NatureOfOperationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nature of operations [Policy Text Block]", "label": "Nature of Operations" } } }, "localname": "NatureOfOperationsPolicyTextBlock", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "GCAN_NinetyOneToHundredAndTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "91 - 120 Days [Member].", "label": "91 - 120 Days [Member]" } } }, "localname": "NinetyOneToHundredAndTwentyMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/ScheduleOfPrepayAmountAndDateDescriptionDetails" ], "xbrltype": "domainItemType" }, "GCAN_NotePayableDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note payable debt [Table Text Block].", "label": "SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES" } } }, "localname": "NotePayableDebtTableTextBlock", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/NotesPayableToThirdPartiesTables" ], "xbrltype": "textBlockItemType" }, "GCAN_NotesPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes Payable [Member]", "label": "Notes Payable [Member]" } } }, "localname": "NotesPayableMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_NumberOfSharesIssuedForOtherOperatingExpenses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for other operating expenses.", "label": "Number of shares issued for other operating expenses" } } }, "localname": "NumberOfSharesIssuedForOtherOperatingExpenses", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "GCAN_NumberOfSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for services.", "label": "Number of shares issued for services" } } }, "localname": "NumberOfSharesIssuedForServices", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "GCAN_OneHundredAndFiftyOneToOneHundredAndEightyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "151 - 180 Days [Member].", "label": "151 - 180 Days [Member]" } } }, "localname": "OneHundredAndFiftyOneToOneHundredAndEightyMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/ScheduleOfPrepayAmountAndDateDescriptionDetails" ], "xbrltype": "domainItemType" }, "GCAN_OnehundredAndTwentyOneToOneHundredFiftyDaysMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "121 - 150 Days [Member].", "label": "121 - 150 Days [Member]" } } }, "localname": "OnehundredAndTwentyOneToOneHundredFiftyDaysMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/ScheduleOfPrepayAmountAndDateDescriptionDetails" ], "xbrltype": "domainItemType" }, "GCAN_OpportunitiesTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Opportunities term.", "label": "Opportunities term" } } }, "localname": "OpportunitiesTerm", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/RightOfFirstRefusalAgreementDetailsNarrative" ], "xbrltype": "durationItemType" }, "GCAN_PharmedicaLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmedica Ltd [Member]", "label": "Pharmedica Ltd [Member]" } } }, "localname": "PharmedicaLtdMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note [Member]", "label": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetails", "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "GCAN_ReductionOfAccruedRoyalties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reduction of accrued royalties.", "label": "Reduction of accrued royalties" } } }, "localname": "ReductionOfAccruedRoyalties", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "GCAN_ReductionOfCarryingValueOfAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reduction of carrying value of assets.", "label": "Reduction of carrying value of assets" } } }, "localname": "ReductionOfCarryingValueOfAssets", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "GCAN_RelatedPartiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Parties [Policy Text Block]", "label": "Related Parties" } } }, "localname": "RelatedPartiesPolicyTextBlock", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "GCAN_SecondExchangeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second Exchange Agreement [Member]", "label": "Second Exchange Agreement [Member]" } } }, "localname": "SecondExchangeAgreementMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_SecondFirstFireNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second FirstFire Note [Member]", "label": "Second FirstFire Note [Member]" } } }, "localname": "SecondFirstFireNoteMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Convertible Preferred Stock [Member]", "label": "Series A Convertible Preferred Stock [Member]" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/BalanceSheetsParenthetical", "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "GCAN_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Convertible Preferred Stock [Member]", "label": "Series B Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_ServicesAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Services agreements [Member]", "label": "Services Agreements [Member]" } } }, "localname": "ServicesAgreementsMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_SixtyOneToNinetyDaysMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "61 - 90 Days [Member].", "label": "61 - 90 Days [Member]" } } }, "localname": "SixtyOneToNinetyDaysMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/ScheduleOfPrepayAmountAndDateDescriptionDetails" ], "xbrltype": "domainItemType" }, "GCAN_SubLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sub license agreement [Member]", "label": "Sub License Agreement [Member]" } } }, "localname": "SubLicenseAgreementMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_SyliosCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sylios Corp [Member]", "label": "Sylios Corp [Member]" } } }, "localname": "SyliosCorpMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_SymtomaxUnipessoalLdaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Symtomax unipessoal lda [Member]", "label": "Symtomax Unipessoal IDA [Member]" } } }, "localname": "SymtomaxUnipessoalLdaMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_ThirtyOneToSixtyDaysMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "31 - 60 Days [Member].", "label": "31 - 60 Days [Member]" } } }, "localname": "ThirtyOneToSixtyDaysMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/ScheduleOfPrepayAmountAndDateDescriptionDetails" ], "xbrltype": "domainItemType" }, "GCAN_TwoConsultingFirmEntitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Consulting Firm Entities [Member]", "label": "Two Consulting Firm Entities [Member]" } } }, "localname": "TwoConsultingFirmEntitiesMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_TwoExchangeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Exchange Agreement [Member]", "label": "Two Exchange Agreement [Member]" } } }, "localname": "TwoExchangeAgreementMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_WarrantAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant A [Member]", "label": "Warrant A [Member]" } } }, "localname": "WarrantAMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_WarrantBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant B [Member]", "label": "Warrant B [Member]" } } }, "localname": "WarrantBMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_WarrantCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant C [Member]", "label": "Warrant C [Member]" } } }, "localname": "WarrantCMember", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "GCAN_WarrantIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant issued.", "label": "Number of warrant issued" } } }, "localname": "WarrantIssued", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "GCAN_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital deficit.", "label": "Working capital deficit", "negatedLabel": "Working capital deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://gcanrx.com/20230331", "presentation": [ "http://gcanrx.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r522", "r524", "r525" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gcanrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r203", "r204", "r205", "r206", "r263", "r329", "r361", "r397", "r398", "r458", "r459", "r460", "r461", "r469", "r477", "r478", "r487", "r493", "r497", "r500", "r563", "r601", "r602", "r603", "r604", "r605", "r606" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gcanrx.com/role/LoansPayableToRelatedPartiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r203", "r204", "r205", "r206", "r263", "r329", "r361", "r397", "r398", "r458", "r459", "r460", "r461", "r469", "r477", "r478", "r487", "r493", "r497", "r500", "r563", "r601", "r602", "r603", "r604", "r605", "r606" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r190", "r330", "r355", "r356", "r357", "r358", "r359", "r360", "r480", "r494", "r499", "r535", "r559", "r560", "r566", "r610" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://gcanrx.com/role/RightOfFirstRefusalAgreementDetailsNarrative", "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r190", "r330", "r355", "r356", "r357", "r358", "r359", "r360", "r480", "r494", "r499", "r535", "r559", "r560", "r566", "r610" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://gcanrx.com/role/RightOfFirstRefusalAgreementDetailsNarrative", "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r203", "r204", "r205", "r206", "r261", "r263", "r265", "r266", "r267", "r328", "r329", "r361", "r397", "r398", "r458", "r459", "r460", "r461", "r469", "r477", "r478", "r487", "r493", "r497", "r500", "r503", "r553", "r563", "r602", "r603", "r604", "r605", "r606" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gcanrx.com/role/LoansPayableToRelatedPartiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r203", "r204", "r205", "r206", "r261", "r263", "r265", "r266", "r267", "r328", "r329", "r361", "r397", "r398", "r458", "r459", "r460", "r461", "r469", "r477", "r478", "r487", "r493", "r497", "r500", "r503", "r553", "r563", "r602", "r603", "r604", "r605", "r606" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gcanrx.com/role/LoansPayableToRelatedPartiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r165", "r264", "r532", "r549" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://gcanrx.com/role/ScheduleOfPrepayAmountAndDateDescriptionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r165", "r264", "r532", "r533", "r549" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://gcanrx.com/role/ScheduleOfPrepayAmountAndDateDescriptionDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r551", "r597" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r13", "r498" ], "calculation": { "http://gcanrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://gcanrx.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued officers\u2019 compensation" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": { "auth_ref": [ "r62" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.", "label": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r72", "r498", "r613" ], "calculation": { "http://gcanrx.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r268", "r269", "r270", "r378", "r546", "r547", "r548", "r593", "r614" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfStockholdersDeficiency" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to net cash provided (used) in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r6", "r57", "r83", "r232" ], "calculation": { "http://gcanrx.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://gcanrx.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discounts", "negatedLabel": "Amortization of debt discounts" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows", "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Anti-dilutive shares excluded from computation" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gcanrx.com/role/LoansPayableToRelatedPartiesDetailsNarrative", "http://gcanrx.com/role/RightOfFirstRefusalAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r6", "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset impairment charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r100", "r126", "r146", "r178", "r184", "r188", "r196", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r290", "r292", "r309", "r345", "r418", "r498", "r510", "r561", "r562", "r599" ], "calculation": { "http://gcanrx.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r122", "r130", "r146", "r196", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r290", "r292", "r309", "r498", "r561", "r562", "r599" ], "calculation": { "http://gcanrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER ASSETS" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r288", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r49", "r51", "r288", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Percentage of issued and outstanding shares acquired", "verboseLabel": "Business acquisition, percentage of voting interests acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r25", "r124", "r481" ], "calculation": { "http://gcanrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets", "http://gcanrx.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r25", "r85", "r144" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "CASH BALANCE, END OF PERIOD", "periodStartLabel": "CASH BALANCE, BEGINNING OF PERIOD" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r3", "r85" ], "calculation": { "http://gcanrx.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE (DECREASE) IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r536", "r609" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r119", "r127", "r128", "r129", "r146", "r167", "r168", "r170", "r172", "r176", "r177", "r196", "r208", "r210", "r211", "r212", "r215", "r216", "r234", "r235", "r238", "r241", "r248", "r309", "r369", "r370", "r371", "r372", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r406", "r427", "r449", "r470", "r471", "r472", "r473", "r474", "r531", "r542", "r550" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheetsParenthetical", "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetailsParenthetical", "http://gcanrx.com/role/StatementsOfStockholdersDeficiency" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [ "r127", "r128", "r129", "r176", "r234", "r235", "r236", "r238", "r241", "r246", "r248", "r369", "r370", "r371", "r372", "r493", "r531", "r542" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Exercise price of warrants" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Warrant purchase of common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r91", "r200", "r201", "r476", "r554" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "RIGHT OF FIRST REFUSAL AGREEMENT" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/RightOfFirstRefusalAgreement" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsMember": { "auth_ref": [ "r69", "r103" ], "lang": { "en-us": { "role": { "documentation": "This element represents significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements.", "label": "Commitments [Member]" } } }, "localname": "CommitmentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/RightOfFirstRefusalAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r501", "r502", "r503", "r505", "r506", "r507", "r508", "r546", "r547", "r593", "r611", "r614" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/StatementsOfStockholdersDeficiency" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r71", "r406" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r9", "r71", "r406", "r424", "r614", "r615" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r71", "r347", "r498" ], "calculation": { "http://gcanrx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock; 2,000,000,000 shares authorized, $.001 par value, as of March 31, 2023 and December 31, 2022, there are 732,638,436 shares outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common stock, voting rights" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r52", "r483" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r28", "r29", "r30" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of stock, shares converted" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r28", "r29", "r30" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of convertible preferred stock", "verboseLabel": "Conversion of stock, shares converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r28", "r29", "r30" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of stock, shares issued" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r93", "r217", "r218", "r223", "r224", "r225", "r228", "r229", "r230", "r231", "r232", "r488", "r489", "r490", "r491", "r492" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetails", "http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r80", "r330" ], "calculation": { "http://gcanrx.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of product sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSoldAmortization": { "auth_ref": [ "r540" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.", "label": "Amortization cost" } } }, "localname": "CostOfGoodsAndServicesSoldAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/RightOfFirstRefusalAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r28", "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Principal amount", "verboseLabel": "Debt conversion, converted instrument, amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r28", "r30" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Shares issued in conversion", "verboseLabel": "Debt conversion, converted instrument, shares issued" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r28", "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt conversion, original debt, amount" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Description of the facts pertaining to a notice received from a lender that an event of default has occurred with respect to the long-term debt instrument or borrowing, and a description of the expected financial consequences of receiving such notice, including the effects of a demand for immediate repayment of all amounts due, and the classification of the debt on the balance sheet.", "label": "Debt instrument, debt notice of default, description" } } }, "localname": "DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r12", "r67", "r68", "r101", "r102", "r151", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r316", "r488", "r489", "r490", "r491", "r492", "r543" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/DerivativeLiabilityDetailsNarrative", "http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative", "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetails", "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical", "http://gcanrx.com/role/ScheduleOfPrepayAmountAndDateDescriptionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r94", "r219" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Conversion price", "verboseLabel": "Debt instrument, convertible, conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative", "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt convertible threshold percentage" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt convertible threshold trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentDescription": { "auth_ref": [ "r12", "r45", "r64", "r67", "r101", "r102" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.", "label": "Debt prepay amount, description" } } }, "localname": "DebtInstrumentDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/ScheduleOfPrepayAmountAndDateDescriptionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r58", "r59", "r217", "r316", "r489", "r490" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt instrument, principal amount", "verboseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r19", "r218" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt instrument, interest rate", "verboseLabel": "Debt instrument, interest rate, percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r117", "r488", "r595" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt instrument, maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetailsParenthetical", "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Maturity date description" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r21", "r151", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r316", "r488", "r489", "r490", "r491", "r492", "r543" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/DerivativeLiabilityDetailsNarrative", "http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative", "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetails", "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical", "http://gcanrx.com/role/ScheduleOfPrepayAmountAndDateDescriptionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r21", "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt instrument, periodic payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r57", "r59", "r564" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "auth_ref": [ "r57", "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.", "label": "Debt conversion, original issue discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault": { "auth_ref": [ "r31", "r41" ], "lang": { "en-us": { "role": { "documentation": "Discussion of the facts and amounts pertaining to each failure to comply with an affirmative or negative covenant of a long-term debt instrument, including violating payment terms or an inability to meet certain minimum financial requirements or achieve or maintain certain financial ratios. The discussion would generally be expected to also include whether or not the failure can and will be overcome and a description of the terms of any waivers, including the amount of the waiver and the period of time covered by the waiver, and if reclassification of long-term debt to current has been made in the current balance sheet.", "label": "Debt instrument event of default, description" } } }, "localname": "DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r99", "r294", "r301" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "DERIVATIVE LIABILITY" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/DerivativeLiability" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r131", "r132", "r308", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r419", "r421", "r422", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r482", "r612" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Total derivative liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative liability measurement input" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/DerivativeLiabilityDetailsNarrative" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r10", "r53", "r54", "r55", "r56", "r150" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivative Liabilities" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DirectTaxesAndLicensesCosts": { "auth_ref": [ "r540" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax incurred and cost of license directly related to good produced or service rendered.", "label": "Cost, direct tax and license" } } }, "localname": "DirectTaxesAndLicensesCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r139", "r157", "r158", "r159", "r160", "r161", "r166", "r167", "r170", "r171", "r172", "r174", "r304", "r305", "r343", "r352", "r484" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic and diluted income (loss) per common share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r32", "r33" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Loss per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r9", "r120", "r136", "r137", "r138", "r152", "r153", "r154", "r156", "r162", "r164", "r175", "r197", "r198", "r250", "r268", "r269", "r270", "r281", "r282", "r295", "r296", "r297", "r298", "r299", "r300", "r303", "r310", "r311", "r312", "r313", "r314", "r315", "r317", "r362", "r363", "r364", "r378", "r449" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/StatementsOfStockholdersDeficiency" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r2", "r6" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Issuance of warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r8", "r11" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Financial Instruments and Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r125", "r199" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r79", "r146", "r178", "r183", "r187", "r189", "r196", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r309", "r486", "r561" ], "calculation": { "http://gcanrx.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit (loss)" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r0", "r90" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r1", "r77", "r105", "r178", "r183", "r187", "r189", "r344", "r350", "r486" ], "calculation": { "http://gcanrx.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (loss) before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r147", "r271", "r275", "r276", "r279", "r283", "r285", "r286", "r287", "r374" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r110", "r116", "r163", "r164", "r181", "r274", "r284", "r354" ], "calculation": { "http://gcanrx.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r135", "r272", "r273", "r276", "r277", "r278", "r280", "r368" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income tax paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r5" ], "calculation": { "http://gcanrx.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r5" ], "calculation": { "http://gcanrx.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) in Interest Payable, Net", "verboseLabel": "Accrued interest" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r5" ], "calculation": { "http://gcanrx.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "verboseLabel": "Accrued officers\u2019 compensation" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r37", "r38" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "auth_ref": [], "calculation": { "http://gcanrx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.", "label": "Right of first refusal agreement cost (less accumulated amortization of $15,833 and $14,583)" } } }, "localname": "IntangibleAssetsNetIncludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://gcanrx.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r140", "r142", "r143" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://gcanrx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r62", "r607" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest payable" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r16", "r146", "r196", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r291", "r292", "r293", "r309", "r405", "r485", "r510", "r561", "r599", "r600" ], "calculation": { "http://gcanrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total current liabilities and total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r76", "r104", "r349", "r498", "r544", "r552", "r596" ], "calculation": { "http://gcanrx.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 (deficiency)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIENCY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r18", "r123", "r146", "r196", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r291", "r292", "r293", "r309", "r498", "r561", "r599", "r600" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, current" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Total" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [ "r202", "r203", "r204", "r207", "r556", "r558" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r202", "r203", "r204", "r207", "r556", "r558" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputConversionPriceMember": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using price per share at which convertible share can be converted into common stock.", "label": "Measurement Input, Conversion Price [Member]" } } }, "localname": "MeasurementInputConversionPriceMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/DerivativeLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/DerivativeLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/DerivativeLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/DerivativeLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/DerivativeLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/DerivativeLiabilityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/DerivativeLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r141" ], "calculation": { "http://gcanrx.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r141" ], "calculation": { "http://gcanrx.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r85", "r86", "r87" ], "calculation": { "http://gcanrx.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Cash used from operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/GoingConcernDetailsNarrative", "http://gcanrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r78", "r87", "r106", "r121", "r133", "r134", "r138", "r146", "r155", "r157", "r158", "r159", "r160", "r163", "r164", "r169", "r178", "r183", "r187", "r189", "r196", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r305", "r309", "r351", "r426", "r447", "r448", "r486", "r509", "r561" ], "calculation": { "http://gcanrx.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://gcanrx.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "negatedLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/GoingConcernDetailsNarrative", "http://gcanrx.com/role/StatementsOfCashFlows", "http://gcanrx.com/role/StatementsOfOperations", "http://gcanrx.com/role/StatementsOfStockholdersDeficiency" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently Enacted Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://gcanrx.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expenses)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expenses):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r12", "r102", "r608" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "verboseLabel": "Total" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r539" ], "calculation": { "http://gcanrx.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Officers compensation" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://gcanrx.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r178", "r183", "r187", "r189", "r486" ], "calculation": { "http://gcanrx.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OtherCostAndExpenseOperating": { "auth_ref": [ "r81", "r353" ], "calculation": { "http://gcanrx.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other operating expenses" } } }, "localname": "OtherCostAndExpenseOperating", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDepreciationAndAmortization": { "auth_ref": [ "r6", "r40", "r81" ], "calculation": { "http://gcanrx.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://gcanrx.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.", "label": "Amortization of Right of First Refusal Agreement cost" } } }, "localname": "OtherDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows", "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r17", "r498" ], "calculation": { "http://gcanrx.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Loans payable to related parties" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNotesPayableCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://gcanrx.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Notes payable to third parties" } } }, "localname": "OtherNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r534", "r541" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payment for other invetsment opportunities" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/RightOfFirstRefusalAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRoyalties": { "auth_ref": [ "r4" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for royalties during the current period.", "label": "Payments for royalties" } } }, "localname": "PaymentsForRoyalties", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherInvestments": { "auth_ref": [ "r84" ], "calculation": { "http://gcanrx.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investments classified as other.", "label": "Payments to Acquire Other Investments", "negatedLabel": "Purchase of Right of First Refusal Agreement" } } }, "localname": "PaymentsToAcquireOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConversionBasis": { "auth_ref": [ "r45", "r70" ], "lang": { "en-us": { "role": { "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.", "label": "Preferred stock, conversion basis" } } }, "localname": "PreferredStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [ "r501", "r502", "r505", "r506", "r507", "r508", "r611", "r614" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfStockholdersDeficiency" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r70", "r234" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r70", "r406" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r70", "r234" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheetsParenthetical", "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetailsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r70", "r406", "r424", "r614", "r615" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r70", "r346", "r498" ], "calculation": { "http://gcanrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock; 19,000,000 shares authorized, $.001 par value: Series A Convertible Preferred-issued and outstanding 9,111,998 and 9,111,998 shares, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r23" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from issuance of convertible debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r23" ], "calculation": { "http://gcanrx.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from notes payable to third parties" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductLiabilityContingencyLineItems": { "auth_ref": [ "r205", "r555", "r557", "r559" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Liability Contingency [Line Items]" } } }, "localname": "ProductLiabilityContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/RightOfFirstRefusalAgreementDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ProductLiabilityContingencyTable": { "auth_ref": [ "r205", "r555", "r557", "r559" ], "lang": { "en-us": { "role": { "documentation": "Information and financial data about the reasonably possible loss or the recognized and additional reasonably possible loss from product liability related to an individual product.", "label": "Product Liability Contingency [Table]" } } }, "localname": "ProductLiabilityContingencyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/RightOfFirstRefusalAgreementDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedAndNonrelatedPartyStatusAxis": { "auth_ref": [ "r148", "r149", "r321", "r322", "r323", "r324", "r400", "r401", "r402", "r403", "r404", "r423", "r425", "r504" ], "lang": { "en-us": { "role": { "documentation": "Information by related and nonrelated party status.", "label": "Related and Nonrelated Party Status [Axis]" } } }, "localname": "RelatedAndNonrelatedPartyStatusAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedAndNonrelatedPartyStatusDomain": { "auth_ref": [ "r148", "r149", "r321", "r322", "r323", "r324", "r400", "r401", "r402", "r403", "r404", "r423", "r425", "r504" ], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated party status." } } }, "localname": "RelatedAndNonrelatedPartyStatusDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r262", "r321", "r322", "r400", "r401", "r402", "r403", "r404", "r423", "r425", "r457" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gcanrx.com/role/RightOfFirstRefusalAgreementDetailsNarrative", "http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetailsParenthetical", "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetails", "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetailsParenthetical", "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyMember": { "auth_ref": [ "r148", "r149", "r321", "r322", "r323", "r324", "r400", "r401", "r402", "r403", "r404", "r423", "r425", "r457" ], "lang": { "en-us": { "role": { "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family.", "label": "Related Party [Member]" } } }, "localname": "RelatedPartyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [ "r430", "r431", "r434" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets", "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetails", "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r262", "r321", "r322", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r400", "r401", "r402", "r403", "r404", "r423", "r425", "r457", "r598" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gcanrx.com/role/RightOfFirstRefusalAgreementDetailsNarrative", "http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetailsParenthetical", "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetails", "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetailsParenthetical", "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r318", "r319", "r320", "r322", "r325", "r375", "r376", "r377", "r432", "r433", "r434", "r454", "r456" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "LOANS PAYABLE TO RELATED PARTIES" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/LoansPayableToRelatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of related party debt" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/LoansPayableToRelatedPartiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r73", "r98", "r348", "r365", "r366", "r373", "r407", "r498" ], "calculation": { "http://gcanrx.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r120", "r152", "r153", "r154", "r156", "r162", "r164", "r197", "r198", "r268", "r269", "r270", "r281", "r282", "r295", "r297", "r298", "r300", "r303", "r362", "r364", "r378", "r614" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfStockholdersDeficiency" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r179", "r180", "r182", "r185", "r186", "r190", "r191", "r192", "r259", "r260", "r330" ], "calculation": { "http://gcanrx.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r118", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r479" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r21", "r45", "r48", "r57", "r58", "r59", "r63", "r96", "r97", "r489", "r491", "r545" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Prepay Amount and Date Description" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NotesPayableToThirdPartiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative liabilities at fair value.", "label": "SCHEDULE OF DERIVATIVE LIABILITY" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/DerivativeLiabilityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r60", "r61", "r430", "r431", "r434" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets", "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetails", "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/LoansPayableToRelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/DerivativeLiabilityDetailsNarrative", "http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative", "http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetails", "http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetailsParenthetical", "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetails", "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical", "http://gcanrx.com/role/ScheduleOfPrepayAmountAndDateDescriptionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r42", "r43", "r44", "r45", "r46", "r47", "r48", "r96", "r97", "r98", "r127", "r128", "r129", "r176", "r234", "r235", "r236", "r238", "r241", "r246", "r248", "r369", "r370", "r371", "r372", "r493", "r531", "r542" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r537", "r538", "r565" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/StatementsOfStockholdersDeficiency" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche One [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balances, shares", "periodStartLabel": "Beginning balances, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfStockholdersDeficiency" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/DerivativeLiabilityDetailsNarrative", "http://gcanrx.com/role/NotesPayableToThirdPartiesDetailsNarrative", "http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetails", "http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetailsParenthetical", "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetails", "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical", "http://gcanrx.com/role/ScheduleOfPrepayAmountAndDateDescriptionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTextBlock": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for short-term debt.", "label": "NOTES PAYABLE TO THIRD PARTIES" } } }, "localname": "ShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NotesPayableToThirdParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetails", "http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetails", "http://gcanrx.com/role/ScheduleOfDerivativeLiabilityDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r119", "r127", "r128", "r129", "r146", "r167", "r168", "r170", "r172", "r176", "r177", "r196", "r208", "r210", "r211", "r212", "r215", "r216", "r234", "r235", "r238", "r241", "r248", "r309", "r369", "r370", "r371", "r372", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r406", "r427", "r449", "r470", "r471", "r472", "r473", "r474", "r531", "r542", "r550" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheetsParenthetical", "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://gcanrx.com/role/ScheduleOfLoansPayableToRelatedPartiesDetailsParenthetical", "http://gcanrx.com/role/StatementsOfStockholdersDeficiency" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r9", "r22", "r120", "r136", "r137", "r138", "r152", "r153", "r154", "r156", "r162", "r164", "r175", "r197", "r198", "r250", "r268", "r269", "r270", "r281", "r282", "r295", "r296", "r297", "r298", "r299", "r300", "r303", "r310", "r311", "r312", "r313", "r314", "r315", "r317", "r362", "r363", "r364", "r378", "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/StatementsOfStockholdersDeficiency" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r152", "r153", "r154", "r175", "r330", "r367", "r389", "r399", "r400", "r401", "r402", "r403", "r404", "r406", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r419", "r420", "r421", "r422", "r423", "r425", "r428", "r429", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r449", "r504" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheetsParenthetical", "http://gcanrx.com/role/LoansPayableToRelatedPartiesDetailsNarrative", "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://gcanrx.com/role/StatementsOfOperations", "http://gcanrx.com/role/StatementsOfStockholdersDeficiency" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r152", "r153", "r154", "r175", "r330", "r367", "r389", "r399", "r400", "r401", "r402", "r403", "r404", "r406", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r419", "r420", "r421", "r422", "r423", "r425", "r428", "r429", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r449", "r504" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheetsParenthetical", "http://gcanrx.com/role/LoansPayableToRelatedPartiesDetailsNarrative", "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://gcanrx.com/role/StatementsOfOperations", "http://gcanrx.com/role/StatementsOfStockholdersDeficiency" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r9", "r70", "r71", "r98", "r369", "r449", "r471" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Number of shares issued", "verboseLabel": "Stock issued new issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r71", "r74", "r75", "r89", "r408", "r424", "r450", "r451", "r498", "r510", "r544", "r552", "r596", "r614" ], "calculation": { "http://gcanrx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balances, value", "periodStartLabel": "Beginning balances, value", "totalLabel": "Total stockholders\u2019 (deficiency)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets", "http://gcanrx.com/role/StatementsOfStockholdersDeficiency" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 (DEFICIENCY)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r95", "r145", "r233", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r247", "r250", "r302", "r452", "r455", "r475" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "CAPITAL STOCK AND WARRANTS" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrants" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityPolicyTextBlock": { "auth_ref": [ "r7", "r453" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.", "label": "Equity Instruments Issued to Non-Employees for Acquiring Goods or Services" } } }, "localname": "StockholdersEquityPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Disclosures of Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r107", "r108", "r109", "r193", "r194", "r195" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Notes and Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative", "http://gcanrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gcanrx.com/role/LoansPayableToRelatedPartiesDetailsNarrative", "http://gcanrx.com/role/RightOfFirstRefusalAgreementDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r34", "r35", "r36", "r112", "r113", "r114", "r115" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/ScheduleOfNotesPayableToThirdPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r501", "r502", "r505", "r506", "r507", "r508" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/CapitalStockAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r166", "r172" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average common shares outstanding-basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gcanrx.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(7)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(4)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13A(Column E))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r511": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r512": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r513": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r514": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r515": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r516": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r517": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r518": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r519": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r521": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r522": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r523": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r524": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r525": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r526": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r527": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r528": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r529": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(2))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org//205-40/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org//815/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 52 0001493152-23-016758-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-016758-xbrl.zip M4$L#!!0 ( ,^+K%;)4+4GQ@@ $!2 * 97@S,2TQ+FAT;>U<45/C M.!)^GZKY#SJJ=BM4.83 <%4+6:I"8H940>!"YNKFWA1;3G384D:R"=E??]V2 MG3@A0-@E#,Z:!R"VU.J6Y._[U%+A%50RZ.R?[.Z:]BH,S"P,9QS): MO!:R *SNGY"8/<15&O(A>*'X< 1%!M2[&RJ9"+_JR5"J8S(9\9CMG#;.K[O] MO%_5@$8\G!Z_Y)DIJ_D?S 8"ELY.W8<1'_#X\Z?#^EZ]43N#/D;SIQOO@7S$ M'A,Q4^\2;[UZ3W[=(E]<,* MW:W6O\#O6OW(M_^1ZW/2OW#)K=OZUNOT.^XMKC[?IOAU\< MTKPES2NWVW;;[SEEGGMHMG8*/1?T_Q(=\V#Z+E%WG,^?FCRF@OR7>B.J.%1I MC3@+B/O O"3F]XQWC1;G>[7WW?V M=\SGFV:[G7U^=<],N!^/L.C^+Q"<5#Y3&%A(QQH4>%1#,8UI3-;5>0+F(WC&#UC/#&J[YX!&T&^*B%QO" AY77A)!,0$V MP!V0)"BR -1U@K_F]2=,L=0(1A%Q'3+J,P^]3+T XV-P4OH0 M,(P+D,5@FN^0\M$LPNS>P@#*N?9!A^IP>VF D6"V/)]CJF.6[Q)NJ]Q]+D!K M \)SL,.%%R8HM &W<]CI /!S%4[)&& 7:0/I) QGO&#]2"%9+[4/_.-SM.Y@ MB22$ D &$L#:M*F-4Q[5(Q*$AD8%:@$X^")G)E# ^4'(]0CU,>)D!(H? M53]^]KGV0JD3T-.X%E RM)@[5M)C/ES6I (0ZS/ ; O][H,WHF+(2!,4=B\) MH43]D%;K1Q6VBU6M'V9S 2^9:U /R$!8P,=&",KP' ]82$:'UFXML);3A@)H M*$L+S=DA[1,HAOFDX]5/8:@5CD)?\885@8;I9_W9Y^U1?,C$EI? M;C_%19D;\GB*69M5 M;2,M&J8P)&#);*'H/#MEW3&KF8-D>ZP2")B2SI BWP,:XGRB2_T$[^% 923L&AC6/&*3#ON/0T37 _,=TI9 M$# /#_8)IE=DW']5^DW?^&Y0>H$^C'LR6R?@%,GLP12^8P6^1G=P@#*25BT,:SX12:* MMD7>C"B6L!S/#Z6)>G-G)6&\8E6"R2[I>8E"L,XEE1Y;M>Y$4L=P$[\. 8U M],WL<&CE"6\"X!]8*BR53KWW@!#,^2<\&B62F7.[UK41U;-<'"XR#%4Q/TW: MP2K%]$RZ1IJ2D-\Q^&,.0RU59P!T:O/-E99CFV8X&YA0&4D[!H8UCL7=BF2+^X%"A0K0[,%V9.Q /8"Q!TF'YI2J6'Z%DT#N64P=W)2%I13A=8!UCBF6Q)EF99 MDU;V2MF[3;)WQ=Q_"\E[M/_+AP6KS;C8OW"M3U][;K/O]DBKV>TVSSJWI'5] M==/L?G=(I]MZXNGY^2/W04?K(Y/^QQV *YJ22_W OJ/@V;%(824#VT$(&$KJ M>T?@L3G$:1MX[Q@:G=.:KEEG%]\+TZAU3O\.H_BVC]'[T/);QF_>\&-#?M4K M@!:HV718\6*OW-BC8]FW&EG6 4Y.DV$?Y$Z;21O^;B[^4J3E11K$_8]J%28, M"_UC<@-"^@0,_$B8\*#BP6\GY'ILG!9+RXB\F.AMR0('X/F' %?7-3@&&&-&9CD3,\[,)L_V=QI MU* OLF[)]68-N]/V6'YZK7J%VIM.NU:[V_:2!#]CL3_,(?4 MB$CF=U.UX"(98Q(D A0[I\M]6^PU[)U9.^NE"??7WZR-@:2Y:W,7$IHDBD+L MW9U];V;\_##H9\[YH)W/Z6>6T<574#^ZTW<&5ENOI*\X6ED/ZYU1]Q)LYW)@ M?2[X(9=-J%4C"0Y;T!B&]!HFX8)P+3VA@4T%\PNX$)>.LW4+(F:,-Z%::!_Q M:1RU],KXSI0?#=V"-%A)AA$&C.3FQ#24,ES:.CL BCY9,&"5?-[$)*Y,?N+IH@Q4J=MW?E:I+N:3B<;EF%7R9[+"2IC5Q^KV^:3C]T3"?&U],[ L#PSNCEUQ6)%[[ MF,]=E.VR60;;,A5[J#5.JMH+IVW8^9S1'8T=JPNOI]CK"N=SGZH?8-0#Y\P" MVYATC*%EET:_#:Q+,$Q'C=2KU?I+3L;A"-H?RU@R?[4^R;A'U=;5\@GCCTNY MS_,Y-^2*!:X<>D+ A')/A'B"CV@W&-\ MEL^=$^'.H5'3L-?J#0U(##X+J+<%9E-W*9ADR))P#ZP;=T[XC"H<"Q;'B@3^ MJID> H4Y%12A[^)*"66P$+@&!I.$P^\$8PG&M7S.G#/J8W#<3+*O%$:^SURD MK;9,QWJ,$^XR$FS&?BA#&C:N4*75(%J*>$FX!!E"[2-D>KNN1**W^1PF@'AA M)#$%N_.S6>J2Q7V3Q! Q)9S&I=%-0%=@N$G-U"6KX3B1S8/JZ_U?MH[1&5A@ M6H.!/3;,_O#T;'3\X!=?,DW,UM?JN!=-0>%24W# (2!0CH.R_ M0N*G=6?R\ T*:RNN.]W_C&XM%/=D?H]Y=[K_!_E7=5FX),CP8H_MT*D_!9]B M[7B?9/8-'\4GA;Q6;'\9H'R[J#Z!4LN-@@IZM62"+O"6$BN)V"I.D:!*"ZB= M%+WCC:QL]7:CM6MMJ7UJO&\I2=S-&OZ9/%/S__3M_D;@H03>NNU@BU6L[U5- MGTI,&4>KNB")0J)1EH1Q]&(LM9B9TA*FG'(D:*Q$55/#) C0":$15!81!R)4 MV5A+5OD;ZX@!/9:$5L829RV#1%E#M,7)EDJ@4QQJX=I)EN^_ BJ)XVF_.;M# M=7;W]/%CF+V3ZKN#%9[]0'3.K!33Z<0R'&L"IC$<&IV^#>;H?&P,+_&]UM#\ MA\OD^2MWH-4ZY#OUX1;@G*Q2'+5Z^M#B7VNQEI5,5:QD]S?WW,?DGS[12R@]ZZ'7KUIPD[.?C M7AQCH[LL(D%*@68)T':P,&GA- M&),9;6& JR7E+BYL(*Y1E#C9)@Q(+*%4RCJEV__U]L?"&WH?%+T[4MFY*Y7( M;&L$=XW?76-X6WJ_=71WG-^WZKB5NN^^$U'%4"LVJK$3>IO K%&R)M$KF(LL M+3O9K*ATIAE[LCYZX9^G[)]>17U/(OWBA/I^Q=]02P,$% @ SXNL5GRW MZP&UW@ 7!P) P !F;W)M,3 M<2YH=&WL?>ESVDRS[W=7^7_0];G/J3Q5 MX+ O21[?PA@<$AL<@[-]H80T@&(A$2VVX:^_W3.2D$"LEMBL<][W#08M/=V_ M[NGNZ>GY]/]>!C+W1#1=4I7_SI+GB3..*((J2DKOOS/3Z,8+9__OXO3D4]^ MZ^!:1?_OK&\8PP_OWS\_/Y\_I\]5K?<^62P6W[_@-6?LH@\OOM>E$HGD^Y^W M-TVA3P9\7%)T@U<$XMPD2\KC_.?CK\ZE'4V6/)?B-_9+TN]G'@V_BI,;W!?G MWK,?/9<:OI=FV:6&?:FDJYE4,K^(#G:%<\/+O&N32#.,D/R\O+^97&[X7S^Y M]+VA\8K>5;4!;X ,\4G9>"(53^5<#XGK1/ \"/X^[ZE/2Y]3B*>3]G-FA.,= M*?[;U#+[1^ M\#P5OM-4F>B^5]-?/)>+AA8W1D.B^Y,"/[_'G_&>1#R1C*<5^F:,4L4?.FYZ+IT5[.!75 KTFD02A4*0DOPK\<_M\G0S)D M_CLKJXI!%"/>@H&<<0+[Z[\S@[P8[YGNOL?[ MWEN/_?1_XG&N*A%9_, UB?&1J_,#\H%[$5\^G^JW'YHPGW7I=(=_(/#6^/N=*Z-C&I/&-2V&;3&4S(E=E^UN[RLDW4>E70]JFQJ&CY(T@5>_D5XK:*(5[Q!VNSGFV;BY59* MC&^__???.J^HNEYQI0KFP'G''=$D5:S"=WK[VSJ]_!,NP;:V"-:.VM_6N?V M8OO.U$@[XR9B"-]8S^BHXHC3C9%,_COK@MI_X)*)H<&UI %062?/W+TZX)48 M^R(&[]&D+C4PHO1DWR=*^E#F1Q\X154(_5%Z^8"6@FAH@NA?DB@2A1HD_!,N MK ,*-$E@MN;%N$=+7]74 6H96M%$TE#9YS2=:!08'+R*2!]\]>CL8J)(G]Y[ M7A',6SU:=G9!U2R4%\W3P;.+>#R9@HM#>>MD/[ M3E-%4S!NR:!#M#-.$O\[ \"G)(0Y>$S@5IF*Q)X%*@ASI_Y!D628TC036&F/ MR"9_BT-*.4-*K3>DPMX.:59* GU$&YZJF[(!CZ@2HL\96":QMP.;E=5: TON M[F])7]&+K/$9P(GOJSJ1J-[K:JB7E)$F F?)('H3546-V=Q;M=4 MKL#)X$WIM:;J.EB[KF1LSKKBULE:SJML\*:L-% U0QK3R+O1O2(=XPJF:(P= M[S0RD,S!QAS,!P^^F@)Q%@&MK;P,B:*32Z*0UPBYD-TIBAW5B,!IO M (UK>A#HGA.]!,CH$O BQ::A"H]L=G)Y&;,_3H\KE0A>Z5\SKK(Z&*C*0H*# M]XY>0W!)%"5\)+C2O"36E#(_E Q>GD=\\+9L.?'S7>O 4)3>KW$M1U$(KNAK M"%X/12&XFWN!HDSPDT#(*-K%I! 8BH*W_*&Y,*E\\ ;FCA]A'D1OJ27AKREI MI&'TB593GHANT!\V)3:="-ZX;$;L4K$4(!K?)U+Y1O0*G@]@*W-,G<$F>R(W$=R391QE* M>J/KZP""]0>'IB,3-%7^?E0VA(!T=9)3;*5H79*#M_%K3V+<1N@[K M?.M\#Q,._-*5B,;1H1#?\J)R[:MWS7;ZYLGKWON^SWK;D"Y5SE*A&^!+X+KI MQ60X]I,FO\W<1MABZ\5DW)/7BYY;[.\]!-A?6BR=S^<)ZK/Q9/; >,LJZ(R+ MR0"<5UB_!,VD P2@ETEN)(7")-M4'2R34G9U0_A( MANZN'ZR?1"#F92A+@F1-X)PHP96L/'>RPDI'5%+$NJIHKN$U#=XP]=*+I)]= M3%WL&OZG][YOL6]"^L A@9(G>']9 MYG7@ QT: P)6R'Y8C0MOQ#)$R#@D9(1J,^9F)P[+Q?($0JE- J%4F('0FH6> M!ZIQNF9\L ;2T*RB+.]<[!GFME5JSX/E-2MG(XR$CI$#LB.+*G:/#BETVO8; M:F115K,H$5IVCI;]LRU6C)"!@86\N"-X>&> M&+RD$+'":PI,^@?NW*P)!/_!OPT$'%C>:EM,"F]3S;&H5.3F'5$LL\%>JV/! M\9[[B8<.G,C1W#-'\] !%7FJ._=4]QQ"SN)]Y+%%'MO&(/<4%&RCU"1RN/;" MX=JQW"-_:<_\I1WC(7)W=N[N[ 8!AYN8VPZ3HE77R+D+!JWAY]IG=UY&SMU; ME'ODW.VS<[=]/$3.W7XY=^$O*(;0&>M8T!)Y,,=72KM.P[1CP?&>NT"'#IS( MA]HS'^K0 14Y83MWPO8<0G/Z1$0>6^2Q[>_>]$-ZO%RA/ Q"?<(+(VUU/Z80-SJ^M[U/Y8/3N)78*SU38=7EU'%!UMX]M:;RB MLV;W^N7(_8L+>0Z3@IWB6Z,A^!@E#4CH40]Z-BWH$40P;U_65LF6\DX5R<+K M>HID03O4%9:I?JL56=+[_%=>[O(E1?RE*GR?_O%&%64Q.XZU<,H?&E6B*;PB MJI>2_D@T/--8@L#4U/LW-^4W"H_E+#ERB$R%+8O5Y6WYCUNW-?N8XSKD)/YZ M4V,$[@C:=&#SP3P\+MI+IHJ!<@@I0J+#+_]VQ>UK[3.[U7UP(^4"FE""#78F^;] M#FNQ+,2$&D:Q=^0C?$;XW""HLM"S7E U!>N0SDJ"=R2S*\ZX3J9,TG0#_H=< MRVJ'EQO#H:H9ID(KF*JF(A[-DF]X4W2XB;A5Y;-#5\)"7IA&VWI'(L)YA//= M&7\;A>L5=TVIQS8R:I%21$KQ9I,)$;HC=!]$EF3BVN18A3O]-*EP#QKGD^8J M=-\"KQ,1=S: (.G6AM(SKXDH.8!V0XDRB&^O0^9WH>"SQ5+^9U=&R:^*K!/N7@B.:.";V"ERF>L.[7F MEE#6L^:6_$*UYA%&=HD1[U$8;F&'91KRSM;HHFL2C\2^4].0WV2O'=81&+?H6F@0EG7-'B2/-O8?1UAY"@S>OY+\=5JE)SV M@44UZ+!\?@^U0T@U;VD5/);LDIS1[SK'&9F[?DKU!SFLOJ+ M&Z+KK3ZO-+3*7Y.7]9;:ZDN:,;KB1U-=>-P*?ZBPPMU&SEZUID 4'GCJWA*T ME!O!9O8"LJYOJF1B&:*9Q!H*::E-Z>6M(GD^%R($[SN"J<"HZ.J20MXJ@N=S M(4+POB.828P*[S/XYQH12XK8>@8>C-X>D)?$AV5)_R/)=*J MU'VKAGIMYD1X/P"\3TP5E=Z41.'KBM3KOT5SOBYO(K3O&NUS3_UR:HV0JX>- MVDE9D*H9+:(-<$C8_62ZM:_/F'>8-=UF^7DD]_V1^V[/$_?EQIM;V@D',NM0 M<#Q[#O;\I C+$B;6VXACJ\LMX753H_Y031F:!BT]O=,DX< ]O?VJ1I[F\JQ& M+I/##NUY8@O+\@&AE]V'O(\@O',(^PKC6''L/A*%^B4!(;KR,B0"S)8XET=P MWB6<9R6Q4T7!XOA> MTA^K&B$U>(%&=..>/_0DZJ&#>;Y$CAS1R?4ZD40AXG[C>(]"Q.064KT!H3<* M$?<(POL6(H:*X\G";-(I] X"T5&(N"]PWK,0,;E)B)C<0JXZ(.!'(>(>87_? M0L0#(6G!.?*>4RZHV5#7:NX;]G"MD,^ED M-G?HL-[6D5CKT'1IZI)"=+TD_#4E7:(-@R84S1'(+MV3/3P#R5*"8CR1BB>3 MSJ>,5PDN5U2"RH 897XH&;R,M0X*!#K'4U^RD@8LXU0P&C!_;_$B">P4^A;" MUH.^!<8P/?,(\!'@0S@Z9 JY8:55BO%4PODTJ0BT9N-C/#QT 2J=2^:/?M?) M"937VLD)%&V8L_\"()75P4!5CA$^%? 9C1$VFU05^%.?KA:=&G<$G+F'%R6* M]J=D8F?P",!#L0:SGH>2]VX/V0Z7'5]E)$NJCB'.<2CGXH!N>K0[=6?W#RSN M4^XBB.S< 9R2=5AGQZ7@/\ZG="3U?3 ,*).U#0.*+VS#$$%D/PR#6]:A&(8B M709-.Y\RQYRO.(S+U,% F81N,3#R9=3[E(@3L&@'3!B/C MZD"RLL% 48;M841PV0>X>#T,M]S#,QBVA^%N]APA8'\,Q@8>1MB]GO$=[#PL MZU/1Z8S[K)9513=E/$VL*FD#RFR)Z(>-G8V[B2SAQZ[1M?;Y6;:\PT:7URP= M\@K6/NMP(9[,.)^R!\[E@JNT8V4N%T+N" ?O2";BR8)/;?8/7@,+8F"UL7., MXBKSK\O45EZ$/J_T2*FG$;J ?AQ6=I5R;3_N+;>FH=KZU[D1ZY"&E>.-;@DY MT"-3/)H/BYTZLU0+0G9F\1WY2.VLP-ZYG#^ MF$/9?:P&7D5/%@HL&#(.,\K?LRK\93-J536U.GGVGQKT]:?5A;@X="6=WTY[ M!2Y&T^OKS<:;FF']P\Y(82.%?:L*N_TP-$D/O+ ^)0\[K48'L[9]2[K\F;#L MVP'RU@M%-Y/"@B+XB$7[4^K \^AT,&M#,>7:I!,6% ^0MUXHNID4'A13:>=3 MYL#8-0O%U-J5HG3<6X#BH?%V!HKA[M!U]\:>US?'Y= =K3?K/]Q=AE.;-I/> MQJD6$5)VC11/E]KP^R/.F(D#LZH'I5@'QMOM0S'C0-%=IA?9H3V8L=:N[K&E M&+9B14C9JQG++?+MF(D#LZH'I5@'QMOM0S'O0+$8V:']FK'RFRA6<0N*%2%E MKV:LXM;-Q(%9U8-2K /C[=:AF$PL.S$OLD,[FK&H:-95K%T>,1'6HTBY4\W=9I M?7+:P%0E33?@?\CD?).C!8O/6'>-EORZVU-M^84ZTT88V25&O-.(6]CA>0R) M2-C[(&P41/C"3CJ>@E6I7O+6\3MLN9;5#B\WAD-5,TR%=JBHFHIX?#OE_%O, M4XQX6;0<'JN\?_YVM)59OVN![CZ* M<+HJ3NW38BPI1#A==+2,ATD14D-&ZN20SQP]XJ1=L]EPADEYD7&V1K95YL/(:9I_-T]_8L(][U M>6U 1$G@;PSQL"$]WP;Z#'*G,-FPEW?H2V$1.'8]%4Y+>;OUDM%4&$V% =FX MO2]0BS ?8?[@:EC1<\@[;73I6IJN&>U;29$&YF"J:X[9\6?1Y/RO ?S#OSPH MTI#HNLK+-R)_V+ &9GRXIUU@*&#P3P]OM@?3N=P/.]Y?(-5=^[QK+TK;( \[ M-/)3*?XE4JEY*N7F3:12D4KY!!AX_)#S*1^I5*12AZ!2-G+7CEH0Y*'.4@54 MVW3"^92D*E7N2Z1;>2&":8!'W.AV09C:E/X0[0F^U1T!'_A. =26EF3(,-J: M(DI/DFCR\D21%G!DBVHUA^>[SDWG7>')RKGI?-@UI&FGWCCMK3<^-N@>*G1L M":UG%=-;*#]..=!)1=#92^BD-H%.*FCHX'HWQ>^PF("O6CC=P!]=W/>0^=#'][BO75S0#3> M4'TFO#5X,$VCWU-=+[TBBCJ0E&6O7?JY)F[!S]XM#]R UXK2+CFJ >?5^)Y,N/#7QD4.]B_.RU%,^82'S^]QP=>?'H_O#BBL4V/ZO_$XUQ5(K+X@;LW M91*_XWN$B\N-(QG233Z^);$/V>>NSNJ!DAA=U_*O/#(98!SNBI+ MHI<^?(IUL?UD=GWR/&O?,1$.HL[Z7]<8WGL&<41R.U),%B@F.Q=&: >S5";E?+#?:U5JS1/3TKU*Z[RL_RY5+^N<.7&[6VMV:PU MZD4GJ$JL=.3J_/R.9=*9#/%HQSS6U#=:N/^%L9#'XGNQXOX MTBXF4FTB$BD>OU(%NF<)PXFV@,%:(IE(MMOT4QK"J''W6^U1>\G^+-0Z\#QP M+115H;Z>)'"6BWU/NM,QO*%. K\S3N$Q;,(DH/M]9Q?)1/P;=5R/N%LR[%>^EOI]0=H8<5U5&_#&?V?2B_&A MHZHRX15#,XD?%*=H0@$5\YGLK+*_AKPZ]8>J^^_(W>Z=G U$'$; @[N[CE-:'/I9,Q;GI$Z:D1525=X.5?\. J?*//F50D^2\I M_-84?'9@D\K4J\]H\G'N_!)-.T]&RQHD] N+YIWOC]\K3\.Z\6? MI720\TZ7EW7?B6>:*FOFR29WV%// Q@:+9ITWA#6G4G'F(#!FG6Z $RN M[?D_SE"GOCE.KARSQ,OJ8"#IN/QS>E*59,*!7>@0[8.??Y&U+!^KL\"KV<7^ M%D\8/MYE?U\6:XT@IN'I=](%L7@VE\"*B&BV/9JQ?9(&/4[7!'R,-H 8_F\[ MD4B>_QGVSCA>ALGOS'Y-GTB]/AUH8?@RR4$7B\.7,^Y])/I#&IN=3_(\C+Y- M)(*U!> #9Z(_(DL*F77*O*;IGO0DW:"GF((!\3=/7TKC1J6OEZX&J<#,D_>] M9Q>MSY73D^O[2JE5N>?*I7J]=%EK8J[WKE3_%>-J]?+Y7.-UY#;L7>6%%XS3 M$V0ANI.:PSJ.USE]2 2L;! Y":1LZ!PXEQ@$_[L;9H2OP0:V 0VRS)\+TA* M[[^SQ!G]>\B+HOWWVF-U+"[$]LP?B3H:W_ MHM%^)B&RC M57OY^9,A3BT#VASN3*_L,3:M-:1,\9_0IZ)9#ZCJ,3,U19CL4*)=&?.<,:(R M&,KJ""ODCA.X7H/*AE97SV?0.K&8[ZGO>'$TD<&1AKB^:PE%SX1>$D6-Z+KU MSPT$NDG_R=R\J1<>\G_^MH:;K]I-3^8^+S^[2&9/3W[P\B-,'*4GHIB$:YJ2 M06 TR66!ZQ'*;8.\1,Y/P&7XV-!:ZK/B+]Y17BBT7G[^?#!S08MW\NJSBTM> M-J2!BM7 OJ*,694],X/*^PV*.AL-[0[B$)A\YX0_B3]?KZ](1[B["GI@4Z\_ MN[B]FC.LN8O,GN?=J1!6R;^EX?Q8KE[H5<>=ZI?TO1ST:#QO/[M()5.)PC*% M.V+U>V>QY?1$[7)##00L#7F9(_8&/'!D<0<>/ %^DDW,EW# / ZYMZ.4431+ M;LO:SDW2H*TK:82?K\%?&M]_Z5]>I*MF,@ -=K\/,)O)I/^=H[/Q>=/$C0IA M[%U?51:NK%6NU&HB6/TA!_BKD6,I(YXS:6J M:J#)]J*+1C/)X-KS;';EI"['BGA$3D T6@P40?O@QH;[39P"K=,3 MML)&-)#NT*XI-EPUQ:EW':>PJR08'XY7#Z(EN<!+;6 .A73BL#&Z7([S0 MYP2P2WKPZU+)T(>SF[6JU';DI/&H)&Q S=&@H\KO]'\C*:TZKG1A&U+"NA2O M,A&[^!-],)HI]7J8+FUEU\/4#0N[.X;HOI-;?EPZ"SL-E:;0L%/[8 M_IBZ(75'@:[Z*=@9'A?K.R.(P0C,)D#!(QAD0E?MT2=W5/.\+%M!F@[__C4E=/'!L^\0ZP)XYGJ;.$Y/'RG9Q<"+\K/3HM4,,"),I MCF[QTKEW+(;D=!.F#;VO8HF>O5_ Z//&--W/O)=")(_=;-'_;XSC%9%[EZ+C M VX0 @PV.W^ ?+R!7@MW(3W6@V@+(DJ%0V QP8G\2#^?R?1?>C+]95/3X&:V MV06>B$L(\_:4Y1M#[3+]V)+,X'+]_N\_N_B%W6G\ERZLW:-<7>6<[3Q'J1"1 MMD^T!C4==& @&0:H#9%!%S1504]*'G$$O*H1AVV#-&RJ_D2X*][@.;J58\H8 M3)[ACO^Q:]0#/F/J73JW+K Z$NT&'>(Q;@> MRZ 1@=!LZ,;FX?1DVCXPBAVM)_J_LSJ=G2K)=!B!?+!4;,Z6/%YYSI2DJ\)S M$>1>^/=#K2::].@Q;QG PD$HX7!-!I#8]!H"#7< [T_98#],1]?] '8 S@ M+9H]EYR>".H QC;"Z1X>!],DLJ/']33UV>ASUJ_G,!Y":1-)5U+HAC\=]1P7 M/E*)C_,HI#\G/]J7S;W@],2ZPI_RJVF#"R"LXE 2]!O4$L853,8G['I@23! AY :4(U MHVTNZ?N4 0JS,"\SL]55*P-[>JHV\G8#1LO,I+ DNJ,W7YJZI!!]3E"73FO7 M2E$>5(N/8?8"\J%G61^@MZ!R%6L&9\1XI_$9V18\LK5OO:8WE=D]_C)._OD[ MR-7R8_(03(.;>7TW%A"VK/7&WNG=;/IS7]**452R9E32/3V9[_UC#1.+6C@[ M:*$QB]3U2T'0Q .X-8I*\P:FS@('& !K2.73,@1B#WR5/*)J_BS!JU&Y%:!? M13?_2=*IGZ3PBB#Q,GI/N#$1*<53S41>$W4.=S9*XKRJA?0[WLED>MQ[)MM]"&F<2>0=H);&M6P?^20@] /,O^?<+Z#/ LS,!)3T.A?XGH7S MSM/UE]+CL,\+E<(6YATW/>@!KNKI'1=BCEH=K,V<"%M6@8H@9KWL.=4TJ+U$ MPVFOZUL0ESQUK*QTAM 4#VC) "PHIEL-F IXW;X%3^34#;"[F,>D)9$]R"GU>TU"%1W9N0&-"55NJM8>2:*E*-IEMCS^_&)4O7Y6<>-=U%*2J ML8-!9Y=*%CS[S*-/)7;\:AH/2TIFO3H$?!-50R2"!+[X&6=]T/\[J]6K9QQV MO:>/L$\]R*=3L5RZ$,ND<[8^V01.NJ;9$G#XJ2.1%C=O^1&7S,8X)&AK^:9C M6H8]_G[X,T5#2SOB.QWT]Z@?_@XPYY47CO(C/."O210!;V1#IL'4+/_G'C$P M,[HI.ETZG4[WOF,V#3N5+9^$XB>]]HG8ODW'6P3N<.-$#.9MA=N1F M1VWV>1TS;-$(_QCO$#"60,V0\M(M=\:%H5<'J.@G[QIZG^[&X6LA.(NNE6 9 M<.FE<[[)RX,M])T>#7NH2Q8@BBTH/5KC8 M[.\"4GJ::BHB@5[4/G-;K MO$LE,K$4N,^I;/;?H $<-$M*]RU&8"W @O7PZ?[$;91;56 M+]7+M=(-!S%-X_ZVU*)'RO!!MO&:A^-MU^0&#=H??9/ \8&A6XZG(F$Y#-'60$"W@:10*STX]=;)F5Y(NF+1) M-BU!*BF\/-(EFN*9 +JL*B);_L!K[HENR@:]I#$DK'?!P0,]$YE?2ETZ5&Q[ M$5D,<@C?J08,-CAJKQ@J%J$S&,QEN$FH[QHS 0Y MA ?%U;:KRW9Q1;H\ MS8<^#'%O.5$D57/A]^ SHY&AW49**2R YLXN;B6%@('M$K"KKD1H!,SC,Z+9 M@\1H_NRB0?<]U!16TWP,"TJ1V634Y0X2DH6SB\I+7^I(1["&7XCLY#0H\UL, MF@)=Y6S":WCC*%:$BONX"W?2@N9MIL_,BU1D-X?TGC.Y+PD:"8]Y3 M]8&UE(H+@-N5"M0_=2[*O(DJR&NCTY.Z:A#L)L=K=%-B5=6>X2-WHZJ/^+>[ M^.^X-QSLI]:6DX)&"5GUYD -N]27]].2O24_FED=6AQ:Z&Y.7%-J3$X4> MERVAZX[0.6P%("ETM^F \(JU;]7>U)_*EWR:DTY:DJ9INM.Y.EEQ&GSY]#)U MW99G?=64Q>EO!;\OGR59GOYN*(/$IK[KFN@$S1"% I(4D\0F MPQ*MTV%AV'@2".T"1SLT\AIM[6@=&$N3SZHV:1O!WH!-*%&J^!Q# SY8'_$! MHDH;1F@$=Q7#-'9Z J@Q5 TG-P"Q =#1.8D=>CE: !DJ.ITL A72VN&QHP1M M6P>(Q"-N33HJ$"9OC8#VI"0"KQOL/#'/&&*< -K1(1S?[;)V%YT1#)<7 %^X1V-75 560! RW-Q9Y15#DE'<0GF/@C&RS,Y"+*"\D2F+6?- 0! M!()K %&/B7T99(E'3P$W1-/NG0L$^X.P,[T,_I' PSBU V:,9\>?XG--^%N M(9A#W(8^Z1Q">XG,?W#,Z13!8VL(QB!DK0(63IHD46)3*+:/2GZ&5YQS)72B MR.D)"A9S@P@8MCAHL1KXH%.BJ'"DCDEASD;-Q( N$X, NX,7P;O3$9_2 +Q' M5 YZMB90/-34K@3NE"33/?D 4F"=K#Y;M_-#^%$^/5%P?<="@0U88!R"4Z-L M=[JKKB)M;EK8'#4P^#4.-<8ZNPPEC0X3V[$P1>[0SI!4+VSMG-)&58%!NLT' MCD)2GE09'C&K#U178EZUX";&R>*[^^0M^/[TA*F8-9WHUJQ >Z=A\VO+QKF7 M=6TS2;D$IMB6H:E1X9O4P,$IA;&#M>!U*:2-#8.I)L4RP^&BEW"+WF%9;]1?--*#(4QMU( M5I2] MZ(3Y%MJ!S#ADJ8 ]LMH /3#:2MDV4E,81Q69FC$ F=9TL<(<04W4'R(X,#6!+81)32-TAI"E@630MLXQZQTR X^H>=2B@T[_B8]A^'UH@U M>!4(M# W1"J+N7PQC!-&0K"C.+\RZJ@Q>2;4/Z!*C2X AIL")[$($KHH%G> M/,X]]GP'-_&/Z \3.E&S*19^4GC9=FHY<"LT5R^X2;]/] !$9TF646+=Q-R# MH;,#X$WTJ@T0XGM*UK9=@P@LVR?KH U@EY=D-'H#0NQ3+%R'T5C)*+ZG$>L; M&M]:,?TS>F#6&1=H")U4 ;6(1#<\$0ZZ[C0,'/(C^BR+$)6^PKE7M?>8TK 7 M7\-B32OJM8(CL* LA0.OU:1>G\;M=CH(/[/'T,A"Q.!#';*@"KP[,.B"\SYB MD2$278"8UXXAW6..M.LHR(I,\3Y*)3+%7E^T@RE$VQ/5<1& X*G6=#L^^)*6 M5PGFU#)3"N$U.]V"_B@&3,P6#@9TA1/=2AW(YRUO%=/KF"JSK"):..O ![C0 MZJJ,UT1F[SC(BLS>/DHE,GN.V1/ 'D$ SAN&1G/T&J&V"LW10#6D)_3B_F)S M!QJ'@UNGJV# Y!CXD0@44^9QR98,AK(Z(OAJ< /15>3MA3P:85M)Q*Z5%I]X MF1%RCX*LR,SMHU3>M)G3)WZ5=R&0EA#013\6^]I+[=9:G;-6Z-@H&FGC BD[ MA!'-G=+C>S18C2!Y%&1%]FL?I?)V[1=;4F4$JEV.GJB)\2?A=K;#S M6=9P+8FP(CF,6'5:S]=359$5IH@F*_["7^PH%JZQJW#I5W88C785+2&USV V M38590B*Z;L>O%#U:5SX2LB+#N(]2B0RCQS#2B1NR@WS[$:PMM:80VM3#=O&0Z_#LI+(1SH2LB+;M(]2 M>;.VR=]'POH[3(%AR5J'+7R*Y*])MR0ZM1YX$@,'D1_NM +C)5GK PKN6B)# M5HEO$&TP6=_TJ?*P]SM$YNTXR(K,VSY*)3)O'O-&E"=)4Q6T/W0G1,^4>>=D M&5FR/+((9$=!5F21]E$JD47R9NOY%XZ>'*]'Q?W'0U9D>O91*B&8'HN6@\ , MW5%N&2"G>8I/*1@S3#1LTU3G@4:Z%VE M.TYBKFKLGLEKO&(0,J>5!^TWM%(OCW/NEVIRK"<4K=Z9UUW'6-(5R=X." K" M/[*&++SN],MB#76ZK/T+VW%]CIVS"(" U^U=C;2'B,P_TZ%:#9TF'7M "7T[ M\UBOF$\:[>XCJ+03CS4.%Y?AM^FF*P'T\]DC]$>J_1K5!O28NJMWT70;.J>Y MV36H*OS E4%%(7#68Y/N/\2^IJP.@+"9EFS/,WW;S,GM "OK2YB"G!9K8$?8 M3C)L-#?]:LY^#U=3A'-L="33(A<;G4Y?-7$OZ/B[N]IJ.&KL& MVM@U'35VG:,3V\+[@78YA2&U/E=.3Z[O*Z56Y9XKE^KUTF6MR94;MW>E^B^P M;?7R^5&-][9T7_Y\>I).QKA4(I4^JK'A 9&G)\E$_-OQ#&L/VRF_1D2U^E7E MYS:ELP>MWP^T3UK0YSKL(#\W,X IQZHSZUAM/D3[# 6GSQI$"5O0*/0LI@_X M/;0C/T*'!O#)>T9'(GE&CTCF:N"CU>JE>KE6NO&>,8RG;'C9&N"@MW/@1C6> M"A,6KS^3R+)_EGE.4HN]$WQXP9$ZNZBU*K=@&<"!MWOXN=O\'_CY0"'C(E!S MX85(:E\@DCZ[**L*G31H]OZ2EVD6L]DG!-.JM#79+:\)?<[VM;EW#PIOBM@X M]E^:T+\B J$MTJTK4A&PMFMPUD:3%P.9(%GG0=/$UB",&I.-8UCTM/+ZR;].\Y8/D(A[719=#+2KW5C 2[ M;V-Y@ROF4]!-.] M-^K-QDWM"AAQ=7IR6;H!_%:XYN=*!9%[+!R@<=>D8(![ M9RY-8A[#L)>MY"YR[1 K+^)+.YU(M)/)9'NL?3?KC5965PP)'#]S ,,9T4L^ M3((1+LXM2"AOL#R\FFYAL[>Y$H[5+3%1UUHS\63AP.1 MR/+_SE(3/F:*E39B+Y%. S-)YTFZ2^@_LT)AVHM>X*G[43M)*7SJ:-S["U80 MLR[M@0XTAP--)5,XT(>;Y\3=W^1EZ8OTRH%Z=-09:VJ#L?ID) ($S').+7B4 M)Y:??=YK'S__4?O,E 54;X$G7P:B5.CKMRMZ6+MOC MZY_?QC\NYA$_?&YG\;2_#7!?1X\E6N5"OP?N M$S7^$BW/2+3,NE-/!)M(HFASFEX=%7[UNMD-1#LO*SY+1+>\EE_EGDH6>FK*0X&E>6+>EYM^U2#3+)U[;J?K'+_?V?Z>I6?UY MF:D'6@+_)+U\4%2EBGJ&W104?@"/M23W827!G=%S,>#1]YB)+^F-+GI \40Z MGDZ><6P/TG]GTHOQ03$'HFJ(1) &O'S&61]TZNV:BL0>\-"\.KM(99.Q;!;< M*"]Y%W.DD9PG#3\F^F,\DNM*7VN*@\E9O-7%WN2*%..2T5FYI8AS+0I@)8'A:NJ5^,$ ][=JGA MNYH)7\N>+2G*ZFH0Y!RZQ][(?E'C;X=2,W:HKBJ"K]/[X\G\U25]^?XF5 /4 M:'VNW$<>[ZNDFG!)M:88O-*3.C*QY$N,FMVL_5I513R!8N+PTKGF5--W /@"F#M.36OG(:369BV<)/ZK&J?UGK22F[**&0H#R<58 M,I=?ZKN\,F*+A!60CB1BF61(TGJ5 SKMONRQ1[!?U*P:_:*/:86]U 7))37U MY^WXQP]SDPQKD"X("XB]@?"6]7Z#G,R&860HX74N$/AV&#=RR+U\;R M!;"PFDD1W1MB,.-JC#RKEM+=[\)ON?'E2B#;6[6\ MJ94N:S>U5JW2Y$KU*Z[9:I2_?F[<7%7NF\ZFG4JU5JY5ZN5?^RB%_:(FTL1= M<]T_%^/21/^%92%KB/E1]S8[Z&_'[9FL,;MT7VJ3WN#^M7^OW#N)3?)-&V>D[5)@9\7$K-ABR=\7W6]VQ\ MN1*&UYF-%8M;7]+9*H->&VOGP$8D US5\2^,JN$,3W1CH1[\^3$8E/(_Y=9= M;EMF#QBMF;1#):-OMXMX_EP*0R\RN5BR4#S0M M60)16!D,975$R"512%?RU *XM.3FJ3)^:#Y?_R'A5IW9JJ%VNY+@VC8OJ ,\ M;Y=FR'>\YKV0;:$D,8KI6"+QVD7P ^+7:Q,-N2#XM=S-:F!WWEFWFFE.W[GL MGK6DA_"WKBI6?_H[7C-&N%O!U$LODMYN3U]-+[BE=>83)=0>;G-/C_U"JI?> MUE1UH_**X[KA-G"[P?Z0I[WT=XNM.1)8I(0VI]NSC'Y-DO%P]7,='EJ*N;<\ M7#[IT='2G@8+G<+RK_Z#E/S\-9'<1--6G>[FYOU9TP67UAE]29O1N6-= 9PG MHU#FUDPZEDE'B[1ABNBUTWF8(O*W&&G_O)EKH1"MQ("_*34KX\[X;WN MMGXET_W??_9BS= NHI4GU-/*&8/^ZOKVV)'J$E\8]J.0*<1RR4)D/X*5RBM- M1B&5C:7RT5+CT6>]W4N-BQ87Z0+'U]:?9EY_R&5+6\OT^2TFOINL)OKNK=TU MI_>+FN43]!T]64(WK)-/JJ)HV)B)6I0TET%_P6U!]?QIWKGWK9*4Z= M>F&,T^EC.-YYCKMG#*,AN1$-5H6L>O^GZ( M1FGR06+C]T.R]OB[:%S*\U$ ,2OW1/?1S4!POAJL0H0%Q>^/V3Q?_GQU_5E8 MC8@UI#V/C,50G"=:\$SN-L'<6E0XV%N%BO-$PF\1;C&\'%Y^L)I?8(<4P%L) M.ZY0)=L]F0,Q5@R MF8P5BWZ1YF)]1<5;M -I-65CUC846&;ZWPL/O<^"FLQOK&R5S90MQ%%5?R8$ M5?K=O+Y*[E#9[(3](2O;]L>PN;(Q@<;P"%H\0EAZ(O)HM\L[/M%1,'DP':(F MXK_I*9DZT+6P59FU=GHJ3&8M7_0JJX.!JBP+CRM?O_^I"B/QL9P,-CURP=X_ M+QI.^%.Z0B@LYG]^:RG]9EUT3*S[52O%P1N\W8H\OC;[WXQ&0?R9[J_Q^L4- M2>83L*/P=UV*@HA]4W;H&UKX6_47^AJQ;Z^5+CUW?UW^R#_.$?Z*@>^:K[>P M]_/QL5Q3A\KC]^P*KU]5PKN*=S=W**@#GSP@IN\EC^]7Q[,S1&6JNP#@'KV9<5 M0Z]MFKP5'=17D91/IV(YF#HSZ=RF%L_%]7UR0*>=CW"]3\;'0ZTQ7HE7@3F? MP?!JA6Z6HBCA@WGYCI?$FE+FAY+!RW.\T$[C[P^^?GW9VV07TAJ%Q@Y18.0E M,2XIG,#HVG&YK#^SPM4:K)?-Q=*IUV[). 2F!:8^03'-7X%R+@6Z)P8O*42L M\)H"UMW=.88=)V?XZ])G7?Q9N^ZF/[^$U,C [\39E0N5W"UU1#:,PR][>;<8 MJ,LE&;2BZT#=?V?QF3TFL70Z&ROF VR-< 1MA,*1WBLLSESII8JI6#&Q/'6T MKO2BXJ;]*7(I+"QNLIJU6C;?L&R^NR8UE?B=Z'Q._58>ME3OM*0F5?OSV8U:(6[+VV4(^5O!=SHAL_>MD%;QMSV8RL<(*+6]?8]G]MTLOZ]5B ME;_;%F=B:)YA*M2?!P]21=S%;IG6=$T[3FYM15Z! MQ;';Z8'>98\"0^Z:+5)Z[I4=!'=.AJJZ\1F.ANX?N^ MSE44$>8MGW5\]*DXS[F'NS\\>E^/8JVTD\ET>_RS9_PM5QOF\[?BRD>Q.C_0 M>HK&D&BTJ8_N9OT;/Z"UP YH32:2;==1K:/&4[FA#&X377YZV!OGXY>V2[LD344SB/:CTKO6B7"9^W"M: M*N"B4^MU'_8QW[]?U/B+KC0KNJJF#L"64^G]D(Q^F5;D$ZWR8IW/@,W#X3]B MBW]I]W7-P,T8JF@*1D,#,_TD"62JVY7UL[UI@A\H-4/XG?GYN,F*Q3H[=.EK M.9V7-VYAM5*_3?>T'=>)$)=>XGU)% E< VQ.22\=34XDT_FSB[@S)X>*I$#) M+FQ*MC_D+D.$G+U_!WT14S;@SBHAN@V\W(_^_>#2^/%T'[ 96CN9/:&/ZY*C M:,^R(I@RB?E@.HQ4\2Z8E@R8:EQQNEN>_R]=O^W97[//G8R6SA) M5&.DAEZ;MJJPTENS\L'3G@G"U ?JX.VO0[5?U/BK=,:S#T W&ET\7(NN/[%I M4V^JLM@>Z);F5K]F*CU9^]%]Z>QBC1=)Q'S!T,]S>P-V/A=-CNLS;8%7'=+D M>*VIN@X.:!=+1,/?J,F>@Y!G$U1E-3;4,[NOE\-ZXB%LNMH!2SQH[/5WVJY/;XM%>N) M?O]>2O8"]/FLY9A$_AOKZ!K3IU?JF;\Z*@V5RBC&9?=HG%B]/?M+VVE=DJ %1 M=( 0EGD/+'>KZ;=?GU_2^1>8_@7!N15/AL T XS-\C,E MLEP9?[FOU+N[2(500CG5<8J(Y10=02BR'(1S!!2V\H)IC)J\ARZPX"Q&,I8L MA+0#P=^27"T*H.C&&9H,0ON!*56:#+H=UI-U05ON^?LT W: MB!_!RDM TGJ%"9_7*2-@6QZUR=@[,^Y>?ZVKBNK%FN4R>-8PBFGU[]UO\_GE MYR8!_&9KHERR;;?O7_T8+&0&4K]@G<]LQ)K(:0ZYZ6Y1HM-7Z<0U"_U/^ M^;/V5ZC_#/?T'YL:.X@*FZ=+3*\?6O&^ZCG=Q9VD;WBG2,*TD7 -G&G48&DCF8593RY[O;&R7U0Q1#ZAJWLHL[ MO7Y8\N]Q[<+=7RP_4B5@WI M"MDHI%N?:4''P5$:?W\\'G1+#/N[ /X[OD=4F@I\.- MLWKG9ZI1?Y9+6ZJ'.;N@;Z<=^T1)-K&EG.2))2$JP,U#]%@ZI'9#GJ_2*&>) M;OKR;74S.G5FG*\RNH\WW&)HMU7F^!BP[;%F>!X1H('_IZ# >.=:>4)VR(M!L%:O O8 M =GD(,;]L/)A\W13C\&?H]E$(2".1LWD]W(L43/Y;323ST7-Y"WT M!.8SCG::YU9I-'\< X^ZY:_4+3_73B8S[?%U\?9OXFOFYD>/W[!;OOMH*.[* M.\;GOGT0U^18N\[_8#)0J(5TZ0SSYP7(08X8"?# M<9F<-.EV,%B6>5V'2!)12+LJ3RX!)!&]=*>1+M$TPLXPLYHKSSZ'G6JP M.0!M[[-\'S).Z-6G.^,+X1^"%TMI@/6A>RR6-XS#]-KX*=/DEP<\W7$QU7PB MB2_W(3!S[]$S869B;6:6X)68J>'E.UX2:TJ9'Z)%MAFKRO?9G^F'SO!RG0,Z M5F2L]:Z#X&Q^;&R?--$\]MF&6!,$U M\=,V,CI17F7_X]DW%W-&$HXD?&S1_ML+QO<^Y Y^WZJ'BU-SI6?_ MF6OL+WF95P0LR#.X*R+0;+-MRY+3#''.?EAO[EAYOECGT B;Y<6"^Y2:F7)6 MY*Z?1%99QUQM(7/5%/^RIY^_6N_*U(SCA#,I!EEZ0G*;@. $*G8=FW[??CJ^J)B[%D,ADK M%I?O$'.A[)5[:G>J#QOL(WL5%&8,USY@8;;3$L!@>:.E(X' 7).8"L@D+C%D M/FOJ\K->OWIXE"_-QP.W8C.#V]IVAR-!YV$8J$W%/&-YF(2+D73W2;H+"U4V ME70J5LQD8P7TCR-9;R3K)9M -Q2V?^U, $WQBG3WW_*.K)N(>Z8-023IN9)^ M?0^)7#&6R(7C'T:=\R)J(FHB:L)LOY&:VPUI_"-3T^O??CYIV2 []R[I4T.Q\E2TJHPVZKBS1O7&F^G*-K79YW5ED*NU>TLE\NYV;U&K MO B;>X3-0H3-_1-*,1+*FF'9!NWCPH["P^HN%TGQX)H 3E;;"QNLME?:X\IG M,?'M62_\,3=IM+5"F= *B^W[Z!ZOO(!4.9 U]4IJ+-RF$E^^%0K.:E2%CN$5 M2U$AK3]-V]$]7T4_C"DSF&:K@>0PMRS?#5?&#T.L<^U6,B"[M?["MU;O/SU= M/EXF_H@'9VIVM]1]&'#;8RNR]>7K2&*OE-B.EZ3?DOR"67S<4H";B24*B5@Z M=03GK^VA]%XMGEPR%\MG@C]_(.IN'U$341-1\]I%XC#26.OM#)]J:AEMA(NH MB:AY ]1$'DQ$341-1$U@96[I#$W3IITT;7JU3;2EZ^%3YTNOE?L;\%FF"W?) MIH+AZR2'75AE\]8T<_9O[:TY2AC?^_=7C9^]^3O!])FD>&@I[X/:HQJP#J]R M,%= V99#V/X9KH6<:/)E0)J\_FI42:A^OGK\+?:*XAXJ7[#K33L\FVMG>A78 ML@]CWO)EGV-A7"BK+^E8(I&+I5=8?=D!&X-*HV]EKQVX7\54K)C8Q(;O\-3* M]9CX:BYE,YE8(1WT\956[YJUW>[??P?U^RQ@H=5Q)I*53@%9VPOWF<">\/"S ML",;E]^VG?!? MM*]]\%=3Y<1-+E<3M[I79^TM[NEI1AS>?C+_1QU&Q6B ;-CYCM5TM&,UPN:> M8C.3B+"Y?T))1D)9,^1:OCDZ[6R.3F]I!T ZEL@%7V$>"3&1--2)&/=53FN[ MQH^)7,JH]]3D]WRHB?<5/>7#1UOD8^S)=):-IK,(FWN*S5R$S?T32M03+O)_ M(__W&/S?:%$IHB:B)J+FU8M*5G.X]FKEWUU5)O3L>FV0+YG;5LFG;!]GS_RF%XVWO4)6C+\GV;W>%6 MZFH9RGZ<^U&N^4U^ROYYY@_/UNQNN\YAX&V/S[@PI/?ZDNI"/E8(TC%>N%,KN5EH^_<7P\F[@.-UD[=YO86S*J432T9V(-$. +-L8=!B_V&.*1IWYH$HL\]>.OS#=V0"G^#ST'X6%K:PFI9E)3 #7NM)2MQ0AQ^X!+[/^L*F M(C%-@T" 4]I4J)D;\IK!J5W<[J43KBLI$)](\+UN)W[UN-1H"!26-[TC"1ZX.1I#QM:XB"S/NF][; M=^$O$_MB6Y=/[X'3?DS7"/\8[Q PD?#L(969&V:,QPY6V4\4:1.U'WJ?[B8* MB672W@SQ?IQ;00NVA?C#5>+6Y\KIR?5]I=2JW'/E4KU>NJPUN7+C]JY4_Q7C M:O7R^5&-EST,\V'\8QLV4F\UN485^-+\ MS%5O&C^:Q\.+%FY*/CVY9;N2*SZ[DF&"$VF;4N[=@\*;$+(0\=]M#=[Z#DTH M?+,;QV6U&<7.K:83A78RF6J/*W\+F:_?_GQI=;"9K#F H8SH)6#1;7> BW-E M5:'3&7PC3G[0T8LH\WJ?J\KJL^YF_=GZK%YMFCM;K0FW3YK63RJO#QJ!2!3$ M?V>I"7^KZ0RP0]Y@_-$/ZW2S7[//"?KS_QKR2=V,> M:ON=ICY)8((O1P\Z$6M*8T@TW@"^ER#$?)(,S&%W= ,CSK9TV1X/="'W^4]2 M[3P^AE-J..O'-NXJ]Z56K7[-E_WIX?Y+;P,I3Y>VVT^P+'\N\X]?N()[,B5*#_<.]V;.))"L MVU/_+$X:V?.+[TMFLD/VU=,T'<%FAH6,. [N[NXP\%68ZZ^"&9<*EL0_IFY0 M]ZNEWA,8H2#)Q#/NEKJVF4XDP5!_YL=_?^5R_'4FO2U#[1H-9ZB<9H^'4Z95 M&W_&+P7T-X?6V+AW)HSM7[B24^WA<;PSONAPI@UM?MH%N(;1)]H5&8)L)!Z! M75+$TD %6(SIGP">U&0:N!QK7QI?*[\_$S[ :< '."X*, RY1Q;@AZJDZ08' MVFGJO,R5>A YTB!&4'4C; $LMDW+&!G\9#!EIT M-^F&N!WPAL"[5YCZX#FW MW+ERCZ?1O2(=XTK2!5 /XTXC \D<>#7M.RE57P8/PK">WYJUGE(Z$6CD1(M( M/72$K+A-.N_I*W8(Z%XJ^7#A72S$TIG7-JKVQW?.A6]P4#3"Z^2*L']=+HE5 M5.#R1U+@CU2EK_Q@>'7YU-FD*>+J@(^16*AZ-6 K0"*^L;9H)49YDT;AO*)GE7=@^?#J62QRJ#[\Q M_P+3L5RLF$SO0,=H]&*!^6;B3'@5K5BX3;V\].Z_!GVNXSHZ]Y&;LX9BJZ+: M[4H"T?3__9]"*IG_R&&U$5%TZKH>?NGWN@">(]C0K4 BEEC!#!Q&[>R!B"\P M(Q2F\):GCU=?P\.D<*L],)AY0C/U\T^W/?Y;ZC3+OY2G'\5DB$'97#M4MU/ MF/B=E_<]?"0O7^9848K;\_T+L4P^?_C%X IM46H/]'KY[O)A7!YWVN/*TV^MIGXV4G^V M5,\SUQFX,S6A#Y[<*@N AS^=K+C^D4XDYJ]_O+V08%6F)0-FFK_ZY3>RNJS2 MRICHH..-U]3:G^8WHR!>_=D+;URRB3\J;WQE$*4CS5N?:9D0-2]R./?&\R@O M-WU5MA=QKL/Y-?.W(??RW;$6;G%1M58OUR+C M;I([7C-&6/'@5!/KPR>0](]KN:Q)@_S3)M7$@?J8%LU<%XBV=M1:B[]8DFCT M)4VD6VK?UDRWH,8FFNGF,"T9M&/NKW'9C0SM)-V+"N@XF#][A;^I)!$S_=VF M>YV*W\[(WK+^1IW,9"I2O?69%K1G'CF9>^EMN-?AT?#A?[';RA,O8T+K'H)3 M31+ [\ ?2HKH_<)UY1W1)%6<73(49!/!4GD1:-'@/?@PE6Z7H(/*K">UFLWO MYMMR6+'!L5P#[MM*U M@RJW_9?'KA:MHM6I?:5F>=3X*M@Z +V2]*&J\_(U2' (=] *>\60%).(UI*K MJH 7W&R/\_>CI]^9'Y\?I2"3JG.<*]JOX[)T4ZJ7*S'NLG)=J]5 M^UKCZ@B_)U8D_G\[%L:@MU M7-&LM#>STM7.9J5*>WPIJ7*C="^0FR!CBI5FI4K]:N?ST39:Y.[<)KVR+CB5 M3<:RV>45[H??JZ>BGD.L^/W<26C;4I)2;)@Y5059U4R/>;G&ZDDD6WB2[;'DCK\_NVF3JY^;R+RC7H$V'1P0R!D0U;.6/Y79/Y3^:UU M PB4[,*F9"_OX\8Z!;7X%Z)[T/+S1,ZJ7RW=<)/> M\,?#E*JJG9[ G,;1MO#<*EWACV/@.VAMOPM7C:6RZN8 [A)6+NH@NL /<6[Y'5);W3O("[%K(35/[ )HY*Z,"$JAM7N!^;<.YBP!8GH+7CGI:P* MCW02L>.H@FVQZ;C[^T+]G*=VG2[F.+#A:V796ZHX"-%=JDTY,21[N# M)#]R$^-%N8=-W6[[ORO9#C^ZS*;/+NJEUL-]!=<6K([=8,6X4OV*:S[_7!<0^!KV%IR#:S]4.<- M4R.-[B1=32$[FJ,'F6*;"#!4=1"/+[VU/7[J:*F7VY?AM9 ]'K!/@3N7:(]_ M%G/#)_GG7:>6 G!3OIR>0 0V8N1#(Z&WM<0>L!,R)5Y18$ 1^?*+!(' M[U,1SKEWZ)N@!4PE/EJ_T+^2'__EGGF=KO2PW9+,6TDEDAD.ON#=:!C(4YT%,A?3<7-3/L=K[&_H>WGNN0]!XXA3GQ5XB6YV=$F4 M>&V$.8+F2)94?((VY-Y9Q+/O'-IQ)I,MFI,)]+"2^?,CE?-1@[BAG)Y\,0$( MS$].%F(46396>-8,0)R:O8N>HKQ+4Y<4HNNTHO(+:E6GLHB6UQV#;OP#CB >_)0B*?3K;;BQY=>I'T=MN>< #W1"DC M5%5F5:TSLB>/<(XH*LN\#BX:/7S3^Q#Z2VGF/.+V.'E?-6^TZ[R0%<\X0S*0 MW9.AH:Y(NHZMT#"X4$U#-WAVTKO>YW&5RV;?LJ7GS3CHMXB<+,03>3SRE8VM M/8\_UL]S1K[B$G2M7H4I7.!I:CKE6H]&>6(+4+^2**I&_UBYR"7\PU5"I) K MH?4#&@'S0"1^3P?&E3G7T!QC17\[/2D[Y@KL*[&*DG%D,V@NN)=1\0TU2M:5 MJ:&_3JN=FY0B4"SZD^Z@-8%'',W@=@7062>\EU6%YN(Z,O$][+TM$BD>OR$] M7JZ T35&J^%_7/@V?A9_9/.D^NA %SQ$^ VY9_&7<7^ETZ*7 M'L;IHI!S4%AV:7*,>Z+#8:M=NH/$^;%,Z)":*@KR9_S9184'UX>"@KI,J\@? MO#+!];.D&.J,)LX\NE7V!19"FD3=,XU)5RF MX;N&%8O8!HV&%[B^B =(@A28/TGC'(T-P_4F>Z*F X'K) V8A)M[" Z6AB;\ M<*BI+Q(^"XSQM+ID0G5#=S7= BYE-_4]K5O*=]&..[PFJA]];7-:0 M9K88SQ*]W-"$8>E$/X>I0 *WD_:(F*B*-]3J\R*GJ.ZS)A1U("F\S'4LZ=C] M34&YSCG,)VM(JSR*>16PS^NG)QVDT*!) 9&ZO#YD,1N@$8&=N&$?YM(96:-R M;K 'Z(P\9BLLYRD]\"\K /D.276/6BPL#(1#/8H.O*8^X@-)A=GU&Z_G[;@ MD P\J4,@0W8*C<)=$8'BATNQ<#://+?CV],3Q"=])A#=D="\4-OGI@C;WA%J MUJ)\Q@$.SIE1$W1 "(4$:8FF-S+-+'3V%<+.N:D;_].27JH&/:STC M0!#LX#* 0'NB4T MAN9I4D$&H3^!*7]6-5E\ED1 D@03I\X2#7B-;%(C:FB\H@], 3<'<$/>@/ ! MD&/@/.7\&)FMD[/1&)#']H(P09DB/8"=\N5JN@ M2>^:&AHQ]*0$3>JP]#)>ZE#KD,@[1^(QF_W%5(BM' 6&]3N8 @=$E 2>NS'$ M<^Z=CL>OU]'+_/)OA.@#'%P))S=6->'XZ58T1J?ACOI$XA/P4-PR[TGW>BPZ M $3H([[ 'CK&;Z "1!%R70D],\Z9<\&YD55P4#1:E4A+- SU] 2\$7#!N$H< MPPYT.L&Y$&D(!@_LQ2RLH@:] P##5(\8UX?@ P+B1:Y#9/7Y7PZ4100713"L MMI,4U&Y_J:;H!N%%[PA ;13U&>*G'OBYXNF)I2@B>8*G#NDS+&\!*9,F/A)Z MWHJB/L%?3XX.*JI$G2*-'Q+0>4'?"_4XYJK:$+0#TP36D@A%KM'75+/7YP:2 M&,>=PEX =56!MCL%2+A!@FA%I8"YPCHUCMI;0 <1^HHJJSUT;B=3!MIZS_Q MW6O\ MR3 ;K0CMD'Y,F8A^&84981^1KMP(' A+^=">&=2J(2JT2LU\B\#^ 3 NF>QT$EP2A!945\>HG'1!#6CJX@*>]"BJ>VY+\&?.$"K M;1==] 1+P*,!H$V["#WOMX.F1U>U#FOLA>1V3 %'R)[,\F7T:U4E&2C M3T7C%@@ER^K')_.F(K"?;:IQL, M B\5.1UW'MCKK-8 .5I;ZS5T#A, /V G MJ%DP9$ QA6/;%,F:,\^H0?$\#8U(J;M9*[A"F6(62A/SJ:>HSS,9(O_UJ'%07 C>V/+P7MB::BM>3L"#255@A,.W'486OV>4SW_28B>>2:@H0@ZDJ"Y;W9 MR_F_F[:CR:#N&"; ,U5G "8'GA\:BR]$P_[I9#!9[G"_X]8R1&5*'_>N^?NV M_"^S(K,D"BKF;%G$9?V(Z7-&#GTVS*I$=ELDZJK8=PG(!]M^B>6=: JK!!3 M4X?Z"![*X\9?,,22SDQ$I' '.+B2*UW%7.!9B$J8%?NC@I9Q6,U):UP0$1ZO MT+XZ9MGU9TF6&3:9+T!W?-.P#]UL&6875!&PV#V-'Z#[RFM]@E/@Z0E,=E?: M.5<2)=PD 6.X/;\ZYZZH-ZO22/,.-(S"#T8*>$0MY7B#0T6+<95!#XY6."[=LXCI7MF$:,JU>D%3NNB)+*[39(80([9Y99&7 MD@K64'L!-XT6=I9DF1U%:U=E=G@9*+*6+-PY$Z[//T',@JL6!(,-A6?AAFNU M!"Z;L:O3IL=E";*9]KB>^W5EEJKU'[?=7:CXUO=D C=H^E(D%XOV9Q:C_9D! M[\_,'<[^3*HS-DJBS9K[M+OK#6[6C/9D1GLRH\3_X3B9/EL6 ]B2R+USNK_] M>\3AQ\(I*^#MB;0.31I4[1# *7-=LDVQ,MFFN/(C(,;\G3"^ORC?\W_DXXVE MT^UQMM$J=3/WRO<6L1IW28/3$X=#7-/5&^;8@^F=.&"[B*DE)F?_<)JGP?/T MC*T1SK2G.3I_3\+;H4:&O#99OK/7+>BB&*\8=OVC9LI6G*R1GBFS%7HG]=@$ M+=4FU7].62-6XDLZEGO3M06=N&FUZPBQPEG!RE'97NHS-8V6,(K(0W:QT>>- MF+TDJ@XEQ5K1GRSO092/ U4(!/0ZAO^TEH?K\A(N8TZV^#M5I),&AM2^\;2V M$"L)):#6.<4;\\FF;+ 54+KJ0CVD ?.0B(^'9-&A&@XM$FY)47#%A98> 'V M0W%8, 9<7N3(RY"M2=IO&A%>PS<@%4X9G/V6MY74/9+!E8F&.$,EGH /0<^4 MF>!JEM-ND^D$A0X-CT56H..C]8X2PP4\79ZD#Z-+B^X:8B?;RO6( OB6<24< M+B!#8U)Q]J!0,T'G#G!FWL[,_3$55BA/!ZZ:H/Z+GL'JFPRBSR@[0I'-;,@Y#C7]^67FYAL84U<9X^S6:AUUB>ZO.^]/[V^.?M(#7N M?OES>R4>K\M8:(_EOP^9[GV)C LRF"-@"A@ T /:U]?%G^/W%X]ZGJDY]93@ MHX$)I]X4%GY)/;H[98"M3; _!;@BQ00G\B,=K;J,M:#4)4$/!BTK>BXS^Q_I M@8YX!:Z&2"*KAJ+%8/07,H'1.=I%-*VG)T.Z_UBW73$BSNZDF=XHEIU28Q<^ M2T:9US2L"*!+![@A3%1Q&U@JC6U5V^/+ZF6W\'OP5_A=G.QBG*+N["*0-Z:2 M*7QCJL:7?XRT4;Y>6/3&I>WLY[]SY2,'L.4L;L!Z!D\ F+VP WW@!/D=Q[,. M08KJLP',?T>8O=,2I_]IY!VI9N]J&FYIO$A@'FU@38G5%TV_IU69N(S$YM.I M:=B]T7.E^]OCFZ8PZ@^__2C\VLD2Z7:FX51[G+QJW?W\5I >[OMG%[@Q0V?S ML,T9;L*:XY^*WTSJQI[L!A #8AQ(J[$A"E.?:;R&88BHFAVC:\J38@C\%B9S M6CXL<1)(DP -PTS)SM,XPXG!_4\2GB]VM\5MANVL;/JW:-V%\$S*B&3+8&=(YE6%Q;%KP.\AA)AS])9HI ML_3E<^8^=[SS((2C?WJ]S'5&-!-RWSY7XO2$GFQQ_-/>D4>@K*N".Q4Y::>+ MV45%Y"$8 !,FTFZ[K!E8J5G^E\MG$ER%[8&:%Y ME6D+!:+P-&^/N443+/2(8_,$=C"C1RESO,&J*ZR"0T[O$\+V[]J)4V ";BNB MAK]#C&?:"J+/#EGI8)]BNE]BTF=BNN$":\3"\I%H[0=6):7BG5[=?1T8"]A* M! [#&2B^TWH5)@7<;\(3*NBJ# OY[241 MF6EEO.U)[O1$TNT]9B+WW(=!2[28?Z!J6.;_B/UCZ&8X7$YAF0D?.EDE/U[" M$L(R %%\6_/;D0SN!T""K8,Q> EJ3X&?IWQ$!\,@;X5T)YW@U(!DVGZ3>[BQQ".\Z@'4=HQP&WUKXNNK:H8Z\E9O"8 M%M,=UQ38%C9VF1I>EL%>',(?:,(H8ANS:CV6;'88(S MK-.3R;A0V^RQV"] MN$0-8\+U,^IJXY!!KJ 67)>(]!&JQL9.7^(""5W88PZZ-4BV*7G.W9X[==;A MQ-0F'73 BJMT)HD!5@EG48-Q#J61/=UAC@U/FS]ORTB&'P0\Z*31K=@Q\H)\ MF/?"]GC8'#2[XB"O=(_8X2^UQT^_4L)HI#?UK^+9!3"!9@ :MJ57NA_3PHWK Z9.!)X,T0?=@9155W,2F:'8*= M':J\I-&%LT;7*=+$'C>:Z:IC75#+L-+][7'B#\FI:C57_2P=]5QR\[NG_OSV M)]M-_3F[J$Y"7!=+J'H@V]@6,U2<27FLZ[IHXCGHP6'8V%4QJ\"5FF7PB(>@ ML854(L9]DBY]K;GC2 8'H#T]0;Q2:.(ZHPL)NI4QD03" MP/0\J<&TNC,!4G4BRW19DR;F<*61E^@/DPXUKF0K2Z'0O;>8Z9MLP<:,!\N" M @L>B4$/PY6P>2=57>8\N?!&'2ELR&$OI>$2F5<'_;1EDI.DS72DOR9QBK)? MI &PAB5NK;16/MHJO/]YZM%4\VBH>;14_) ^D'FT5 M#Q09$Z_)[25->U%K,\#C1,UUMLZHJ^!RJ59_@8_S=68['A.':VV"$^=920E= M%#?8T9 1FYQ$"^"J'$8C5;H1O,>$ __-57,RML1*D;& M.MN#25>,V?>L@E<2L:^S="Y54JF;-FC6/U_3Q8T#R@BAU0=E-: 5&I"BD+PG8><7/FQSEE[G] M_,ZY8'P4._%Y.?2(_^\%A@_#>9RY1+9=Q=N2Q5$P4E:ZR.,V_MR$B) /I)>9 M\E3(1_4%@X+A'\J&NO*H'%W'HQPJ::UK0V^CM4\/\7DF 7I&8\DUF TD,=C*!.<*$3#7: M+ 8+HQ>=1;.D9^:RDB&-WHV>@ M.O@K9Z(?>AAGCT^MGTKN3!$[VYO^4'X8_\Y09.(BQ*[X MPUP36[(X3(>G,4HE@,- <6N&TH@65-+.PL:0-?RB/[X0^8?14L#KX16>-I30 M8W4HEC0.5%V!%&DJP+V_0\WIH*W(G\SQ^:;( M9&-Z?P.&/)L8,<1K0=6N050[0#.P1Y#L\6<)\BU9'&IR-(&1:O*@@7BIHUY[ MF0Y/3D"MA)5*FY[NY]>.5)>9L) ,&FS31G78;->GB?B^2)@.JY?0XI )D0Z8 M[0%9-J"#A=1Z,7@[IE):_DP(:'9'&SX^8[YJR*15*^KA%.L,2+&V "4L_"F6 M.NLI@Y#2X'7J!?! E!.LTLV5&RR_]%"X&5*P/+<9//P-&JBA745TVW!BI1C@ MGI_*E&X3&B);M.\-+MWL/E;$32GB9''>?D&F%)[O@&JK^F2%JZ.RWF& ;Q/8 M;_H\_5Y;03I83OO1JTABWV85BU2.38HKAI_CC4PVR @DOC">%4)Y:Q:0VB/U^A>&'KO C*<*FAIQ.NI&7^%]QN& M>Q@[F5JA<&JV\S?M[=5@BP_CV\[):?_I][%XI>U]!:(< .8$.2R4+COE=:,7 MY]]09J'SP,G0A&L'Q""DEQ*)Z_5M!604O8=*+G=)0*([6 MM G37?V'4VG:O:'QN#UWZRIR:\5=;NV*)!>KTUU&Z'%&L!@CH*O,7Z8>'EH( OVZQ;NL"0I\/YD(/,!B M(OXXBHJLRG+LT%G&4?M,!:(D9*NQP3+\1#@?,W]%L M'MM^5G39,*V@YX*O7I%,326S(P/OJU\\R!6)>U)H-;Y*@X:(C*R8B! ,IAK$ MDR13IWI6*!4 2XT00!;V78 W_P#>V!SBC;Z5ED[SYM<2 ^0:37O.,%(YD'JZ M:I-OPD0D=+%)@N5TNVI'110R02,LB]V# !=,Q_!;E^8V^6;S!:BUKX:2P3]I M!J:I*7]:>&E+%E?1[#XX[9()BW -B"@*-L,IP)"'ENQMTQX@2]_+YF0 M#43(0TP-FORB!$XU2-' W";FXDZ>U$6^CVDT_%@RR4V9@%@-J?J@D!18*L!>'[';$HNC*3['=Q5=A5@M@SO MSW(HW'D@K(@?/C15+JL=:QJ4LV-8-+3@!V_@^9.>KWDJBY)"'W!V\5&); ^ M&5)1[)A# T,W7?Y:%YJ=O->7IPD>SD M":T839()1I6=XK_1BZL0J4MC7B$A4S]>K<5O*?IUF=S,'=#Z$ 7=_Q./UADZ M9F^A/H[8KP-%5LGM#[-!D6] /(Z^%G[0@*G:HQ2.:+&D)F:%L*]0E$;'@E U MG=F0,J$@:9;AJK)@OC#\1D"Q?=&Q>0?\UHMAIH@@AM:*EGNW#7!^<,T *56? M*30Y%NWI$1C.W^:#30GGRC1MJF[("B2"=9$RE(J<#AC>AQWURA*PYV97PW - MU5Q\;X.L.+>A,?9? =JKX_@Y4.$ M=41% / 8J1:"3391B8* -M0G\;1:%]@70LYL74RWBUZ1L,B"0F:;(IMC BV) MEM"7L(<-W9N^.O20AB&E(G[1-!X>/\T8>N(LD,.7)JP035<\)RZL5<2=,[NX\XKCSN5=W'D7=][%G7=QYUW<>1=WWAE? MN[CSQL:=KRG(/3S.Z_KNB&E797T9XYU)_F;.BPWT,.X[AM0UOI]F?V\WA/KW MD\'/_N-UKMY6P;V$1$HFKCU?Z\[%M-&+<[?4YS[?5HSAK=[(0/]@23:P%,72Z#'CXM#BP>I]]A#4-Y)!V*^_)!-DZ.^2[DCF M2$!E3RQA >M4QT?Z7,KM5A+H_44!089D(BK4M(2G,W#8<.89]5KRJM!A4G># M6Q0/']L16B%9#N11KWC$;6:,]2V\5AUQ@#1:#41,4EI,2W,4(+PT-;T4A7KC M*TXFW.YIM!4!C8 ]*P>6K0QAF5"Q\&<=OLU$B%P-&&0FK^IKB]\5ZJMZQZF7 M"\7R:N:^TLPK!&7LCNAD_/'P?>L+:TOE2IQ58=TMP5V;Q$Y_)O_X4VF,-B$& MS;[9\^JS+?,2UQ?+)[1T$ZN8O[M@QW3Q<+P=3L3 I(B5(FN:QA611]X E:303 MI"/INM1&Z%!#=CJLEY5K1_>E0.H]IOH:6A1;\7[FF%*K #:".>(Y'$/')(:W MYPU@^:&NU9]B?5LQL37E^1(LKQ\J2^TDU @\*MC2$_G:$+% %IJE^2Y6E]] M14;A:A$NJT)R;KQS_L3GG)_QY,/X]\]BX_%\ MD23#N'U4NAB>W1F=7':K9=JH M+W\O7UN]LM$!2##+PE(3 8FR$V@;O3A )X9"0<=6!%VA.&L@L 2K3Q$VI^)! M)Y7F$0:%,H4T52'A!VNH= ED\=M8$34%%-<[%&]$50_7P]B5J,VH,C$$*B9 MF #\"H,Z;DKXT"%::$<;430U?YGMGR4YMV1Q1Y*E=@#4+[#M-")H\3)6AV&H MR>JS*G-4?Y==&<3UO18T+*!\O<\Q%9&-DPD7!-PM M&L<\>Q]VN/?PEY#E3 S?EYX190].GZT>N#/PH.9DCPCN 4PFV%:@?H/9O2SQ MGF+W:1U'PS,=J^@$0[5LE. 54TX'# DR13[#IKN&&GN4)O^XPJ71G;RC*\@X M#QW0#M)B6GQXP$_9+/FTJG<_JWJ[=F4J- B.3SNC I[ D:O_[M7">P3XY[@)OA$[-[728(>O0M!,RY!,^M, MT.?S=LU\3%]>RKFW$Y3JH2C';KZ;9L]0_S+7Y/0%^-_=\] M]=7^FX@AV;!E2=3/16.'1KX$YVJN'957.OC M&UQ]%(7,R*M4N#(-G7SL4+\M#8O,W_=QT:$>QN-2Y;C4%[(EV1H&".H@+F$S4=*D352JR_>&7M2O-?P_X4&*05IP>&1ANX31UFV*@ MA2%F5IHW^)<#7Q70L=*V78F)/] "(*_Q&MSJ#;2G&]2C+.PWG;:-]42Y8OH@ MDZ8&OJ\3*]3CN)T8W='G:\CH&YVV4/O"BHT@3*1:N A3D9T.BQ)Y;G)?]S_: M:(3&@OP^$!D6J$YTC/1_8>AZ6&@P"+ %7XA=B A[Y!&:T]1S5!K+XL"E_GZ7 M5L<8HK-;07+!=R ZYEL[0-A,MQKG_>8,MCST2!T 0-^!Y;1IFZ&#-J9$^59* M!F;>"(L67A%[ED;,;$XM=3 T#7=7%RU('KQ =F0D1&*)SJJN1NT)*)D2)!C^>*3$,4 M^ X5.4R"G:,=^$S%-@T(".*;!PH9 I%I)0;9$_[W+LV"56E(X8X&'ABP'WF( M-_OA^6_0@*CC]0SB$\*^H^Y9X6UT0IIH_V%Y%ENR.!"4WQU=@7+% A.3[MZ& MEE(>&7 6>!$DR%1> >G*UK#';H:(].D53]ZXC]6-0WS]@9A-)1-\8'<6/C!P M%!*9?ZI$*JBV<$%;F.W3>LYLIO#E;^'2!RU*6#?X3<*\D<,&*SMOD@DV(S[+ MP^A'XV;$90S(%$4#0%1$E^; GQWZ'&O&ADC6M ,;[6QF$SG%4$MEBBK*VLN# M\'J65 U\4X .>P!9J52D>W%*&D<,#BB$C9<2W D+9)(#LE";72E$7+;A)0 [ MC;U! YBC-C&#+8"QQQYP##/TM%*Y@AFF\'91)#G%LQ(L3]Q3V8Z5J0@TQA_F MH*]XB9&[QNVV1BE%(\H*2[65H*+4O7R"M$0X:*\Q%V\MRJ&B9;A7;'\ -I30 M3!IZXHY2$SN7LJ"L&SIG1;<3_>' 0XH_L]V8N6NIB840^C+'NHO4"O%HI%F@('8>B4V)PL[U ML6$>F< +F:]R()/[^I H6WA'X(D1)+PD+2_-!#@D"'W+NQCJ-$2NZ@ J3!%I M=0&#'KZNM(!+'&R4'6QXRP$>,>. MNEE_ %GCRDW-'"A&1*D 4R1G-R4LL)0 MWV%WR*^"\[*\B:4(5W0G.ADS.I*]QS0<@ ,T%<+^CDEIYQ\8#Z\^8C!^4S2A M*,R3Z0%4DT*28(,[?UTF--4S$=./(A$#2QP+\^K[Q#UTS=NK#8BS*.,4$;;*2/; MM3@TK8A$5J4<$H](U?V>[N0=Y&)=:EZW;8TGZ)>:V M1^>BH=Q4]#YY9G7 BWC '+#LK0P7]@3 +4@0?2@ X'\/H!>:1'?00*W"O<4I[=Z@,)@0VOU1K;9M,B]BD #R('@(L8@0_< MMF4T@B@C7 /O%.G"%OH.Z")',IF ,SGAJ(H_E7BDR!2#:ERP]@>JG<''!]_[ MG\ERE:SO0JZ2+U5T&?X#465R$(&]*W95,LT161<:^@_J&2OQ@3J4\?.O[@C4+%:O1]2LH<]4>I'V5!S?-X[VOF;R8RN>S414& MA'2&330C!/VAS?5F2*@7Z.Y\+Y)=.GHZB&?=1"W[<:JD$'GO_N M'4R2+U\NIM*%?!3YO-H]&\VR 37+E!"S#"4.!S<0)*]6,(S&A4"^EWV&40X( M-Q+B>K0-UN>-;QO'C;-?I\\%L^U2N<[>,HL9 R^)*ZT*VA=+4C>7)<2-Y$U@ MS63"@;2/*0)5@@0"$71E&L]$EY"/1C?DD3.]P1LZ52#<@>]!2*/=<')95AR9>=>AQ7T6F6+G3^OPNB6+:Q%&ANP<"[&/+)YQ@"SC$YVP MU3XSW>T1#*DKKS;E.JJXF KE/IX>P$5Q\,H#1L;O2WQLVK\9ZC]YBHN;F %- M"DU@.,YHF)V!,4-(\_$8DJM^M($UIHSP! A5]YTK/B?O2IF<'#9"A'0(M-3X MN/BER=FPOO-$N+#^BMS$(H_[SKDV CW>)FO#YIA8F#MQZ>! *4I$B-&ED@ET M1TANE-H'$8&H%^R^(UHCK=.%UHUL &P#V59"MA7FAE>GNYVX REH/^D2/^5N MH/LK[% @V9@S O60M84'#'@PU-^&1 MB#]-'4L\W8CG^TDLW=TB?[&Z3+$G?_=Y$FAR%1Q8HHP3649XUL(\1N^48S;6 M8FN2#3R/[!J'B4"K$R X_;LOCY)Z2RT+L_>9$N Z2G6VN@YDT?.CA"G_&EFC MUQS%73.[#ESDH.GOHNO$3P"4(]!8F,IO3WB3(XRZ#G.\0GD22%+='OE;.L]_ MR(,G.I"/,22/'S25'E"'IV&DTRR-)38)*/,PKF4&35%\O)%*Y2T)2(7*B!G9 M/_E=]L^JLW\RN^R?7?;/+OMGE_VSR_[99?^L9_8/L>,&*E4JCUT\T:B,GZH_ MP!C[X,/X9_/2.>I;3O-EB]J&TBR?JEO0.YGK0Y3)H]RY]BT[^B5?%?>^7I^= M?FL!RL+)V76S)5S73FZ:1%15B"Q'4;5+_]GHQ36@C)+U?LRF4[ZBA5OR M9:QD$BXNJFYEY'GKEA=$IJ9C<$6?5+B21B@2R$5U!5T>%=D"R80E'F=85A4, MQ$$(CMAIF3*&X,BG;-J'AWE-K<0KR;1'+:^WCW4T\O\E"&])YLH0++UQ0$UO M="N K]=#>M!'PF09?]8R;;(:VN*C839I2"GXINK1,@& M#1DID.(&0^-[)A8V+5(=0BTHQ./FB!TN2-30 &(:+H9,F7\B9&;HD!Z]V.L> MIJG!ONHN^.WY&JET*$(DC3CZ.JGRTY1,[%./#31B&4JJ[/\&?($B+T#0!9+) M/#K[ZO<"M&;U0T/'Q*+E-F']UBU/O1LR0L.7X-<0/=*I#Y7]2)^C<(X06B$' MB?:#D55R@OAY(81RRYP#;X\XEE;@2$HZK02TP.MJV#@B3_2T[YHMARI:B[_F38*;V9N\KM-BEM9;3=7 L M3P7X;TJ"EP-ZG64WNJ?0OS:*^<))SQ/< M_G5B5?C,_+>Y2+:Q8AD+XZG> #7$KO!2+0C\87#9+:('-S.+63-6=,6,[9=\ M?U9PYOV[LT0=N-DVG?_L+S#*P_CE19.>]6&M*2K;9N =AY1Q'#^,S9+Y>-_\ M/:I8I;VO%XU*/8 &?5V[0(\4PX/^4TV[=RA0ZO05V='(11#%GRW0T2(8O!PH M4UIPJ(>QJOT\+3>/U/,3:4NX_ + ,)()'PPZ#\9Q('2LQK! Z_S[CV+=+5G< MJD=RC])1Z6'9-4::A(9GQQ\9>]KL_JM=GQS@;BCC"O2/?:U!G;9"F)[7G21S=WE"0R9[OF_[#7& M)3,!$OQW+[/GTCU7KF"S$#$#^)S7^E"CWT+'60ZY]GJ^;E2Z"VY4!>_)K#6S!O6&M)">E&NF$V.D* T M>@$FR?XQ _N7[&X4^ B\2AFX4*[H=>(KE>DO90W6--7J2^>2UI6(3?7+T*4^ M_L -M]<7N_'8__&K5]#VXK>"G'?")3W3<'09SKQADF7WVON9="Z5R992F7S^ M2TA_;R8)"KF_PI('<,TTTX7.5,#9H6,()TM_3@DL$PX3;%@Y4HC+)>!"#31G MH1U6SC#/-UB M)RU/8.^WN!-GI14A2R@1A=G];:.0K>93$8J9B2Y_N1Y28-P MHVX/%YK9O$=SCRB9AGW"6->GVOA7YO6YD[T=W3G-7* MIV>UUZL?-_G6V?VNG12W*2]BO>C1^Y67.T8=[/,V(5U:3"UX"(S!V)F'1>9294+A52A M4'AK/RDB97D+*2&\@Q0R\:02P,1^YJ\(O27X-3'TJNK]K*HDINB/X9QQ S M]=1Y!URGV82KT^7W5J=/H/9%EXTCU7I23(A2J#U)]]U&I)RGSCQ!A<@$)J'+-YRW0B:-^S:>..0KS:MCE#]?:YB#YNVANG7'N MY^]3\UA]E#=)J+C?2>6N-L7G@S],M\BF/H/LQ/R=TV;O V[FR!];$% MCF?; N-"Z>7IJ--P3IY+[Z.J1YSF%JC7GW3RIVS[SS_T;TZX*FR32-YMS()" MEE5\SFJ,7BD^C)^O'],_*_;%Q?.69)]L=>;%%:192[J-C8*@Z0SOKF>;:MNA M'8EX!J0ET/)_["-'J_;$$BT>H=A#V+2&=;_0#[#-B@(=BA2) OKHM#4&3? & MX -5]B$(L63R9 *A4%BHDB;&&R:BQFA03()]?6)AYZX5GA4?3)J"3HE@>XNE M=!%R?]DGD67@7D/&+C6(\>=+Z54=.(-Y,WRY$0WG'J E?21T] QS=]2P;6@O6F#7>+/9-/N)Q'6_1!<-M,1 MYUC4F[W$J7PZ2H2Q(@O3@UGS0P69@#M, =RPE,+T"+BO2)U^2I!XQTQ"&R+2 M:1)P#="*W6YIR<19EW63HS5.$U\49$.A_5V,#H#$,00LL<01$Y%-0XZ$=Q@" M_*X.!HH,^%S:"'L_PE<1/QFK9"FX#/1C\F')44@@S'J#PB=W@&PT+0_" MF;4@HL 4H&)AG076BIANIR(Z.T0R9K8P1=9))GA-1\<8# %&0Q@]D=! DB. MGH)=J.!$#TU K6-#BFDB'T86_))"&KFP8.P+':\_*0 "D7,]LQ>.'_8B]S"6 M[%]W5L/6SD\_!?;B72K%W]KZIK #OU@U^$5V^\$OPD@WQ[G8> ",/PWP8@=P ML0.XV#Y B^T L&CV#=.&\D?0S*.*G/S(^.$//(PU[7?]XJF0N[W]O2Q-+6'"P1HG8B>:N0FE+%O=^%4JUA_'3?:U8 M>32;MS_S\U0HS2GWUJ(^:8U*DHJ^E@G'5J?9Z]X-Q;O,DI4Z6Z+%DHO7558G MKDQA>Y9(Z\4"J_OD\K&,KWSL]+[8JMX__?IQ4=XQ)=LQ?R'<5O-E9GF^_*Q2 M/TZ2U=?ZS3%R>$9"R=]D!S2SN.QD4%#/=(NHOM/1G"NB,ZN699@C&(:';T;B M\'LSG>T:^:?/*.7S)B7 K%A8CN'(ES (411\FNAWHZ\+K4/"CX:=$KZ;ARG! M#W@[ MD9=+C84EMPYAP7S/:IG3KG37[!_]*+LA-Y@41%O8K'QD@6#36Y)6\U?DIZFD MU=M:__O-TX_>3>VD>5O33FY&%>/Z]#;]ZTZS.J.GWOG)4;\SN'7DT[XFGVJ/ MO^Y>AI7*P\.LD-_\NQ.6>B 6P?HCN\2"?*';P/XV2<]%\C:):0G$/LCX0G]7 MCDETPUQ4S.^O%+:;B2LZ#:[]4K(=4[5'QV39#[+LLF 1P[QKQXS=[O>STI%N M7UQTHIEQP-:$YWN-F#':M\ XJKA*WH+%8ZA5ED: SN1ABH6? C\G$+M)&=I4 M@>"",0)G+,6CI9@ [ ^,(GIE,!8J^6.9;A TMKME<)*^9..J.](5#"2R H'U MXUE5[?_X]OOH]#*?]]K,39!AC;AT+I$9LP^KEYA1Z>PWS>,KGM)^F$Z+D8D0 M0\+&R)2'ZU^)&*)US5-?$$;1MV:69(MAW2^WL.IS7EI/)'ZO+:W#=?K*JG3Z M0$E*F'I_,3Z2K?SIM[O+-VCWD[GE"Y<2KLZR#):T1-L,8AX#E*+?9L!T*/*/ M(IQJ1EO2A"#0Z E9<1!Q^>3$ UR.LR[2*[ N,F(Z*^;GO!QG;?>2-7B<3I1, M 2H!D7S5JLI/N7)WKXT>NZ5-NR<7-2TR(HAULD4<\'/&'O!2E'F)N1KS(ZQN M+,[\R"QB?B"/8I;I9G*K<6Z^CCK?\S\;A37BUIBX)F6Y]$?7&&^>8C1!5E+P1C/KZPRSW2^7F MCW1WC1AU+K$:LA7S*,F?)$VGE+[HE&W(=%K '(YAR4E<@XU@R=.;JWHZ/1[5 M*V^J?-\$EIRP)=:>)5/0ZQ%ZOZO/F'K_K^4,O^ZKD+KF#+W RW97"+_1*)^Q MN6\N7*#;>DO3!E>5&XCQ575;@@?1A)J_J;UKQY&:\ MPYJ)%$8*)0@37E8>B7A-)B2(N^K04DV#GD91WJ!HI_N)U%$J [_%O9''9]0V?ZH9L?3] M6(H^/I.DVK03Y.W5&I^7*94AGXMOUH6P$(19X950YTZ8H]-7YN/K? !ST6LT MZ5L[1WW8='_\^:7Y=%>_J?>&H@]TD2Z98658 .5!MQBWIHC-O=E#E=DU)8+(9?Y ME\/Y_7S^])ACQ>J8ZM#MWKWA%MQ)\T^3IA4);L5\4A<+Z<>@'GFH[$B9&]AXC)](@+U*A%WF'D$U2=<(, M7J?(WAQ!I-E8Z#T5)^*F0GCKYC/!)ISMRVXBF_M';=^T?A3OQO;\U8;N ?++A@L5"B1\U=2WB\ M1"WA\ANL_7[JU+I'OYZ-8G3MWWM6WLVUK\L6V$U=F%MR4VSU-7CLF!@)A2-' M?7H,F)DJ;%X!,%/8YKLG)S$0%KXGBW#@\%-Y;O]!Z-'KC2M6OBXZIJ&Z1^_, MY]"RYNKZM)HKLDA.(/U4]AF]J[XBQ>RJ[\C"V^_(E>VC:;6,G[?=?+ZI?MH= MN>K]FP9SS[[UDDPFHF[)!0KNHWU]//%;3^MVLI5A(>>>O*;?@A14W2=! M/N2R%--_?K?M/NRM7OGU3=R7= MN<^Z*B[QA((V@\-#25 ]IZ2!=>^H:F M0"\@\AG; ;5' /H!O7S(4YBW8FB:\4*;^R@#U1E8VXI7O:7+"A[.";#IXX=Q M[4?K^5Z_4J_%;B38-#LZR02Y.:YHUREZ6V*J%039!%^4+1ICVH\I/8DYO3"Q M PV%Y@>)NX"Y7+QDV]%2@^#P'Q79:#WUCA^K:F4N\BT4JE=.X?.L$L M[3*W$M[]8(9=&X).V@)BI"TP,P,'.V5B-1?:Q1U%ETS5F.B(J5A6JR_I#;/V MVR'J=,MH]55H3$GV<2H')]:4./';$+6+H=$:&N?7OY^"B6G>XRDAD RR1#K+ M'&O@EL2)WX2(,UD"\>SHB$20SQ H M4;!W:\/T6?& 3JZPDR KER#1^7PKD2#TK#5TI64TU=>E)@Y MPB/UC?"$H?^JTZ]G\^\N-Q9>TK!S9 MZ1AO%QYY(CQ*.^'Q/L(C&F5X5<+#NYGQ4$T<-/+K&H -+*-SW-?NS_7?.>7N M-1.4'4,:C*,9,*E O>"2XF.Q12TI/;++:"$N/&!L/=O)P_ANW/_]Z[Z720\_ M([K_+HTB^<&/=SW?K6RV9.+VN55JU:Z%:J=(^NN-QL79Y"K<"RI9Y4)H MML@O+FOU5G-[]O[$,&EV=@NSLR]I=G8-L[/=QMRTWAQ2<&BSD&U8^/Z-+CDR MT=CE+]NQH*VN(ZCHHV3"@[#RY2B;'C@MSU=V$;H0[$"UH Y6P$S$E[ZB8X-QDH@XW6[$'7<$QA/Y/[ZPNV091TW1DD$PCO!-^&P1#& M@?Q@*N0Q,D-5PS]9Y+:&M^.;>1#]F((KN-%U#V^,3+LO670*H/*2V1$*ZY 1 MR1:&[W$794/*)5F IM+*]7WUR\RJ>_;V"T/OD=]A,0R@F,"(?HB; M9JW*>0<.P;Y*MM_0%8&Y8P0%S29AGQC\7]#8]S)LJ<#'*A*:4VD;')Y,@&-A M )N/:)XN6X3AV)9-I@5KA]DY.G)U&%:J[PA21+RNHVDC>@K@4;+A!Y)E*98% M5$LFO&ZW<-(F.]Y.%([0N@(_'7S9^YAU[QVH%E82!?_J'OR4H$ ^#2R]^*^* M[5N^_H5YIS"V1!X"O;6C&19-269\/#5%7MS2A9TD7X,?30GIA$1GOS($'\=A ML40 )=!RF4[5>;\8=S*>M-,@9Y#3O& M_@/&7T@3L5V9XQX?.PPSV8:+UB\TAII#Y%JG8]*B.'KY)1/[Y#EB$5*Q,A(F M;\ M*,(5>18^DR]T'1,EY%#1)0U6?^B^Q&@3)1B/M05@^>1Z5Q0]F4",+7DM"K-V MIL>"S8R'9(/Q-KYCH+V5E/OQ"/F0_U05R*U+V,^6H))%("*Z]MI7VRIA)C%] MF$O!OWE\@GPH@/1$A8+B/()(,TPT8XA5/A!*!^?!;LF%5#(!!W4MN&A7";_8 MXK!"[EG2'*KQ<46S32P*#@;M%HT#@YCDSC;!"R,[KL414D$?P()&R,#8'APG MDFJB$[[BZF:-+N->B]UN.:9-+8) 2XP7 R(X81!.+T>E7T>Y_J<;=H<4V%'%CP"PL'I\)=Y?JZ M@H[?K5QK^$9.:DFK+[0^)B,]2V"?^NJD*[K\39%[ !\-IBMJEX"*3&QQHA9& ME&!/5 *\?=B'<;T^U&]KF4I^5-J2ZFP6X$@F3H2#"4.\E#DF*QYT?UPH\LOK ML+SW];AV?79;:9W=UH2+L\K1V<59ZY?+&>L1 MH2: '.I!>JU%8U9,B*[5YS M+3#+HP '"A& XL,^3#.7C:;/XZDV[+XN"6N9SVN8 OS8%QTFK(W]KYR=2?!9O? M;H>'AF@ ;C1_XA87MF>)L/\3J]O,QLV1/)[Q8,[&Y4>K-VZW3I^N'G<\3AG MCR>XU6R>>0\V#^]Z7PXUK'P*)H1'^KX>/X9IMUB\"](7)WH 3722XEZB1EO. M#1O674[)[,5?4V\LX6'W82'WUS09_A$BSG5<)]V :];%P=,G7')T'CS(MD#W M7> &M(3:IC;<>PH4T'425VF!V(V<%K1XO. M. ET57E+%YOKDYLG[>['[?7WVZ>;7JNF'?UXTBZ;M]?W9]5^[?[G=5^Z>QV? M-RO&S>G)Z/XNGY9.;]/27;W?KCY5%@@:>[:BVV8IG,#+A=V #N@KEJ712)%, M19^_E\W>UV!/FLA$^:#8<2&9(D_4U_^9G,W\XTT*!7XQ^J7V M@:5T#M37@[XJRPKY#N&LC/K:-K5T/EW:^WH03Q(QBB3SZQY_*G'+[T?<\!LO M/<^--U9?NX7182Y.CY)9WT#ARS!%6(VFBLV M0\?_8'KE5DROZ;*H&851Q8>QQ5$)!$IXE4Z7>+R\_L*M@LS@B%RVB0[/TYJZ#O^/IDV[.I4VG@9#P,+Y8 M_,<*)&%BJJ>)!4PT^TV?;.>%_7=]69NS+X&%>'-#H ?0P81)GXB8\,W!H:L:(="A0P[&-*$,0>.@XN7+VD= M1PNDBX3..L"S9-J33172P@N9F[ O?J'>$F=]N6R/[5/F=KHPJ?3\\0@A9!]Y0 M1 R0L6;CPL^D5VCB93J("#^+'MQDG+74N6'DL]&M @3H01-"?N9+_/A^\>[ MBS:/@R9 _3D;Y:Y.U&-G,*B,"]O%1J'KG;\E02$R"2K 3=DO6%, '!32(,++ MQYXBA9<%YHG-VBN(:$4&!]:#;!]3!G*=76O#2OYY4I=%>,!U]X?W<^YJ.RM:&^AK" M2KDO@L(>$)ZQHH+?BO%@H?.+)LA&7R^AA$?SUETL9Z;AZ7FW*!SWF3VNB:+ M/B%KY@43UY*7SFO?730>=2F;O=:VB\>B%[T$HT6V6?KK'13_0+V^Z&K]R00U M>N=M7_AFG4V$:T46 ?HLK5^,[![U)K7_K7?K MNK)0A-I_^2/]JN9^E+_KN>WBH^74_N)\S!2C]:=7H_6+KM:_-IP4IO5?C\RK M4B_;^O8M_A)=2NL77:U_13SRD5I_-I=?F=X?'\^;0S%;&UZ*T/MK+X51MG^M MG@[CCDP M78Q5[X%9 LE@+#H%.5VZ(6B&W@.4# M>)6-%UW Y!(6??789A_X1C80 (M'9./X[ O6KY-O$YO1:3^2RQ48*M3XM$WR M#,52<9&,ODNZ W Q:(&*Y2DFC$D/$//$2*NWS>QU52J#B-F*'9V!G!J'EEK: MH:6N&BTUOSEHJ1\HUC8>'/7#\^]W8*EK"Y;ZL;28'SSU@Z%3/Y8,GP"EN@[X M1N]0' Y^^KZAD3O7JOUVB)H%ZM]L[ -_UL[<8SR,C;&==[+JX\_3[O;H6Q3H MX#0$Z(!HF/F31\.QGW*U1GOO:[5R==9"2=6HG@N5^O$TRL=Z"*Z=';4P%UR9 M2E#9\= 3&]U;PR:& M$G<8T6^1(7TXD:YS3RREBP'G7LC000\?69NB5ZN&.30H.NR49\^%**Y"C5NC MBQP^X2:$OU2JF/.,?^9NO!_'S:+T;=1W*E[ZH[B /@_'Q]./? EGF$Q4@BGIY ^X M,J$J^-;FXH:SO[EL#"B5'"$:\@;BDE&0# CW+!\CF!S9"=60:?R.G$7\D^5R M*[8FFN+;.9@.#K$"M/'C?UG4G> ML+/8=3X2A:',,?9,3S/JG.2(9^M"*9_+BOG"FX(>/$);3N5$,54NER*CM+KR MHHTXZ3Q6M1%".UAY09<%_!LL#6%+$W!M5 1S#',/DSL.H#Y('2\@?219ZF9Q MYZ,UZE?,V\O+&Z^-ED<@/.\IO_NU#2N<(Z3[8;P6/!RQ&[/WM2810Q=Y!EB& MSD2(YXY)Q'* -I]D#3_$E?=.MK64L]DK%%G\./:(QW".9(F?WYXJO^\?6^=6 MSV4)'S@]E"I1MF"'K\.7-DMRS23-)PBMI815/O**9;1!*-Y@GP" @@9$5"0L M!L'R:>$9\^+(EP 9FLR&Z!H6!-$DB@U 8R@@IIBU/%DE%@43O:6J]M;;$2=* MVZ3AJ1R-3Z7\]QN__";%4/YMBE0YG1$Q$0D_Y=XBBXZ6E$6U@6)7I:%J2QK M;^B$Q7V8&N1T]*JUR]>3O)?)QH4S$H*H!/3C3&3>)92G\D$Z2[^8YB;SXBFF"R INMP*>+F"^NM@]?X4H3--H( MZOK8% 0QPV5:Y8I-6WRVAALF[BL:-D6 \::5K\)"RM?:5[QQN"0,W*V^/ "OGPM85]"<),7+9&TB M?NG]R6=*A2L1\T^*S?*&W530"=,BF0B\$6:J$;T;.N7HTYG&E4C,(]_R)])9 M17#-=-:7=>N_<[=/Q?/;I[-H?"/?Y@78&&D[.\=J3D*%>F#62S;[=*FC"W:%"EHAV;$=#G#^WN7,W/:H=YWJ 46 M>J3&CIE5+[K6U4E&>F9M/O) S2+6<5;FRQD%]7$*OY+D/X1 M:Z)L]*T43ULM>_]M?Z7LLPO/;O3B:CSU-YE@>)&8 MZ2X64V@A&+JN4#F$OC8)6XJJQ.JUAF221K<[80@(V%:W.=)4P$H6*B'1B*V M")C.,RI]%G#6%-/9=!E-6_))3#^,GV\ONNEBP1$'O4]TCA0A9PAN%_I)3"\E M83.%5#F=3Y5C$#I\_E5H61;$V%J18VR2U@O$6RAC %_P:]*L?!N<74E=NRRN MTSZYAM+$A)?SBZ>RQ5(J5RS,NB!1QV'K)^J-[S@)^Z8R)%\!1[G>F]K1TBHS M(#JKV>'BV.ZETZ->)>L5;O-A_ '>%&_PR;(8GG&";O'6IR0NK) ;8E(2RH?E MR!.]0%)"J"N& IJAOY%);-IW,ZX$;B%90/1*)@LRZ>QRG)*M5LZOAB6M;F8_ M5Q9DR/^YG[+O(@N(G9K/%%.YY#\%^$FF[OZ MU1P\;>+5L"INB+X:2NG#="0PP\350"N?8^\&8=;5L#/%-W!QF&'+ZC87B8L? M3X1A/-^2ZS/T @Y37C.QG!;A_+-/N>7")[??=7GT=&RVVT_!^(D_'.7W^GE1 ME87\9XNM,RK@#77K[J?PBX5RJEB*#I)XYWS2YA.&C@F0MS3X-P&3/!67 MJT;&Y4ZDCD+=R7@)#-/#M,L#2^Y\]H>H?'_MM\KY;'3DK$O>+T@X@<7B9-[$ MH$B*][!M"O.I[S?A6+T'3\D.FI''4H:*N=3.U/T[0R_GJYH1YHJ;3U>T>6Z MH;,^Y"O?I,>3;]62G.GD56^3*IV.2=-TZ7QF;> K' EDC@(GN9EGBF87HI8NW[C_-<7C0M>6"[4NSSEFU M^@@>HZ-?ZKI&QM]5B$_$NJ/5.5]RQ;XI 1HY39^ F_R6(S[X(DA7-"/#-)Y5 MF6;+4[1S[-:$?/@%4C\&J@T_<_XC7P.6K?IXITZTWHYR2/\N61:]8LF[[8 6 MT9=DO%OH>)(@JYH30%5/"2]]E=B)MJGV>HJ)8[A%/&1%G;YB'P#4!0>YP+FS MVXB:I?[9L]'8 BVT0R6*DN+'59SD%FPE$'JWN?SZVE$@=.NS 1&G84)D\DPI M1/99Y@2,],?RD7D\^G'L 4W3.4QU-4" ^UC#-6KR,:H*2WOR(^V\KQ MEU/9 M=":2SQ5W[7;83AUY.^6"C 76N_(=PGUWM^8DT&G OSVQ&Q,^UW7:%A&BL\7H M?9ENL1"/C_LFBV%E>R;+FV$HO,\VO\E02":XI?#,#/^IPU?P#M^%0>2,[D\X M@%0IIKT1M8WI?URM:QD?=T1A:L)4VQ>9;%GL$5UF1>MTD(LQAH0'[^3=E)@X M2G:^1SW(G'K!;!2FD]%<4 3#&% P#&4*#",$%VI+7"D[/]$JZR=6Z!_JZL6* MDK;UU_'CY]8Z?+#KIU#.I\3,K'C_;-UW+M=^>VHY+*'K-B0- R? MNGQ'2Q$HQ59H&![?.O7RI7YQ<:*X6UIWVWZQ H@9MS6*]< $/\7&"J#&N&+)*G^.FB'7Z$I1*]+&BP3U&MM^4\=NYR83[[?F0^UE. M,2-MP[R&#I$U-@;:^^X?+?97:Y6^FJ-:Y?M ^J5\_UWR6:K^)C9P<:#U5 CO:H)86$#I*;]5Z:;TY,3"E9K=SU5Z M<@=BWOU4^(!K-%O*I0ISI43$JCV>?6B%RM[BG &OSFKV\_:X>/VLZO>7Q:=/ M"76M>/.F[%)R#\?ELF*P4!X,::B6G[]Z6W1K!!_4VD.MSS;9=>75 "(D*4L MCQ_'U:LG^;Q^JWV\0S[G.HP*!]GT>^Z[F!53^6PDP/TL/WQAIA_>'R]9X?8X MCQ=]*5>]KF8?/]8I_YY;$^F4+Y9C89W *9],Q'KE:V]655:W9R/[U\_3GZ?/ MY]W\9ZLJ[[2'RZHJ'^1R7^&>IGOBW77IUYFA2>OH>?\X09J+OT'?R>4.L)EN MYY&=RWTC%P?&)WJ3RC&F9TPU7-F3#=1)U^CZXXXGADG>_*QV7)&>SY38\<]G MRK[D[&N:6 %'8M3R/%?6TJ.4 1HBJ6JT=)=KE8 MZXN#4SG$EQ@(MV+VAL7F&BLJ9JPS2AKD#S(E]U.92X,92U@N93^7F;/8>*?J:R5)<.T;VAV8LU)//HJE1#?R;"D?P-TV30JL6N0O*S M"IV27/I&Z-J54(6.@! M,S"+S."#8[<])-H;#N 'D'^I^ I\PNV\A_C(5X_XC[ML9#8T( MD8E=J#FR\C6VN5%YU]QHU3MYZ.,#K.<6(VOMO1G];=Z$_N M9K0NW8M04?S(_D6[?D4[JS@V).OTR,""F%\@)CM;F9ZPADN %,D^Y1_&1U=U M]>BT.^I?9#_=7BT=B#GW4WXY'V0QOX0A"JEAZ!KDYBC$3K'6HM.!8"(6$K/% M"!2P%K 36Z!#3YF8XIRY^Q,;TS[/5XOY;Y?'\@=[_-^T"],^_$PJ$X-Y/MM* M+"UMF4\0]/&LK91^%A][OJ*K=;',5T3S^9A^3JMP6XV]K;]&PJ!?O7L$KV4. M$@D>-][.1*AP2%C61.!-T>RN:I(KC(])[C079]:MRN-@WRX6+4H 4-;\0 W3 MH7:6=>#F*C+T->HH-I6!I.KPH)=2T98TJ,'#2KHIL5Q>),]%3(NEQ5O9LZ0^ M".LT].E6]F_Q/\=&I[RAP:IN="OP^IXR/ M]S,2+B=H) M8D>HGL#,Q0UCZTP^E2]%YG =)A.@B !/4SYN*Y+IB5[)GC(UBO/XE[Q[U?1\.K;SG]I!S-O2[%B5VA^-'*%F/CN"W8- $] ]DL M$@/UKY0 $!@RV*IZB 5V&>%CKK(SYATABYE:71B$@\19_LOA/-''M?O2YB&72.NTZ$R=8B MJ-9ZW0:\1H=!&#T[B*Q%2[V4WP[1'&R#F-LQY;21T#7@T+< X=,/3XBN+"RB M:E&(E4F9_.G6K%ZU X"+IG-B?FFP7SPCNSN1K(#+D=W:O'A:/4 MC!>X"@F3H'.#XA3)F,H[%ZI(/-G9L,?2R'J0[>,'!RY-. M_[B&XD.Y,L?#Z M>%3*S',(;+8Q1'C.3,9>:#\VG.E=3F<D M>R' K4,=AI9"""2'>"%=AV$RP3V&M$T530N%GZ=Z7X;UM_(7OU'X+)Y&Z!9! MD['T0%=!"C#-!T.7Y?2E]>9RR _H.#CO$6HB]:-.T5*I\B<#^50:'ZN5UF^Q;N\G5+H^TE_O.60<^*>#SA_7<,QPQU%R<1;/471.(RK M\Q2=D'D3%@F7K-8:W6;Q+#:^:ES=G!U)]P,YQB__B1ZCN>B\P/T52XZW>HX* M\1%2O)$LSW?WR_/W$K&76WH6TCJP]PR2)1#0,N)(F MNH1FTF'F/>NINX!]']O ZM/-^VTY04[V)E,_ZY4Z8FZ#S?P-/%OO8.Z?O-G< MA^.P G-_6P[%7?[QO-BZR3?ST@:9_6M["-[)_$\FT/[?TARLK4\PJQO/M+VT M*"Z0J5QX.U R"#DJVT0QS60;^=_#^%MY<&9<-\IG[?4'/A9%G>='-DQ#*[.3*9-+&>[C*MEU/SYJFH;<#5D3D0R_Q39KG2<3&5 M*Y12F73NW:^.:*M_ZNJ +?F\JV,!FL;)P'*LAW[&U5%[T]4Q3;#];3&6*[V]S1.?CAEP?U,LWW46OFOGET#R3_"CZY]*%5#J:OY.)V1 FDQ?"XL;G]#YD?V:_'3V/ M%2T?FO6QUE?^)UWJK&$2B;";*CC^6VHI;?^\VRHE>U=C(0O%%/I4G1C M\]DF5&8Y$VKYD_EKT&^_7M7D2Q\"W@?:4!^Q26(Z51 _PH:JS&M#!47KN/*[ MT"FW?YDWI=P'V%!!Z;8"\F8SJ5(V6F&<84,ME'? ;:@P,H9(FG4QFU9-\@QA MZ7PV6NYX+(,70)C9M+1G=8+X&^$SE%;#T,10 M*I2C*3EGHR/"[#M#:>L6-\-0:BI#F^8LO-5:6D(4>M92T16'Y:5ULO&/LWOC MN7YQ\W/=P\:75SFDO)A-]>FMDH?8:YM/3> M?YZYM++-BQ'S65%,I9<*.;TA^7OUV_*!]M%'[(I82N4*L4;LBNRC0IQ]%"9& M@V1_/Y,H*,)6$-8H$.TP'RVE9IA$D^4@"YA$ M2-([Z 'CFY>+RY=3Z:9?"RV57.NK_+,NZ^4,I.(.26O(*8R1.Z6OA7ZG5\]NW%7^69?UN^?: MA9R-=S.05L3>66C671!W!M+.0%JN1DD,6D>FTH%>WQ2\U9-)P!=8T<916?=C MB\V1A1@'X1$3%ZA^\#\I?'0Q)@7+ MG6KG-4WA\AMTW942_J/TW _8DI(8J1I\P=X3T]#<*\B\%]W,^R7W96Q:1XW3 M[]JWFKGVCE;13=E?U;Y&N&"SJ6(YGQ+%A16,?>R!Z_9MG3IX1V_5OU>VW^NJ MN*]^;^.LJ'Q<_M&7G:JR@8M;H"P@3E,)V'$NQ#PQ'&+S+UT_0$6&I0&S-[H, M)=-B!SCG'N#YDX\I5.8)=*TE_Z!S)OP^=:V7KCOI6<@\10RJ5PFOI'IM(9I>ZT[W%DE$ZAWVF1]G;["NP#$X/]'7],-4R6L+6GP MV^GJQ%5O]?CN>[ORLUVXDR]BZWF])85S= >RX> MB#GW4][%=W[S>8U0G]/S-H3AG9."POO-B$M+;^$295#H&!-4+ MCAGT7G0GX<=EJ3B? ^"XL5SOE"3QY_(R*]R'J'@\637NJ0#LQTM9-N M97X-8KIY^$)-J:E%O1E]?7)-T5Z*=/S^1QTZLKE7_. =IM/Y3#K2:-W62_+? MMGM/MK].K)&LDA!#>>UHCJQ\_??_'!P0SE8T^6_A2NHI_Y Q?SL*49S_)BS] M#S7\5+:GVK)1.GU[5*JW8M5"OU>N7HK"E4&Y=7E?JOE'!6KQYNU7KKC5:MF4RT M&@)9.5EGO=FX.#LFJS\63L[JE7KUK'(A-%OD%Y>U>JNY/6L_@5:6H'^TT(5S M25TXM>EH4Q8M?_(ALQT+W[_1)4=6B9;U91VNZ=4O<*M-67)DN>?L(\_BSANQ M6F\$E3"B&\]6=5#7=85E/:AV'VTCU>=ME28ZF1H#\E?#'-'^I;;A,Z1.-:-- M#*S&<&B8-BCPT GUQ-'EE'!Q417V_[__6\H0+?3D!#^(_WQ))KQ.J"=?4L*+ MPITBU,'MNJ?W&?,)E93 /QZA@.0_5;_ 7(8.69]D*;[P%63<^4-8*4$"NUS3 MC!?K[RW=ZJWF8[;CR40%FNH- $WXY"2P^7&MCUAO9S9(P[Q6>WV[[H -VN@V ME8YC(MM6)4U3Y*,1%WKLBQ9O'?H9,?K: %SX:L MS-?DV3U=]' %SA8<+5_'9^/UJJE>V5?'UQZ4$C\>+FTF KJS[/XER17M#1#= M^.<$/29]!+/6O5RJ77Z!ULY3+3AU07E5S(Y*R!KM&3J:Q7PU-@;Z3[P %2>A MN,XL5RN>WM;;XROKV(]/,TF3>0-V;R+/NK*8WV^5/DS'H($0*4:Y#&X]P^GU M?<@%[*K.;*MKZ\^XJ8[FO:G2ZWA3':U<;%0N7N72?4:_>M8V\*8Z^HR;2GS_ MFRJ_/C?5ZEGNI#7*WMK//\X;A0VXJ3Z4Q29NJMU%]>=>5-6-OJBJ*Y<:OSK6 M64?[<7M[U=_ BZKZ*1?5W,D1VV!2K9[EBOUBO7A=M>I=>0,NJ@]EL8F+JCC' M376XNZJV:W$UJ=-/)AC["T3^"H;=)YM*&5 R1V0"Y@ \O(3=P+^MJ4^*+P_& M J(F^/S9#_Z(O(_1X;=.47 MT]O%Q>OHW%_+2\B-O)#7R"?"B <86125K;*9@*,"CDIIX0=A1* M!^>!C%2QD$HF@/?=%0(R(.XKK\&._8= ,7U^HKR034=4FVKSR(7B(V5\O'333FMY?-;5"BV4'G8GW5>&1'JA$N(QL!WE?T8MD]9 M6G1K&_0S;=ZE6!UI"$G!)L :3=;A@ZK7DEZ/5:NC&99C*BTRYI%&'3M#E_=+ M@>JYN,<>QH7[6KTCBM6?WY[VMF-[6 9G,O%-.)CP#98RM8?Q6,_>]BOED]I M(ZIXO=JXK FMRL]:T]W170[9)BX.;QI>OP97":@W-SK:SFBO6*!Q6*JL2B8D M?W55#8N?L'P ]9D3159,20,CG)P8P99>R75D.Z9N'0JGY K2B2)5-4RB#>%E MEL(W-'2;C&<(54F79,E[Q8AH1? *B_\%IL2_'/*&+=V5K6:YBLW3%MW$:'\1 M)7B I&=)U5"-!4.^.\UA0X*PFZ0K1L8I41[B*:CP:X3AURTX_@4:(O M@'(MV62-8/4+CD5;B!C=KJ60>70=PD"-PD6@2NX5:,.O0N;75G2EJT)!)7DA.7^LL)O8)CI3]P@=I1[Z M"H2V!'-VAJS*39%,G0QD"7V5Z">>I<"F"\>+:(;H QL89&G@+=-&0 0=?XG4 M@ ?8)"SA125S;I-IF K9]+$B'PIG."98/V!Q$$90N\2L()/ID&%Z4 *J^U\* MV9]B\1]BAKSHBFGUU6&*40.IZ]"0"KQ+(8H@TF&:*@J=23+15KCW;G>\-W!Q M%=A#.*,CPJK6!'O.<\68RH <*+^AJ[R2N>CTU+5'.!["*P%VP#7X QT%IO.L M=J:],I,:ID_A$XE>HW;&]?M2WR"SV1Y-+JZV,*Z>4-S5$ZZZGK"T.?6$'RB$ M-KY\\&,+D=:OG/##U[_&Y84?2XLU+C?\6$+\H>6'J_>0$=6,:-L82J_H$ M#-[+8BGEND655Z7CV!C#$V(VGY;Q>IR2$BYL^="MOO7^P*MP4S#@F65*BJ9" M1B8ZAA#V7'D=:L36);>5:8.1[3V+X,N:1BQNAUC50Q.<,_;(Q;N2B9FM&4.< M#N@5LFK9IMIV>'Q2ALAC0U\G SX;VC%!B,!29ARGIUL#I&!9B_VED MT=2/A3-!1$#R5E/I$+L'QB<_=R1=)Q86:Z8AN91ACCF*R\7).I1&> F!Z\"W M0)QE;,#S6"4OM5O2JP(7&%N(534L&NX4R76724.X$S_Y4WNN%0V#>M;1R/^78!@4IUOUN<9YPH\[*MB6C6X%PI;4&1@<317CLYB3"48&H4L4Z_V7OHKY8X"VKLK@=\KDRV(Z4W+C$1?42XFG M3<'4+$'J=E5-Q;@('EK&DJZ#M-I7E2XYZW#NX:PWR/?)P4E!G@@5$C0O1"PQ M9'1=A^-H&B-)P^)[!# S67>FF(;A%7SPFC]W39[ O#1YN)&<7!ZVM=J@=74O M>V6IE4G: %EB&U6$$&4-^18STQ@HWD'&Q\171'W>^QJ9FO87][76%5MH2IKB M.E^G1++/MRH)EZJN#IR!P.A)R3,*S=/WIT>R[]5>AS#V1G)5ZZ>H](:_,H\C M+]V$+U^AZYHE$H-46$-NFH95C!6">,$F$]X-2P8Q@MU#5W!B[:M M0!L'HFMHJ@7I\ON8?!=]NH%+FCQB*C@.<"B3O%[$F B_9,)W>6,R+P3Q M(-\-8@$*38ERY^D&R(P.3<'C8">$1$0S(XP-;E0R" L@T"3S(; =#TX9;:($ MXD98K+F7/4$+(I$MAXSA>]@5[5U)U3"6" LCLQ[1K[*WDM_2/CZ2110:<(=; MY$U6ES$5.ZC^2<']@=11R4_)Q'XV_460I1&Y KID083>$#@SP:%L49Q6X07J MC"#[RQ!D0[",7?AL Q<72,CH*3J$2,GV&KHV(B=.AU--=AUC7H3GB(0!#B%, M85F*[9;&3+0!%O>^28?*%V=7E>^%TW.G^8XRNCM[,>9K@ _G+F/5?$I:V6;E,\]*V+K M6_N[YM/'D 6GICHS63-\JI^V;85RJAC3 9(HX.&G"WN-L98,4UM3\#1SMTE: MHUN%/!6RXQAT)8H,$,)B&,)+;,[PV?EYTSM5;=\)ZW7.0*E1^1& MH>X\:]IAE1V?MTLTAP"[:TRO%@6F2HPXO8<0:$QV&O$GZLQ]@"Z8:-FHH<&1 M/34,&9)7EM^[TO>&=IU_^=%6)7_KJVA*S/QO.>9[P=OVJX9PC8M#AR; M7@UNAO<;YQH\T334K@I&9\ %-^D1X?J\3PN.8*><&0O8I.2<7C]R"3S@9L;O=!@ MG@4,2V:03EI_(6_PF _3*XDE[!"U37?GU75,L.IB%#R.HFD0&A/%GG5#YDHO M:R3&?/O)!+4162YLA)/&+0[UAFQTV8#^UI3I=)&WZ$V7 _4[Z^FP&1,3QAS: M_4S-JV"=()O)R#:C32/J-#'DB>@*G"[RKL#ILJ](:!T].3Q'-Z0.S#M:K!@L M/5N#K81JL!7:N=-UJ6XD5UU?&[5#>&HXC?[I5TWFAT/N+4R M+Q.Y=O$<9(EHM+T&;+33];=I<7/GLS2=]L$%UYTF,AB:HP& <+Q"\O^0W+D& M4;PN9&F7V[*QBYOHAR>6@_WPO/P6P<<7DXDM$6SAYK?PO_/LEIT V<#%3405 M P'%L$JR'H6],#SNP& >N4\.%-<]8 *H#(O*M0]X]@9Y""K.>)B2,Z.M=/JZ MH1F]$> (R1'Y3A [HZE.."[ V0&B#1;&P;= M:.S)F8CMF2M.? L9?Q+59;) M;VL2Y-C \Y6NB<[]\*RE9 (&#? MQ&!02"/".5-"RKS%)'[*/SQ8IDWT*]" J/:#/[-@T:(:$SG^$;K2#"#J1 MHCF88S"4[$Z?_(H)2T4FL@SDS[2TW5W7&[@XVEIH)&1"_CJ4(;6\?1N3>!#;(E(;HZGS)!%RAX*/E48+(9\#)9?%:>4U53'AB M7_TB5)P>H12OCZ+(6_LJ^0,F.%//KV1[,\0R>D$SB*@R YH QA6!$&PJ7"^@ M]SQ.4H5:=YO.$"YYH)0LJRR=&4JC(>434X,D78<,:,L'^^71C#X[(J]W=)M\ MX07+\C&5B/HKDPFF-H N0C9@"'E]9!A,/G*?DLAT?CO4T4U&[$%F->8WD7G% MID1?,9WDQ# GG7SY3)XY^?*9XB;< ]5>];Y1KFOYFN?GX^M#0L_MF@FC2I1O M+W^0R;N?BI]Z&4QG1,]$=N;Z^=!4GE7#L9!U=R)] Q?7,I()$'(I3\ !M D" MA4BR@E*&7O.05*BZ.')W2<\61M?/4;>SB7$]=UJU""]7H M&(R*Y:E3%M7;($%:5U[("-)P:(#S1(ZJ9@FH=M5:PRM+ZV+Q.DG/TDK"EAQ5D5 \R*;=3R)J)7'+=,$PPQ?Q]HJLN90/PD.' *,['<^F&$.* MAWZ03$S!'TPP^I"6PDCD#K.ATG!&F4L4'V6R/(V6?,IFQ55PPNVWG&IFSAJY M6VDF)TQ,^7B>*6?<*6=6->7^\9G=^EUH:I7.QS OQS?PT W>BSE7--^,.]_, M^\XW&W68PD\7^T^*&XWDS&M_F";W_NBSQ*BS$//)KF$3BB@8C;+O^$8^\S 6 M;_+G?;%13S<>MPTQXSLJ#*+XSQ1N1N5A_/NR;AL-J5&\[.Q];=X<-6L_;FKU MEE"[I6 _.ZR,#5YTNG2'E_K M6:MVF4QD#H7+2KURBMAZ+$6C*1R?-:LWS>99HX[P5>0+%[^:9TVA<>*#Y*LV MZL=G+?Z=ZUKSYJ*%7VEUP>K;W=L+\PV[0I.)QC,8,\K+;B\W&#*L,B8F,T4$T=6(93\1&*9C"B^Z'%I*]C "( M'[P8IB:3*Y "O/L!H6AR%OZ&W-2#"80H#0)_%"9&407;B0 M8 C#Q&^:"D788<_HABI;;LIA]>B8.RV3B?U#X:X/;0\ EX%':-U748JG!/)( M2J"806 X B0\F:UET4FD#[-_$0J09?5'LFFX+]7<5[:^53T_*<9=K%&G;TAH MF*,G!?H? O2G9+. LT*CW&R OMKK\R1\0.>03/71D70I!;%HF<*N.Q2; S,U MW!6T1[AA9#-3PK _LI"TTG"H2":F[^,N&D2=%L@<87&@PM X 2&..PS%*H#N M>HC@CU_6(#L$2":F_X+= D3Z+P'MVU=&I=HJS<1#B!H(64LZW:T 8!AFG@A# M3;+!34))3A/I EYCS9 P+0'IYR*4M"W#;%-T$L3 =SJP6#HT9 32L%;;D$>' M0D6S^ZZMP8T%G!:S)S3)T3M]?P8 95["DXH*@&<6E&CQ3I1\@:B!6B$'RH?Y M[VBV"K@EA)@*I"C2I@5#Q[0<#A)B^!O@,<8C?X N!YI*R"Y#D[,NL8'DP/QY MY']H8-4:F4\7\P&,%[N/.\U?#4OJJC8KYOBS_$);LCA_P2'A!EUH=&P#"RK+ M+ ,FX!D'NP3Y%%&AHM)W^A+TA+A79.5):'948**NV@DB$C;OFT%9YL^]Q<-, M&%.0:"[/=\5T(.X\<$5!X!V73-97<7["?O/^LLI$R/04.P8DTO@+.#&+C4X' MQ]8-D$@^H8]@RJ8T5!QBU/DO-1M."H]\2^2OUB E6)V^.C:&?5/152)9KR3S MB0AZ0W?')X)6D4"25K1Q7R'[8T[^"4\9/<.Z KG#(.=5R3;53C)!OD/EPV$< M%5*T&2Y%_0$\#Y3QAJ[PVTE#" V;"#9RFL%QH0XU58>P&30M093HOF$-R?'6 ML)<'Q8JD.XPY(="%0[;H5 E)A1*M"@/A"ULN/*L6W!D230?!W8"-X;L$,N6: MOPD&.?;!1V*+WV"8="*T;4!C@H@A%9WH$+(=6:7] M1[@2\&@XT @"?\=3K!#83!L8A 3D? L=LGC\K@U 4+NN09NXN$J' 9EB\IT= M>OP!!XGP@XKM-WW<%P OY=_FVAJVO\%S3U590*UV>/*+RSGD-NR9TD"P0"WJ M*Z!;D#,R$HZAL%M6P4=#UG!Y>'PH4)1, ],.KPB3XM$F*R5G'20@(,C 64D) M1P:T)Z)!'WYR.6IKTR"RE>&OA@R28M4)!W!0=#PDO-W0I( 3J'PC"@W.U025 M&.B$*CBADPY->V0,C)J81.AJ= $:#MU)Z-Y*R.]!(:(:D*H3,0,*O/_P\G5U MH8$B.''-D/'A5$.*HPXZ%)6^*'!!(A/9J,EDEKM#NX&+(QR73 #+>8@+1#HK M"B:7T5T'1!L+KEQ+ZA*&)_J"H2DF4SN1PQ2(M$H=M/^(E<4:8G'Q[W(3M1E+SRJ:%>1,$TU^@#<'9S-Z!U::Q_12(RQ* MKE!? S T1#&NK6FP" 5^C47.V&5L*^DR$74B5#P&BL MZ0P.B6JFT_L,IUA*NPB?[I/J &8&&+0X[T(&OT(,58Q?T![$2&NG;=D25?C9 M,Q@E(=OS3=*Z4^-"3(2/C>:]H[/K&; M"#M"9A"'C_;.1&",NXG&X &\,[-O F1;W2 Q.L;V_OJMS*PJG6#HQ@>R7CK< MMJ0Z,BLKSR\QDV*"1KB'Y5"&_0""B[;/,V:)CT*ZH7<'SH'(-'#RNSM< /Q# M4!I@];O!K=@N?N%'A!>,#P!.OLG%,:\>D-UN@W@./G/D\IH MJ7VR<-!_(!KR\C.<\Z6_FUM<)K<)Q' V"=#TQKI3I0ZF\.$NL_L(OJOK+B^+ MZP7@&U2=MD7]@[<$'3!!?6G+$+/]OR.H4]1P<-;N+@>V ?@5T;,4S00)!/MHP/ZXUY5.RR7]Q4G M/LG6&O@+,:+@"L[>T\MUK5(_W(^S\]^!X?H(N$K\3$ $H<<+XO86^(, SU_T M8S#C#,LY>6*.?,P@AH)\T;?A(SLYUJJU"HY>7GWJ!0MOX>)0#-NFSZ:.YZW# MILC>7,Z6#X^3+(OA'OE)$)=Z[4@[YL^)6WXA#^=TCW/-0*2M=ZR_ VN"Z*H@ M!IL&QO AUNX$[MA\BWJ[^*7%N1N&+I?JEEU0?<7%_<%5>5#A/U;JNE:O5]G8 M\.X@@IP4$[&KK'+$]2:NE\F'$PU+"@FPE8MK^(#)E+@=3$;L4:MR3?P()+P* MQ(,2$I#WW@E\" B!IPPB]0, MT'^J\F4GT(AOBAYU*CW&..^([6-P;(LW$2V57OV GMLE_FW:U0_2P;O,K1UN WB@PR?%XA6!T*L? M>SC\.)\W[.&O'RI)K_V2R$#65%Z%L]3@FU3VU%%*J',L/TL$&9%8W?I,5'!< MP7'K<%SEYSD.HFPKR4\NH3D/W;J0K U2VG$_,?=VM%R?K6&YG(Y.BG;(%(4514R:6C1PEEL?0PKW//_=#= MMHP ZWUI$8DRE[#Z)-[K#KR(?%G*L-%47V#>5Z),2J3_$%$6W% KDR9U6VT? M7V;?=>ON@.)+D7N4?R,_)XNCJ$+3M5"&[.Y E55@HR9QQ7EF;(F@>HN/#%7! M;S' 4!!['2?@H-44*%CL0L%F]56A2-^3=G>2:P;D)VP2%JA.3:V2BAO[) M(9BHA7-L4X"'07X]OF;-8#C1TPCKY?A_7>.1$$@-L7R5=;V[$V*:C645$)7C M*FM/UB91T@OE[4ZV8H88E,1M5I%.C#PX6:BPU$)SMPU MYX:KDC0R8>0LK D%MSCDC&.5E4*ZV-VA]L*(,Q%R P5@0B1UT\NBB\'^,5RL M\82V*FI#@38&/Y\S2J86NXK%2)ANCZT?5.D51G@H>9-:PPO,%:J?D]([HMI\PO>4;4B"+&G2C@SMB?:0V-W)SDQ!(VGU$-Z5.5^15(4PBHU2AWS MJ(P_1.G()F"/DS:RK53% H&MW1W<7\75-'"XP2BCL#T([>KJ+-R@XVT'LF(7 M* @*3YIL1#%5JWP30%T!G"EG&D1[G:NO^U363MHURB ONH:1B;E/L)>(HA(] MOT(D0= PGAZ8D/R$Q,9DXH_@CF(MO1P*!,,H(WIBKI% \AE MXZD63[ZKT-(3)1BUHMIBH]46]:+:HJBVV.Q2>SFZ;,(Z/I; MM*Z*]*V?3-^:.%CT3K<9]@R[.9"=T3WD "/" ;*4G#\,Q8;12_F1ZVC? 1*, M:Y#B;I2UF?Q1H6%(G<:.J[Y83#D1^O8XO)PSK PMU-CX9Z7"IJFK.58G!(62 M(B.1?U=D(^([_%=020G?D+]W99:B0+%#XTC>[GQ1%,5PWE;-><'_&X66/4E MRU9+[/?K1G?8'C:&[?^T$"66_Z(C_P\@LYW>X+K?&K#&6>]ZR"X;_:^M(>NW M!U\+49D?5FEPJ6!(=Y,WX^:UZ49,0^$?T23");=N0'R 9!5&-D$D"M\1^A@B MV6R%1,D)FZ0DBEY.2)1:"4"GA_U>9X#2Y*K?:[;.08"\,7%1T'Q5FF]J68M/ M9#I:>D_1TLO0PT2(97.N]5CJP#! M P:I34J6[SI3@C\,=2\EYM#%)%W.7#WK!^!;TJO&@5[?N]DG_R;ZC5H/I,5! MR,;75A^!L-^XF!P#E,?$!&<.>MHTT-3"[WO!'!"]/7)5::S!-3B;_=?@H[J6 M'6L>%_JL%_6#PU(5_%OH?U>]XL)\=5.^J$5FCGZJT+DJ:D7W-0EF1- UPE.8 MFM$((?:@ $^ \G&6B#@-0RA.OEJN9=OF5(M>(Z%##'UEA(?LJL@'>2^EY_0Q M[D,.M]P@W.;5_,W(50^"FO/ G3NB6M= -%>< 7JA/S<:5Z57.1.A7^+%A\Y& MCJ;=0AOG">:GBF.PLOBV1N(V ' (9V*"-@M:)WOZ/G %'&897L##;=I( _1L M T4\#9_7J/^RY!=N]V%2/3A2N95&6,XPS(UAN5/ 8;T!8&=*I =$7&K.I?SU MG.R60D/-8&WANC]E>Y7]I>PJ;*WX&&A6PN3!50]]'4$:0#@->-^$4,>JL9$D M5X8HX!FAD=V=,#9"!UATV!F;UMR/1 B4\1A;.\Y[9 (AL6,MPK!ES,$(.'E= M47V[: ,A2A"3 TI"G%)0H[I\7R-B8(X&,^T4EYZ@Q %W\RQXD/$V:;N5H+0"F80 MH+7X676D(T?&PHPPUB/%D&MYWR4;X'0I7B)"1'S24N\8A8N/^'R4I\?#.Y_$ M ]:T ] 5?Q@$Z6S.KS5UHBA@+80E(>U+68F!(1,8$'H'F^^.P2 ,.4;=1JDO M4DFA&EUC3 8L/A.RE/-3^H\6XJ:&D4S!13+NO<:]J I**Z+(C_#A,65B9GPG M7@!:M(,1X)Y[:]A) M63WD$G=RSSD+7T.(#[;7[ UZ^XA6+D]KD]:%$K)R"K^^=1$9[L(U9N:]XW[G MUV-9K^['L@\,/[*.W1VI\X)"(.;RQ@>2C:N)W)^ M& EX0M/"O!BX1%+^;*$SB;W-B]G](R'H>A&"WF@(^K (03]W"/J%?&;/6]OV MLOZ_9Z[3>VYWGTI[#G7BI$H1B<0_WW69%09X_IOR/,R\D[A V.N!CK*[ M8SO"@*!BLU6-)1'+]I2%"FX!Z;+CR@IZ5#.BVZG'U]1GG_LB?A]G6458]/!, M;C*.<]7H#W=WVNT#UAM^:?59NWO1ZU]B3]"7C-3DB9BO'HRK)()QW(3LM#XW M.A2%:YVWNY^+,-R6+J[KV+F%]4]9.?E96JYY,BV!JDD)U"AAKA"[:#2'O7XA M?;9T<:OE!\GT(",51F=Z9710R8B@,PR@QTMDT-G9]LT9J*C1'*.\RK]S!L]5OG;-#HM+!+?>OWZ_;P+Z@&O.ZWA^T6I11=#UKP M1Z'3%")E2Q>79X4FUX1+'^AZ.JWXO'71N.X,!^SZJM?E)[C;[O4C![DXM-NY MN.+0;NGBTH?V,)VY>]GNMOCM>]'BEVXD];\XK-NYN*[CWJ-I<6ZW M<7'I_C^M,]0,$0%05)0K+T!,3FQ4)ZDL.E7'2 #VC(A M&$=IP;CZ[#.%EUA2N714M^R7X-K6PYTULGQ::=_?C ?JOJ!7KKS-\IU3> , .B2128_4IW=8*\9R"Z#XI+]T-PP MWN.YJ!3G(NM<5+;@7.C'[+HT*#5+3+2[YX>D#NUJ)PY6/D:?E4^N2#V31MK_0;C.W-F%$P( M3-AL=+:#L'ECPJ8Q'0=34A8ZEOT=T&H+E@26/&]=; >9\\:2YPHUO>#(&$=V M&F?;0>6\<63'&)G3@AECS'C5;VT'@?/&C%>NZ4%?D$) )GBRMATTWB9^;$+Q M*4T/@[5806Q00X9SPS?8A34UV1Z@;TS ZPEN'(N F8B5B8LG@CGWL[E3]=/* M=<#QB?R'HR+_8:/Y#\?YSW_(VK<5CL.&8W]RH7DI9DYG381PWH/VYVYC^):2 M=8MB[K46=R6"%0A"1Q!46/-&4(^KQOG@H;YY:WD ."FPLX+I(T,@N@D5UKD" MELEA(Y,) %JNL%G8YNC.F-ZPT2,!IE(_+WH"8B&!S5_"[X5XBN\K6W$[4W,V MKS*+"=?Q#GR;"NCS3''XI45S^MQO-8:M/FLVNMW&67O FKW+JT;W+XVUN\W2 M6S5VWBBUGG=:>27 I?%(\] ),++Z0JE;&]5IK-]^\7ZAR<9!S@D"*O]4?*/' M"!,P:":I#(V"+*\VK;TKB5=+TUD'M'_!K50X.3ZQRO$IZU%;S$^L8WA^X>G8 M@*?CY$<]'>_&%\%_X4P>\8<[?S;E/_P?4$L#!!0 ( ,^+K%:-X^[=?1 M !41 0 9F]R;3$P+7%?,# Q+FIP9YV5>3S4_[?'/V,;NRS9&KNR5_9U M\%488U\&(;)GSQHS22K*-DH-44;&.K*$&+O(GJ5L$R-A+!D[6;+DZO>XVQ_W MCWOOZ_TX?YWS/H_S?+_/>;]/OYW. .?@!D8& (@* $!G"S@E =< >CHZ,!TM M/1@,9F"@9V3F8F%F8F+FX^!DXQ+@%Q(4X(= A,4O2PB+RHI!()*J4K)7Y964 ME(0DU*%J"EJ7%944_B8!,3 P,#,Q\[*P\"J(0$04_L\Z_0BPTP/^0#WAZ>=_V\0T-"X^X&QF% M?/0X+O[)TX3$M!D9KS*S<'GY!85%Q?B2JNH/-;6$NOJ&]D\=G5W=/;U] MPR.C8^/$;Q.3LW/D^87%I9_+E*WMG5^[>_L'OP__6YE&X.8HM7F>;>0KXS< MXDJS%[?^HOV+['\']O#_1?:?8/_%-0DP4X/.+H^:'= !]@\E<0\83;X@$:B$ M.4+< J96-+E2HH JX&($=-[&ROX!V"JR,^0P(SE@Q@L]H+4$OC#$= H02^5" M73*LZZ4XJR93&]Z28^I+G5MV?UJV^PPH+E5FOFN]*-0TWKAU&7^WK6X[8UB> ML+MBP[)&@M1,S1_U_"!;3?K8$3^I[ UK[/G?$NH83SPP1(A=%'5QVQU#LH]< M&YCOM"5.>UZ(=K>H]>^.NO*5%'GB%]C=E28F/:W+AVIR8C\0VBI-RF'S3<^[ M<*-"*R MI^Q>V%-X-,+F_'P8!5>P%[X1\WPT/O"7E0SP@9[\,%_/FJEX@I&S+=[?5$^6 M%US]D.$.>V.K4C9G#%7Z[9%YZ13 ^I H*%OSA'L&;I?ZNDR,3@$Y<9?9/?!X MW:);OWV:_2YT:+P\GC-G^OEG] #T==BRGUC$1F=62M=UE(@SRNBNIE 4F]"L)6ER*.Q(.&X^2)^OS+Y)ZAT,=%4VZL]1ZO+-]#P6P2>8/V,N M-V_D"!:@F.C0VW<,S:@BMJI7B MWZ9/7X-\_1!T0N3-2T\QK>%(EV$K+_X5+>-<-:9M_RW_4VD \12H<#AJ3HD\ MA&W517[+D^IQ'8V6(6Q.M^XM<&>$Q.17?/KW#:OS['NCQP]%XGF;C!&)?DE>9K0'?N.]8]'J-?G M?$XF7.CY_9HT.F[:8;5"4)DV4=#W8\:Z&TO/M+X'O['3LG$8$\!(*%\)<=BK M''E"$SN=8RF+@NTIRWE%T')9ZK8G2KZEX^R\TW)YK.EWW&/#!8/^5^LHQM7U M D>4CY?[-HY;YT&%1+H7UCMST-GP-G/O- MFD27MY&N,/3Z 9W$(BQ5;5\Y\_&*)92(520966 MORFCO8:9Q0$V84_>2 UZ$KWB?>W+Q3&/'8%:1Y&VP+5?I21'[Z;&Q.]T#@9 M3 H2D_(FPK:RC?]!B7QGF)L?2FV[;%"+0%?)N83M,7:4E'5E;^/'L:VC6QW" M,B(V:\6SE+23=4LWV"E%L*^%=LQ;L4UMG UTA5_5PQZ6ISL?3QQ.6^9D3 M:^CZFYA#KTX9(K1Y]I5"2 N)4(RX'5!(OVIX[6 ,M:;QPR(.5Y?@A"0__U5Q M:;.K6CL#_U&K76[^3E67.63_6&9"+.!CJ%%GVW<^]TW!=J<7]WJQX=&SC234 M[D,:A?R'4O]D9AN< I;-D9C0CL&+1>T?&\$ M\".@N"DRQ^+U,>_&QI$K12_5[2,Z(DK0K_;WRY(" I;J8*= U88[:W S^:-+ MA7*5!?*^34D=E (9^1G$J)ATT KJ"T5+C;Y:3*_6>'C65E1GQAS# 7/_$L1[ MU[0ULWNW0J$K\EAFY)Z1X G5)O+21L]BTV?HD,O.G_/+,_>Y[PV&']LTM5HW M;MJXAA6].,A_N;1)U1 [7)]*"QM<9%:1ZB+<\!;ZK%[DYX0@>0^U8VBB#_$53^-G)-RN> M HK.I0,-BL[6Q;E)UHT&O"3%V(W>\GY.N-E20O;-D21'_NES3[7KZW;1*I[' M=W3*D S"C#L;]# QHHI@!2=H=^84@*_M\C%'6%5A[P ZUO9>BF'S\X=B19?L M<&GK'GX)GF6Z8;\SVZL?-2-E6#&ILRF, 4)V+483 B;7/@<=P4Z&R[(_#7MDO$L-06LD;M[)_+"8 RT[R#&5,DL64#N670C3 M82612$9E%)@)N_QM$?#&K1G.7;5RDB%13ME3%%*:J.UQS^,^8LB7IQ;7QOR4 M&/RVP^@"B -)!1JJ-0T=YPDQ?.!HXR@ ^W29QH[7Z5 U:-'ORR>J&O)$M_"V1K3?^R]:)H_E MRH[B@O?%H?2_E,LO/PK"2JC8I2;S5+X>R=,T252T-%@6C;?B,]?3',T\OWB8 MHY<]UL??W%8[7.X%9JY,J]]=.R1B*GH^XB=12&+IM..U*/\O9K%D?\_0Y!VG MP'I7G+V8[ W./;0ZP](/K R!0:V,OWYN\0,%/I)497!=8QT/9D"I0"'K?Z+P M%YSKG^L,WZJID\"GL>>,G,_01[*^E/VE=:4,83;5_[VVJ08];*HG(QZ/BCHG M(YO\SV!HVQY=XRN/)*L1S)='$'S6#CXF?/: )WD@9&B7L>[L>:_,]1OV"8FR M6EBSWVXF3MFQBC&MW5HK/P6"5VYM4>+T^9;#6G:0T=IS$WV__3]_M6=>3(>* M^O5,Z:QW35&M8/WNCV]/K\O+I1]D[VL.N7Q;(7+T@4N5,$Y4>+/(GX M!3L-E2(?38.]:L@= :[WOL3-C?BE=(IF8\?M-!5:RR?]'4@B4E<;8[9C43-" M5C!7Z&K)G#^1&8X7"/7!SY[HI:@?&1GK3[5F-Q>S8#&+AT\2K@0&-9&BL+S6 M)PZL"E#8AL.D81)A]>&ABH+W[31Y(D6F)=+A>:I\V(ZT(GYUP[T&]ZI(T[Q, MNW[(1/*_]8W!\O [)U)W.,VS_L2OK'[>?VF$GE:1,ZOW#;LBCOB[NR*[Z_DJ;MZVO2Y-X15\BV8)Y<]YY):9G&X591*U_7K]CR#F MIV5G6>&]=47IK!?9 O?0#I]M6T=& IH_22]ILHEM*Q>V7!VCFBFE.7RI0[99 MUX*6D&KYQW*F=5[KC)=D*QQ#+EQX%K/R(B8N3.UK>@,$;M_G3*F/6.EH*!M> M4Q5TP.*4J<^^[!LT:1UI(6;(_3+Z#Z967I/IBM1_AM?^A%>XSY R/%6K97V^ M!*F%_\N4D=O3=U;$-%;F!>42&"TS2]TAJ#SOFX_8 91VM,/%5@:5?N M%:8F$M_8"L 2P4-"V:$TYV!:[&W@&N3\;>Z+-+= R8R]8\>J/GBO?XXR3X$E'+K5.ZWBVPMU,36=DG0-\A1CDVGIJFN*J.?D(ESNPK?/_LZ.YPOC[DYR<>;WS7? M5/IKR0P$ KO-R_OLX@I=*0I><9JON COQ\T1,HR M&KW+"#5TZ$WSN>'&)/LQ(*038:0)@\RSKPRG&V)=JF-E\0T* PO^ZLLG,]$H M2U?4=9^9NQ]/I.!L\$'L(JS HJ"O.S[FV?&G(F?L"7X]K:8CLAZ#B-74U6.5 MI]2_O9RCMP?%RP]8)/<%WNP?B7)MV>BM_AUXXI/^ NZ56+08, MH\BP%?W8FC%^R*./A\-9N/TKD(XTK>?\.;GB.[_FL@AFC'WS2MI6U9"PP:A# MZ_>A[S)Z:+[H4A?ZJ1AG-0I6F_9JN"",2G > ML&;#4DX?)O:##V:O$T#P%6 Z$AC:VI\9*/:J=T6N63M6:_%Z>7FJ7?S8>TA. ME%4:D=TRQD:>SX&D17G%0-]P]2114Z<6QBB:)LQS=-S;$NT]%L-MO4&? CEE MW*QA*7*C@7NE-?5UVWE35TDO0LD/\]'@5J7TH&"Q# 48Q>,Y_+U%"?55WF[M M[%#]N#5EY5#B9/*XOZK_3M75Z+*T9(O8[E:SB>.?A+K,M(F+KHMJ-,_47 DZ M<=RLH<9*"*8(S*+(()5 >?#^H (;P65Y,E%6,P/^\!\Q<4BB3PIK).29^>PI M0,'?SG>1%N;^RJ#ZE,Q& 2OMQXGSAMD*D@N,]*D6KE-QN30DYGUCS>Z4JDVI M74]A;=O>&B[$/5BX[L=1K(;@6S&35& %"T#QHQ;:-GIR MTT:]9/= >=)P/BXV!'<^SNZM\X,[4*G"<%"2->#PSB^7#ER\H*8/E2-=Z[P;RH=*96X MR:ORL;^68972>$: YD5WL[$^J.]I4P'@:K=PE">@C7V)$Z>]C_@=Z:QQ5I:V MC; %PT=JZ.TB2UVATXE_ U!+ P04 " #/BZQ6SW^U%'X, #6=0 $0 M &=C86XM,C R,S S,S$N>'-D[5W==]HZ$G_>/6?_!R]/W0="/MK>-C>Y]SA@ M*%L"67#2]K[<(VP!VM@2E>P$]J_?D;]B_"$,2;<^2_K0 ]+,:&9^TGA&2,[% M[RO7T1XP%X31R\;)T7%#P]1B-J'SR\;MI*E/VOU^0_O]M[_]58-_%W]O-K4N MP8Y]KG68U>S3&?M5&R(7GVL]3#%''N._:G?(\64+ZQ('\@^BB^H,_&^^G-Q_^\^^/# M*;Y?/'RY>CO%[G>ZOF?BZ]WG1]);L']_[[$_[HUPR MA+;"+- "#BLN&M"\R M[_'LB/%YZ_3X^*3U]7HP">@:(>'YRB'TOHC\Y./'CZV@-R;-4:ZFW(E%G[5D M]Q0)G$B&7J*@)U1XB%H;]+:7,*2)W[7"S@U24DCZ/B0E,:F-,W0"6T=S]M"" M#J _/8L)?=&<([1,B&=(3 .A4<<&L>!>GA :LT1-;[W$HI T[-I@L#V>8=CP M&G2W9+?D.6X>GS1/3V+.7EL?)DQS"U&^DG,YD'Y\=@9TV,$NIEZ7<;>#9\AW MP(#O/G+(C&"[H7F(S[$G)Z=8(@LK9<7S&U'*8!G 6HQ:9-MR26">0\-?+N2$ M..?,P28HK5 M+XV"CP'+12M+G!+A"VR/Z&_!YR7' O@"W0?0$#%&)"5,%G(LW]F-YTF50I:H M(?;1'EZ[0HY<0Y,%QIX(O;?9I/;B*;A.AC*( M@U4+[!'0M<#3F_UJMY]5=[OV9D/P/PX0AL138C0;+65^ &-%D[VD3^W^MRKW M/TG4V$Q[DJF]N:7(MPG0'#H($X]9]POFV)")P<.$6 3RO74>D!(Z-3COJH.3 MEJ\]#?"*5() &XE%UV&/!:OEJ4N-Q_OJ>$B16B#SP"$80G' <3HBZ=2>^*Z+ M^!J6!9E32+N Q],MB_G4@TKI!GP*TS<"ZCD"U'#^(O,FJ#X<)F $^#+4S=NQ MH8VZVNC&&.MF?S2<:/JPHTUNKZ_U\3?9,^GWAOUN'Y),4]/;[='MT.P/>]K- M:-!O]XW) 2+<8^!R6 H6YC2$;*-%C<&'+ :]D71G>S1L&^/A 7IS3.8+;S3K M$BZ\,9[Y CGZG.,@LH3>55*HO?TQZ^UQO_?)E-.ZVQ]/3&UL=&\G^D#3>V/# MN#:&Y@$",&"(0@:[1E-@8&/LR.@.B:>71"0EA1* D^,L (.1#C'F1O^F7PT, MS1P!! /=-#K0-#8/,YX,F8>?W&LN"-]TOZ)?[?R37+P?F<:&\\U/_?$AN[Z# M.7D G1[P@* I<8@7I;)%'6IGGV:=W3'&_3MXIMX9VJ"O7_4'??/; ;JXC9;$ M0TZ0KT,B\P5Q#KE+-+7+.M6N/LNZNJW?]$T(XQ-SU/X<)#!?]/$8,I9#G--] M"A^QB59Q_$@WJ!W[-NO8_K ]NH9(H7\]R/#09JY+O*#&@=D)"9Y,MJ',3$*S MBD#MZG>Y.3RZONZ;,@<)4W#("&6B;0P/-,N>^%.!O_M@C/& DX"1:U5[^7W6 MRY/;JXGQKUOPLF;<&8<9()Y18+Y8I5JM8CWY$16K]B8>_!"W)U2YO"D;*^3\ M$9T:NERANRWSU]Z$<@\1E?(4/XW)5BHU(KEB6%T.'#(>!>E_&HCR;B4"I[EJ MN*A&.&2_/^.)TL$>(HX8RA)"(O/L1U1.H!K;?+']$H^J2 DMT>(09T5Z>[48 M9B6%&K=D7+IR"[:^2 M)::@5$.4VTU)A\CB7;,#7DE5'*Y\O%5E4X.6VTJI#MKKTZQHS[DX#E8A5 .5 MVU%1@G/88:_DB$HQ-%6)U?#D=D[*S[>\@K3MH$8)4#LPJ,':[2#'_S=>\C]Y M#72,9UIP??1KJZ&WW/7N^] ,,9]S2:NR6LNMP=7DL?,"L0I6"1WYHQ7U,V-4].FV%G8\$;?LK4+Z M8OLS= C$[*3$]MOR9>ILXPR^B[TF07"D@*]WF0AIEOC+?F@\O9*@&A Q?0B" M?$O!OL/N,0OR@Y=.@>AM!N'O_FU]^.<$ZB$L=$CB'F0,G#H8GMDSS#FV@T3\ M&KM3^7H!J304O56IB>/(G:;+AL=]&4WE*RW.(V2.'%\L!H-V9E97H:R#2?)'_&B_@9-IP)^< MBLJLU&JD=3#JAC.7",'X6OY"LVE%25\=U-[( ,HMV$Y6!V/^R1;4/!HSYFUJ M7]!>!W6#8X'P'^XY;(JI@;K@9<[73 MUDT%ZCJ89KC8BWX.EJ>4*)3:N:QF"TT=S)BL'<*$W*O)8)%OKX.ZYB-+[8L1 M[AK4"Y+$S,-H*UD=C$E-].@D@4QE8$V75B@E9'4P!EQNK"S(9>8XJ6-SH)13 MU,&$,*_<8L4VHCH8TF4^'^+'XHF3VS&L1%L'LU(Z%AA2VEL'U=-G6S.I6E%/ M'52.IH&^J6ZNM4:J7A6J>E5'5=N%JM8K-8 8Y_@B.(9H82K* N)VLCH8<[- MW,4VL=# LS-[F(5==5!ZXD_5OE<1U,* M>N!K-4M)2!7,.0,;)1--%4DM3 " M\P=PLBC;R5?TUT']_"L2@C<@K$V\\JX<**N2)U$%PF<8Y,5B7L"F/O5@3+=+ M**(6D0=RXW<5E]BV"T--;-R\ EIBUS:BFM@BDYPHQ^G@J1>\ "4__[80U<26 M+XS?R[=1A'5]^&IR+WF0EW1NU3T\'.?%7=/P#P5<-BP.3R8OMBCL=!G%'N+K ME]B/2O_08F+N)AM.!1T[ Q!2Q*TOH*Z<%V-YZ4XVWV!NR9.[/"7@G0A?#>X,BB,U1);L*;3:.S'^O/Q2AVC"IM)T+B,S5&FB8,55Y:OM6BQ!2>V 79E^-M!QT$^ RSX-TAUU#0U) M\C#&MF^%"D2QL*BGKDFK3JF/G#%;(T=FIV.H@&([BKN>43F\7/J7>%;^?1[. MUS"_HP@ &5SP%][BDFXKW=[ _-CI!>MW#BDJ#=9#B,$Z>IRFSB@L =] M 5 9V-A;BTR,#(S,#,S,5]C86PN>&UL[5UM<]NX$?[>F?X'5OV2^R#+ M+TEZ\<6]H27:X5265(E.+I]N8!*R,480>G_1NUWT]<70-'N:YR/J M()=1?-&CK/?K/__Z%PW^?/Y;OZ]=$>PZY]J(V7V3+MDOV@2M\+EVC2GFR&?\ M%^TK<@/Q";LB+N;:D*T>7>QC^&)[X7/MP]')STCK]Q7D?L748?QV;K[(??#] M1^]\,'A^?CZB[ D],_Z'=V2SE9K A8_\P'N1=KP^COYLNW]V"?WC7/QSASRL M@;VH=[[VR$5/7#>Z[//9$>/W@]/CXY/!;S?CA?V 5ZA/J+";C7N[7D)*5K^3 M3Y\^#<)O=TU3+==WW-U=XVRP@_,B&;XE!>UC2#QR[H7PQLQ&?DB[]#):;@OQ M6W_7K"\^ZI^<]L].CM:>T]L9/[0@9RZ>XZ4F?@)[+U>]MQ'E:T'70'PU&#)P M1\ 9=GK@>'G1$TU ]NG9\=E6\M\3C?S-([BE1X17];3!05>]1*ZPS^(!8]^3 M73VS<>4H9HACZC]@G]C(+04ILV<5^,10P2N0[4V7TTF.M ;!GA);$)!+1-&8S%$JK&.T3>PY7+GDN9,=6I"E03B(,46XYT/[P$.N?L]QR*P,DTK?*C".&:(013;HSL46FV,7/,^!J.(K M4*W2MQ)O93Y^O8[U0+@J0GG/*O"-,"=/X.M/>$S0'7&)+PU"!5VJ0#1$C\1' M;AC>8/A]0YS#B).:2]*M"F0FE)PK;*&UG+R,II78AJU6Q ^C*^@(PUZ$( C[ M"NZDT+62G!'<>?A' )IJJNFLBJI]*V[JBJ+^1!9E41X MF)8[@0L.4!0K(@32\'^(L,:U*#7'?;ODNC-!64\[1%:U'.7'^=)^IBRJ80T. M]+'#Y%:KVXSC1[315R+80RH8@7N,L&=S\BBR0VF&2HFKMPHIG1I+2ZJ6B8Q2 MH[3YY3*:PGS@D"@IL*;:L*SKE!!1XRR[+.J28FJ> Y=&7UY4D0;@5';@AB7Q M&'Y/],!K'U,'.SLY0A6US06?^*)IM-MSHO7%UE @0,-_HY8UX04C@.040 M+TN^(2#J0;'OB!)!B_IKD8 (Y ZFR^P$-%?L]+"]397=KEFXG[-$WEVXJ1-X M_7N$'@>"S0%V?6_W2^ZY\&UAP'GL=5'%]UA-[SB[U&[O6:#5K"* M]7+AB/##^!% .'!#U_2'X(4;<,UP[R]?!\7N^[K%W$7GML:X@_E%[V1W'<3M MA).D=]>B%@-/S &%F#X!?]CU7W*V*C)U9%9VB"IQ2@!%3WO&8E84HF^'PJUR M,C_K"@DYUL]FJ$-6-JF/Z#V!*FL+=8)]D]IN(&X(N&;,>2:NF\^!6F\UAD[; M8:B, ;I$W*ZVB:U[IOE)-&II&&^7KG:UO#Q]Y+1O>YAGV'M_K!=JVB7? 9_' M''N^*B=Y[=L>V').BC7M$B?@/3S C@'E,-M@?(DI7A*5)J"C-?'E-,2E)N!S5VWK?(CD37SM$27SA2XR6SAQHQ']HFID#;+C$3O\-* MS$)>[W-( M, WP%8P@L5_(D>U_(_[#,/!\ML+<6$>+L&)9%OXZ%EH79:T#A+4="S.82N6O M@VW4I80V9)X_78K5]# H8OY$;.PM(-P5%?#Y?=H.\G+BY!IG\--O;^5D&[_H MO;%^Q-0KVE+(:-H2YB44<) NQ=.E "2DK0!V9NNV(T"NW??7>@IT[=) #]>D M1OB18YMLK4@=?<6X3_XCXT?:L^U!K\R5H@TZQYN(68 U4N]%70EGN;W:GMB7 MXDNB>Z>XVH';/ADUAE2D$*WCC3L3]=(:['&3E6@[.>U35RG?+;M4$$P894F5 M(KCYKE;0I=U=[MV@%N-
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end